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Abstract 
 
Synthetic antisense oligoribonucleotides can be used to modulate gene splicing by 
masking key motifs on the pre-mRNA required for spliceosome assembly. Yet, 
intracellular expression of oligoribonucleotides generates only a transitory effect 
whereas stable delivery of antisense sequences can be achieved by linking them to 
chimeric small RNAs delivered and expressed by viral vectors.   
In the murine model of Duchenne Muscular Dystrophy a chimeric U7 snRNA 
(U7Dtex23) induces skipping of the mutated exon 23 and restores the Dystrophin 
mRNA reading frame. The main limitation of this approach remains the large amount 
of snRNA vector needed to be produced and administered to patients. To optimize this 
system we used self-complementary AAV vectors (scAAV) to express the U7snRNA 
shuttles. ScAAV vectors were tested in mouse myoblast cultures and we observed an 
increase in U7Dtex23 expression and in Dystrophin exon 23 skipping compared to 
single-stranded AAV, highlighting the potential for this strategy to reduce the vector 
dose. Alternatively, we have used a muscle and heart-specific enhancer (MHCK) to 
drive the expression of U7Dtex23 cassettes delivered with AAV vectors and our results 
showed that MHCK improves chimeric U7snRNA expression and increases dystrophin 
exon 23 skipping in vitro and in vivo. However, additional U7snRNA species were 
produced following gene transfer, pointing at a possible limitation of the cellular 
processing machinery capability with saturating levels of U7 shuttles. 
We have also explored the possibility of using small nucleolar (sno) RNAs as novel 
molecular platforms for antisense delivery. We replaced the original antisense of MBII-
52 snoRNA with the Dtex23 sequence and observed low levels of exon 23 skipping in 
AAV-transduced myotubes. While our observation validates the approach, the efficiency 
of skipping is still considerably lower than with the U7snRNA cassette.  
As a last approach, we engineered the human C/D box U24snoRNA to specifically 
target the 2’-O-ribose methylation of an adenosine branch point in a luciferase reporter 
pre-mRNA in order to induce the skipping of the downstream exon. We were not able 
to observe any modulation of splicing using this strategy. 
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I. The centrality of RNA in cellular processes and gene regulation. 
In the central dogma of molecular biology proposed by Francis Crick in 1958, RNA was 
depicted as an intermediate in the transfer of genetic information, suspected to occur 
unidirectionally from DNA to RNA to proteins [1]. The characterisation of messenger 
RNA in 1961 by Jacob and Monod confirmed this attribute by demonstrating that 
"structural genes" could form a transcript of themselves, which in turn would synthesise 
the protein in the cytoplasm [2]. At this time, DNA and proteins still appeared to be the 
dominant molecules in cell function and gene regulation. However the consideration of 
RNA as a central molecule started to emerge in 1968: Crick [3], Orgel [4] and Woese [5]  
hypothesised that RNA could have preceded DNA in being the first genetic molecule in 
evolution and suggested that, beyond being a simple message or transfer molecule, RNA 
might also act as an enzyme. As RNA dual role as both genetic material and catalytic 
molecule was later established [6], the notion of a "RNA world" was introduced by 
Gilbert in 1986 [7]. Although the idea that RNA could have been the primordial 
molecule is nowadays disputed, this theory importantly emphasized the centrality of 
RNA in cellular processes [8].  
Transcription is at the core of gene regulation as the messenger RNA (mRNA) carries 
the genetic information from the DNA to the cell. However, the notion that a simple 
gene encodes a single transcript to produce a function is misleading, as it cannot 
account for the diversity of cellular processes. The definition of a gene must therefore 
be more intricate. An additional layer of regulation of the genetic information became 
evident with the observation of the split structure of genes: RNA splicing is critical for 
gene expression and more than 90% of human genes are alternatively spliced [9]. Tissue-
specific alternative splicing provides diversity between cell types by modifying the 
information flowing from DNA to the cells depending on the cellular state or 
environment factors. Thus, a gene can henceforth be described as a "transcription unit": 
it is not defined by its primary sequence but by the array of transcribed sequences that 
will be joined through splicing to encode the information needed in the cell [10]. RNA 
as the final product of the transcription unit is therefore fundamental in gene regulation. 
Furthermore, multifunctional sequences are common in eukaryotes as pervasive 
transcription can take place at numerous cryptic sites on one gene. A single locus can 
consequently produce different transcripts from overlapping reading frames to code for 
15 
 
proteins with completely distinct functions [11-12]. This overlapping aspect of the 
genetic information provides a high level of transcript diversity. Moreover, a single 
RNA can be bifunctional and act as both protein coding RNA and regulatory RNA [13-
14]. The regulatory RNAs do not code for proteins but have a considerable importance 
in gene regulation. Indeed, as much as 98% of the human transcriptome could represent 
non-coding RNAs (ncRNA)  [15]. In the RNA interference (RNAi) pathway, small 
double-stranded ncRNAs can act as trans-acting regulatory factors to mediate 
transcriptional regulation, translational silencing and mRNA degradation, or direct 
assembly of heterochromatin leading to silencing at the level of transcription. The newly 
discovered long non-coding RNAs (lncRNA) constitute another category of regulatory 
RNA ranging in size from 200 nt to 100 kb. Although most of them still don't have an 
identified function, the few characterised human lncRNA have demonstrated roles in 
important biological processes such as epigenetics, alternative splicing or as precursor of 
small RNAs [16]. Long ncRNAs can also upregulate or downregulate gene expression, 
as is the case of the X-inactive-specific transcript (XIST) lncRNA which drives the 
inactivation of the X-chromosome [17]. The non-coding RNAs therefore prove to be 
very important components of genetic regulation. 
Adding to this vast network of regulatory RNAs, post-transcriptional cleavage can affect 
different kind of mature transcripts and generate small RNA fragments with their own 
distinct functions. The mRNAs, tRNAs or snRNAs can all be processed into shorter 
fragments that can act as transcriptional activators, mRNA silencers or translational 
inhibitors amongst other roles [18]. It is not yet clear how many of these processed 
species are functionally important, but nonetheless RNA fragmentation further expands 
the diversity of transcripts available in the cells to regulate biological functions. 
This overall level of transcriptome diversity and intricacy, associated with the vast array 
of regulatory functions that transcripts can perform and their ability to be 
multifunctional, indisputably establish RNA as a fundamental and central molecule in 
gene regulation. A gene can no longer be considered as a single entity but as a part of a 
highly complicated network of regulatory molecules and interactions, in which RNAs 
play a critical role. 
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RNA and diseases 
Considering the central position of RNA in gene regulation, it is not surprising that 
mutations affecting production, processing or function of either protein-coding or non-
coding RNAs can be deleterious and trigger disease. Numerous RNA-associated defects 
have been linked to human disorders in literature [19]. As pre-mRNA splicing is a highly 
complex mechanism involving numerous partners, it is probably the most affected 
process in RNA-related diseases. Mutations in core components of the splicing 
machinery occur occasionally, for example a form of retinitis pigmentosa is caused by a 
mutation in the splicing factor PRPF31 [20]. However, pre-mRNA alterations affecting 
the alternative splicing process have been more frequently described and linked to 
human diseases [21]. Point mutations can abolish important splice sites or create new 
splice signals on the pre-mRNA. These missplicing events, which will be discussed 
further in this thesis, usually result in the assembly of incorrectly processed mRNAs and 
the production of defective proteins, ultimately leading to a disease. In other cases, a 
mutation can trigger a change in the ratio of protein isoforms produced by alternative 
splicing of a gene. The proportion of each isoform is spatially and temporally regulated 
in cells and a change in this ratio can be deleterious and lead to diseases such as 
Tauopathies [22]. Numerous alterations of alternative splicing are also associated with 
cancers, although it is not clear whether these changes are the cause or the consequence 
of cancer development [23]. 
Besides pre-mRNA splicing defects, there are many well-established examples of 
diseases arising from alterations of non-coding RNAs [24]. The micro-RNAs (miRNAs), 
components of the RNAi pathway, are estimated to regulate approximately 50% of all 
mRNAs in vertebrates. Their disruption can therefore be highly deleterious, and 
epigenetic or genetic defects affecting their production, processing or interaction with 
target mRNAs have been associated with various disorders. The miRNAs post-
transcriptionally down-regulate gene expression by binding to complementary sequences 
in the 3' UTRs of their target mRNAs. It has been shown that mutations in 3' UTRs of 
mRNAs can lead to dysregulation of gene expression by creating aberrant miRNA target 
sites, such as in the myostatin mRNA in sheep [25], or by disrupting important miRNA 
target sites, such as in the human SLITRK1 mRNA where a mutation in 3'UTR is 
associated with Tourette syndrome [26]. Furthermore, a general dysregulation of 
miRNAs expression and function is observed in cancer [27], and specific miRNAs 
17 
 
defects have been observed in neurological and cardiovascular disorders and have even 
been related to deafness. Defects in other non-coding RNAs can also contribute to the 
onset of diseases: the long non-coding RNAs display aberrant regulation in a variety of 
diseases including cancer [16], and defects in specific snoRNAs expression have been 
linked to imprinted disorders such as Prader–Willi syndrome [28].  
RNA and therapy 
To counter this type of RNA-based disorders, therapeutic intervention at the transcript 
level is appealing as disrupted features of RNAs provide potentially more accessible 
targets than the defective proteins they encode. Different strategies using 
oligonucleotides that target RNAs through specific base pairing are suitable to modulate 
RNA expression or function and prevent the onset of disorders [29]. The small 
interfering RNAs (siRNA), part of the RNAi pathway, and the antisense 
oligonucleotides trigger an enzymatic degradation of the target RNA leading to gene 
silencing. This technique is useful to inhibit disease-associated miRNA expression or to 
reduce the level of abnormally upregulated mRNAs. Another RNA-based technology 
consists of using steric-blocking oligonucleotides to prevent the access of the cellular 
machinery to specific sites on pre-mRNAs and mRNAs. This strategy presents the 
advantage of allowing the correction of a defective RNA without inducing its 
degradation. It can be used to inhibit mRNA translation or to interfere with RNA 
folding to reduce the expression of a gene, but also enables to modulate pre-mRNA 
splicing to correct a mutated transcript and restore the production of a protein.  
It can therefore be valuable to use RNA as a therapeutic molecule for intervention at 
the transcript level. However, these strategies still present some challenges: the cellular 
uptake of oligonucleotides is generally poor and systemic delivery is relatively inefficient. 
Chemical modifications can be used to stabilise the molecules and improve cell targeting 
and penetration, but can impair the performance of the oligonucleotide in some cases. 
Administration of exogenous oligonucleotides can also have a toxic effect and trigger 
strong immunostimulatory responses. The potential of RNA-based therapeutics to treat 
otherwise virtually unreachable defects is therefore very encouraging but still faces the 
need for optimisations.  
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II. Splicing and associated diseases 
As mentioned earlier, gene expression is largely regulated by different molecular 
machines that direct messenger RNA maturation, transport and translation. One 
important step is the RNA splicing process where the intervening sequences, or introns, 
are precisely removed from the mRNA precursor to keep only the coding sequences, or 
exons, in the mature messenger. Different types of splicing exist depending on the 
species and on the class of introns to be spliced. Four major classes of introns can be 
distinguished [30-32]: the autocatalytic group I and group II introns, the tRNA and/or 
archaeal introns, and the spliceosomal introns. The latter constitute the most 
represented class of introns and are observed in the majority of mammalian precursor 
mRNAs. We will focus on the splicing mechanism of this type of introns hereafter.  
Pre-mRNA splicing is a highly regulated mechanism and, together with 5′ capping and 3′ 
polyadenylation, constitutes an important post-transcriptional RNA processing step. 
The relevance of this mechanism is considerable in humans as more than 90% of the 
pre-mRNA is removed as introns after processing, and only 10% of the precursor 
sequences are joined in the mature mRNA by splicing [21]. The complex splicing 
mechanism can be altered by many factors: the strength of splice signals, the presence of 
enhancer or silencer sequences and the concentration of important splicing factors 
directly affect the selection of sequences to be removed. Other factors such as the pre-
mRNA secondary structure, the transcription rate, the coupling between splicing and 
other steps of gene expression and external stimuli can also have an influence on the 
outcome of splicing. Depending on the cellular context, different mRNAs can therefore 
be produced from the same precursor through alternative splicing and at least 90% of 
human genes have alternatively spliced variants [9]. To decide on a pattern of alternative 
splicing the spliceosome machinery must therefore take into account all the variables 
and a defect in any of the factors or signals involved in pre-mRNA splicing regulation is 
therefore highly deleterious and result in splicing diseases [33].  
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II. 1. Pre-mRNA splicing: principal actors and mechanism 
II. 1. 1. Invariant splice sites 
The most challenging issue during the splicing process is the selection of splice sites. 
Most introns are primarily defined by the GU and AG dinucleotides at both ends which, 
combined with other precise signals spread on the mRNA precursor, recruit the 
spliceosome and define the regions to splice. The major splice sites are invariant and are 
composed of the 5′ or donor splice site (SD), the branch point (BP), the polypyrimidine 
(poly-Y) tract, and the 3′ or acceptor splice site (SA). 
In vertebrate, a consensus for these splice sites is difficult to predict as their sequences 
are highly degenerate. The general consensus sequence for the 5' splice site (5'ss) is 
AG|GURAGU, where R is a purine. For the 3' splice site (3'ss) the vertebrate 
consensus is (Y)nNCAG|GN, where Y is a pyrimidine and N is any nucleotide. The 
characters in bold represent the invariant GU and AG dinucleotides at both ends, and 
|represents the exon-intron junctions.    
The polypyrimidine tract is an intronic sequence encompassing the region between the 
branch point sequence and the 3’ splice site, and represented by (Y)n in the 3' splice site 
consensus. The Y-string occur very close to the 3'ss end and can range from 2 to 32 
nucleotides in length, with an average stretch of 9 pyrimidines [35]. Finally, a vertebrate 
branch site consensus can be defined by CURAY, with R being a purine and Y a 
pyrimidine. The bold adenosine constitutes the branch point itself. Most branch points 
are located 15–30 bp upstream of the 3'ss end, the average distance being 26 nt [35]. 
These major splice sites constitute strong signals that are detected by the splicing 
machinery and are very important to delimitate the regions to be spliced. It is therefore 
not surprising that variation in their composition or location have an influence on the 
outcome of splicing: the proximity of splice sites to each other or to the branch point 
[36-37] as well as the length and composition of the polypyrimidine tracts [38] can affect 
the splicing process. 
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II. 1. 2. spliceosome assembly and mechanism 
The splicing mechanism takes place in the nucleus and is catalyzed by a macromolecular 
complex, the spliceosome, consisting of more than 200 proteins and 5 uridine-rich small 
nuclear ribonucleoprotein particles (snRNPs) assembled in an intricate network of 
RNA–RNA, RNA–protein and protein–protein interactions. Most mammalian introns 
are U2-type introns, which are processed by the major spliceosome. In this spliceosome, 
each snRNP is composed of a small nuclear RNA (snRNAs U1, U2, U4, U5 or U6), a 
complex of Sm or Sm-like proteins and other specific proteins [39]. Another class of 
introns, the U12-type introns, presents AT/AC dinucleotides at the splice sites instead 
of the canonical GT/AG splice site consensus. This rare class of introns is spliced by 
the minor spliceosome composed of U11, U12, U4atac, U6atac, and U5 snRNPs [40-
41]. This type of introns can only be observed at a frequency of 0,1% in few eukaryotes 
and will not be detailed further here.  
In vertebrate pre-mRNAs the exons are usually short (50-300 nt) and the introns are in 
general much larger, reaching sometimes more than one hundred thousand nucleotides. 
It has been demonstrated that in transcripts with such large introns the splicing process 
follows the "Exon Definition model", where the first recognition unit of splicing is an 
exon [42] (Figure 2). In this model, splicing factors bind to the 3' end of an intron 
during early assembly and initiate a search for a downstream 5' splice site across the 
exon. If this downstream exon is less than 300 nucleotides long, the factors binding the 
3' and 5' splice sites interact and communicate across the exon and define it as the initial 
unit of spliceosome assembly.  
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 Figure 1: exon definition model 
In vertebrate pre-mRNAs containing exons shorter than 300 nt and large 
introns (a), each exon is recognized as an independent unit prior to pairing of 
two exons across an intron, following the exon definition model: (b) the first 
splicing factor binds to the 3' end of the intron and searches for a 5' ss across 
the downstream exon. (c) Factors on the 3' and 5' splice sites within 300 nt of 
each other then communicate across the exon to define it as the first unit of 
splicing. (d) Intron definition then takes place, where two exons across the long 
intron can communicate and initiate spliceosome assembly. 
 
The spliceosome is built sequentially on the transcript by assembly of complexes E, A, 
B and C on specific splice signals on the mRNA precursor [43] The process begins with 
the simultaneous binding of U1snRNP to the 5′ splice site, of splicing factor 1 (SF1) to 
the branch site, and the recognition of the 3’ splice site by the U2 snRNP auxiliary 
factor (U2AF). The association of U2AF with the 3'ss occurs through the binding of its 
subunits U2AF65 and U2AF35 to the pyrimidine tract and the 3' AG dinucleotide, 
respectively. This protein arrangement, called the early (E) complex, triggers the 
recruitment of U2 snRNP to the branch point to form the pre-spliceosome complex A.  
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Subsequently, a pre-assembled tri-snRNP containing U4, U5 and U6 associates with the 
developing spliceosome and triggers several rearrangements of the spliceosome: U4 is 
dissociated from the complex, U6 replaces U1 at the 5′ splice site, and the newly formed 
U6–U2 interaction brings the 5′-splice site and the branch point close together (Figure 
3). These structural and compositional rearrangements enable the formation of a 
catalytically activated spliceosome, which is necessary to support the two trans-
esterification steps of the splicing reaction. 
 
 
Figure 2: spliceosome assembly and mechanism of action 
Representation of the sequential assembly of splicing factors on the pre-mRNA 
and of the transesterification reaction during the splicing process. U1 and U2 
snRNPs first assemble on the 5' and 3'ss respectively and trigger the 
recruitment of the U4-U5-U6 tri-snRNP, which induces rearrangements of the 
spliceosome. The 5'ss and the adenosine branch point thereby brought close 
together can then initiate the transesterification reactions, leading to the 
release of the spliced mature mRNA and the debranched intron. 
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Introns are removed through a two-step splicing pathway set off by the catalytic core 
formed by U2, U5 and U6 snRNPs [44]. Upon base-pairing between U2 snRNA and the 
branch point sequence a complex conformation change occurs: the adenosine 
nucleotide rotates around the sugar-phosphate backbone and bulges out from the 
branch site-U2 snRNA duplex. This conformational change allows the branch site 
adenosine to present its 2′-hydroxyl (2'OH) directly into the catalytic site for the first 
step of splicing [45]. The activated complex B initiates the first step where the 2′-
hydroxyl of the branch point adenosine attacks the phosphate of the 5′-splice site. This 
splicing intermediate is then submitted to a second spliceosome rearrangement, giving 
rise to the complex C which catalyses the second trans-esterification step: the free 3′- 
hydroxyl of the cleaved 5' exon attacks the 5′ phosphate of the second, downstream 
exon. This ultimately leads to the excision of the intron and the ligation of the exons. 
The spliceosome is disassembled with the release of the final products of the splicing 
reaction: the spliced mRNA and the lariat intron. 
 
The importance of the conserved small RNAs in the splicing mechanism is crucial and 
there is growing evidence that some of them, in addition to binding the splice sites, also 
play a role in catalysis of the splicing reactions [47]. Two important catalytic domains 
where identified in U6 snRNA, where mutations trigger an arrest of the splicing 
reaction. The catalytic potential of spliceosomal snRNAs was further demonstrated as a 
protein-free U6–U2 complex was able to catalyse a covalent linkage with a short 
transcript containing the branch site consensus in vitro, without any help of proteins 
[48-49]. Although the exact nature of the spliceosome catalytic center is not yet clearly 
elucidated, the implication of snRNAs is becoming more and more apparent. 
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II. 1. 3. Secondary splice signals 
The major splice signals are highly degenerate and contribute only in part to the 
specificity of splicing: they are required for the recognition of exons by the spliceosome 
but contain only about half of the information needed to accurately define exon/intron 
boundaries [50]. Despite this concern, eukaryotic pre-mRNA splicing occurs with very 
high fidelity suggesting the widespread participation of additional sequences for accurate 
splicing. Numerous cis-regulatory elements that play important roles in the selection of 
splice sites have been identified [51]. These secondary splice signals are short and 
conserved sequences widely distributed within the pre-mRNA, in exons or in introns, 
and serve as either splicing enhancers or silencers. They are conventionally classified as 
exonic splicing enhancers (ESEs) or silencers (ESSs) and intronic splicing enhancers 
(ISEs) or silencers (ISSs). The secondary splice sites function by recruiting trans-acting 
regulators that activate or suppress splice site recognition or spliceosome assembly. Two 
major classes of splicing regulators are involved: the serine-arginine-rich (SR) proteins 
usually bind enhancer sequences and promote the recruitment of snRNPs to the 
spliceosome to favour splicing, while heterogeneous nuclear ribonucleoproteins 
(hnRNP) bind to silencer elements and inhibit the recognition of alternative exons. 
These proteins, through their RNA-binding domains, bind with low specificity to 
accessible pre-mRNA sequences that are preferentially in a single-stranded 
conformation [52], and use their protein interaction domains to bind to other proteins 
and overcome this weak specificity. The splicing regulatory elements lack precise 
consensus sequences and are therefore difficult to identify by simple analysis of their 
primary sequences. Different bioinformatic or experimental approaches have been used 
to identify potential ESEs and ESSs in exons [53-56], and a limited number of ISE and 
ISS elements have been identified in introns [57-58]. 
The potential for exon sequences to have an effect on splice site selection was first 
demonstrated 25 years ago [59], and it is nowadays widely recognised that many if not all 
exons contain splicing-regulatory sequences [51, 60]. The exonic splicing enhancers are 
the most characterised of these elements and most of them have a high purine content, 
although some non purine-rich sequences, such as the A/C-rich ESEs, can also act as 
enhancers [53, 61]. Most ESEs function by recruiting members of the serine-arginine-
rich (SR) protein family, which bind the exonic enhancers through their N-terminal 
RNA recognition motifs (RRM domain) and facilitate spliceosome assembly by 
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mediating protein-protein interactions through their C-terminal RS domains [62-63]. SR 
proteins that are bound to ESEs can also promote exon identification by antagonizing 
the action of silencer elements bound to nearby ESSs [64] (Figure 5).   
 
 
Figure 3: mechanisms of splicing activation 
The exonic splicing enhancer (ESE) sequence can recruit activators of splicing 
such as the SR proteins that bind to the RNA through their RNA recognition 
motifs (RRM) and can promote spliceosome assembly as well as block the 
action of adjacent silencers that are bound to nearby exonic splicing silencer 
sequences (ESS). 
 
 
Exonic splicing silencers (ESSs) are less well described than ESEs, although several of 
them have been characterised [64-65]. Their mechanisms of action involve the 
recruitment of splicing repressors of the heterogeneous nuclear ribonucleoprotein 
(hnRNP) class [66-67]. HnRNP proteins bind to silencer elements via their RNA-
binding domains (RRMs) and inhibit the splicing reaction by different mechanisms [34]: 
they can be in direct competition with splicing stimulatory factors by overlapping 
enhancer-binding sites and preventing essential interactions between ESEs and snRNPs 
(Figure 6a). HnRNP proteins can also bind to either side of an exon and inhibit 
splicing by ‘‘looping out’’ the portion of pre-mRNA to be silenced, making it 
inaccessible for splicing [68] (Figure 6b). A hnRNP, by binding to a strong inhibitory 
element, can also trigger the localised recruitment of more hnRNPs, which polymerise 
into complexes to coat the pre-mRNA and prevent spliceosome assembly [69] (Figure 
6c).  
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 Figure 4: mechanisms of splicing repression by hnRNP proteins 
a) hnRNPs can overlap ESE sequences when binding to an ESS and prevent the 
binding of splicing activating factors  
b) hnRNPs can loop out the portion of pre-mRNA to be silenced, making it 
inaccessible for splicing 
c) hnRNPs can polymerise into complexes to coat the pre-mRNA and prevent 
spliceosome assembly. 
 
 
The intronic regulatory elements are less well characterised. Their highly degenerate 
sequences make them difficult to detect and it is likely that many more intronic elements 
remain to be identified. A limited number of ISE and ISS elements have however been 
documented. A well characterized ISE is the G triplet (GGG) that can promote 
recognition of 5'ss or 3'ss [70-71], and it has been shown that intronic CA repeats can 
also constitute positive or negative regulatory elements of splicing [72]. 
The overall contribution of secondary sequences in splicing regulation has therefore 
been widely demonstrated but their mechanism of action is very complex and still not 
fully comprehended. Indeed, the various effects of these regulatory elements cannot be 
described too simplistically as it has been shown that their activities could depend on 
their relative locations in pre-mRNAs: for example the G triplets mentioned before, 
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known to enhance splicing from intronic locations, can also act as splicing silencers 
when located in exons [73]. Moreover, the effect of the regulatory sequences seems to 
be manifested only in the presence of relatively weak splicing signals as it has been 
shown that an exonic element can be easily overcome by strong flanking splicing 
elements [74]. Enhancer and silencer sequences can be adjacent or even overlapping on 
the pre-mRNA and, consequently, a competition between trans-acting factors for 
binding these regulatory sequences and for interacting with the spliceosome occurs [75]. 
A definite splicing event is thus the outcome of the cooperative or antagonistic 
interactions between the various regulatory elements, combined with the intrinsic 
strength of the flanking splice sites.  
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 II. 1. 4. Coupling between splicing regulation and other steps of gene 
expression 
The splicing process is part of a large network of gene expression mechanisms which 
are often tightly connected, both physically and functionally [77]. A well-described 
example is the coupling between splicing events and RNA transcription. The first 
evidence for cotranscriptional splicing in vertebrate has been demonstrated in the 
human dystrophin gene in 1995 [78], and nowadays many introns are thought to be 
spliced cotranscriptionally [79-81]. Splicing factors can have extensive physical 
interactions with the core transcription machinery, as has been shown for SR proteins 
that associate with the C-terminal domain of RNA polymerase II [82-84], and the 
transcription elongation rate can directly influence the splicing pattern of a pre-mRNA. 
Conversely, splicing factors that bind to the nascent messenger RNA can stimulate 
transcription by promoting polymerase elongation [85]. These two processes are 
therefore tightly coupled and can be reciprocally influenced [86]. 
There are also possible connections between splicing and polyadenylation processes 
[87]. For the definition of the 3'-terminal exon at the end of transcription, splicing 
factors on the upstream 3'splice site communicate across the terminal exon with the 
polyadenylation machinery on the downstream poly(A) signal. The result is a mutual 
enhancement of both processes, where the polyadenylation apparatus assists in the last 
exon definition and enables last intron splicing, whilst the splicing machinery also helps 
the polyadenylation activity [88-89]. 
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II. 2. Alternative splicing 
In higher eukaryotes there is an important inconsistency between gene number and 
complexity of the organism, implying that the number of proteins must be much higher 
than the number of genes. Indeed, in humans up to ten times more functional proteins 
than expected could be produced from the 30 000 genes in the human genome [76]. 
The mechanism most widely used to expand protein diversity is alternative splicing. 
Alternative pre-mRNA splicing (AS) is a central mode of genetic regulation in higher 
eukaryotes which enables to increase the number of proteins that can be synthesized 
from each gene by modulating the inclusion or exclusion of a portion of coding 
sequence in the mRNA. A single pre-mRNA can have multiple splicing patterns that 
generate numerous mature mRNAs, ultimately giving rise to functionally distinct protein 
isoforms that differ in their peptide sequence, enzymatic activity, ligand binding, 
subcellular localization, stability, post-translational modification, and protein folding 
[90]. This source of protein diversity is important in many cellular and developmental 
processes and is often regulated in a tissue-specific manner. A recent estimate showed 
that more than 90% of human transcripts are alternatively spliced [9]. However, the 
functional significance of most of these numerous AS events is still unknown and only a 
small proportion of them have characterised biological roles [91].  
There are different patterns of alternative splicing described in nature  [92] (Figure 8). 
A single alternative exon situated between two constitutive exons can be either skipped 
or included in the mRNA. Alternatively, multiple cassette exons can reside between two 
constitutive exons and be included in a mutually exclusive manner so that only one exon 
in the group is included at a time.  Exons can also have multiple 5' or 3' splice sites that 
are alternatively used to produce an extended or shortened exon. Additionally, the use 
of alternative promoters or alternative polyadenylation sites can alter the selection of the 
5′ or 3′ most exon and modify the length and composition of the transcript. Introns, 
which are usually removed from the mature messenger, can be retained in the mRNA 
and become translated. All these different patterns of alternative splicing are not 
exclusive and several can be combined in a single transcript to produce a vast number of 
distinct mRNAs. 
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 Figure 5: patterns of alternative splicing 
Representation of the different models of alternative splicing that can give rise 
to various mature mRNAs producing functionally distinct protein isoforms from 
the same precursor transcript. The green lines represent normal splicing 
patterns and the red lines depict alternative patterns.  
 
 
- Mechanism and regulation of AS 
Alternative splicing is predominantly regulated by the combinatorial recruitment of 
trans-acting splicing factors to specific RNA motifs on the pre-mRNA, the regulatory 
enhancers or silencers sequences mentioned earlier [93]. The auxiliary splice sites are 
highly degenerate but are important in defining constitutive and alternative exons. The 
decision to include or skip an exon in an mRNA primarily depends on the strength of 
the flanking splice signals. If the major splice sites flanking an exon are weak, the 
relative enrichment of this exon in ESE/Ss or ISE/Ss enables to define its frequency of 
inclusion. The exonic elements have been reported to mostly play roles in constitutive 
splicing but many have also been identified in tissue specific or developmentally 
regulated exons, which usually have weak splice sites and require the ESE for inclusion 
[53]. On the other hand, intronic regulatory elements seem to play a critical role in 
alternative splicing regulation as the intronic regions surrounding alternative exons are 
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more conserved in mammals than those surrounding constitutive exons. The activity of 
these regulatory elements depends on the availability of the associated splicing 
regulatory proteins, which can be expressed at different levels in different tissues. 
During alternative splicing, a particular splice signal can therefore be selected or ignored 
depending on the cellular state and the combination of splicing factors, and this 
phenomenon is probably responsible for most of the tissue-specific splicing. 
Although it is clear that the splice signals contribute largely to the regulation of 
alternative splicing, this mechanism is a multifactorial process and other cellular events 
are implicated [94]. As pointed out earlier, most introns are thought to be spliced 
cotranscriptionally and the splicing machinery is physically linked to the transcriptional 
apparatus. A significant role for the transcription machinery in the regulation of 
alternative splicing is therefore emerging. Various studies demonstrated that alternative 
splicing is sensitive to RNA polymerase II elongation rate: pausing or slowing down the 
polymerase increases the time an exon can recruit the splicing machinery and favours 
exon inclusion [81]. One can therefore hypothesised that some splicing regulatory 
sequences could act as transcription pause sites to enable the inclusion of a weak exon 
[51]. Possible connections have also been suggested between alternative splicing and 
polyadenylation. Patterns of alternative splicing and alternative cleavage and 
polyadenylation are highly correlated across tissues, suggesting that some common 
tissue-specific RNA-binding factors could coordinate the regulation of both processes 
[9].  
The chromatin can also act as a regulator of alternative splicing. In regions dense with 
nucleosomes, such as compacted chromatin, the elongation rate of the transcription is 
slower than in open chromatin regions. Interestingly, alternative exons that are not 
always included are less enriched in nucleosomes than constitutive exons [95], which 
suggests a link between chromatin structure and alternative splicing regulation. It can be 
speculated that a high density of nucleosomes in an exon promotes the pausing of the 
RNA polymerase II and enables the recruitment of the spliceosome. Histone 
modifications and DNA methylation may also contribute to splicing regulation. 
Different histone modification signatures have been shown to correlate with particular 
splicing patterns in several human genes, and an alteration of these signatures can 
induce a splice site switch [96-97]. For example for splicing events dependent on the 
splicing factor PTB, it has been shown that histone marks can promote the recruitment 
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of trans-factors to the pre-mRNA via formation of a chromatin-splicing adaptor 
complex. The chromatin-binding adaptor protein MRG15 acts as a new regulator of 
alternative splicing by recognizing the histone modification H3-K36me3 and recruiting 
the splicing repressor PTB to the pre-mRNA, inducing forced exclusion [98].  
In addition, the secondary structure of the pre-mRNA can also influence splice site 
selection by masking or revealing particular splice signals. The formation of stem-loop 
structures between flanking sequences of an alternatively spliced exon enables to 
regulate the usage of the looped-out exon and lead to its skipping [99-100]. 
Alternative splicing events can also be regulated by cell signalling and external stimuli, 
such as growth factors, cytokines, hormones, and stress [101]. The activation of cellular 
signal transduction pathways can trigger the phosphorylation of trans-acting splicing 
factors, which induces a change in their activity, expression and interaction with the pre-
mRNA. The modulation of these kinase cascades can alter splice site selection and 
therefore influence alternative exon usage [102-103]. 
A role for non-coding RNAs as novel regulators of alternative splicing is also emerging. 
It has been shown that microRNAs can regulate the expression of important splicing 
factors during development and differentiation. In early myoblasts, the splicing factors 
PTB and nPTB repress the splicing of some muscle-specific exons. When the 
differentiation occurs, the muscle-restricted microRNA miR-133 is upregulated and 
silences the nPTB repressor, thus allowing the inclusion of PTB-repressed exons [104]. 
Another example of ncRNAs implicated in alternative splicing is the brain-specific small 
nucleolar RNA HBII-52 that can bind by sequence complementarity to an exonic splice 
silencer on the serotonin receptor 5-HT2C pre-mRNA. This direct sequence-specific 
association seems to prevent the binding of a splicing repressor on the transcript and 
favours the inclusion of the alternatively spliced exon [105-106].  
It is therefore evident that alternative pre-mRNA splicing is a very complex and tightly 
regulated mechanism that controls important developmental and tissue-specific 
programs and that can be modified by numerous factors. The downside of this overall 
complexity, which is necessary for proteome diversity in complex organisms, is that it 
also increases the potential for errors. Various mis-splicing events can arise from defects 
in regulatory factors or splice site selection, which can have dramatic effects and lead to 
numerous genetic diseases.  
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II. 3. Diseases caused by splicing defect 
Considering the wide array of factors and sequences playing crucial roles in regulation of 
pre-mRNA splicing, it is important to consider that variations occurring virtually 
anywhere within a gene could potentially alter or impair the splicing process [107]. 
Simple point mutations in the pre-mRNA can inactivate splice signals or create new 
cryptic ones, and even a silent mutation can result in splicing dysfunction and have 
important pathological effects [33, 108]. More than 15% of point mutations inducing a 
genetic disease affect pre-mRNA splicing [109] and the mRNAs then produced are 
often out of frame and contain premature stop codons. These incorrectly spliced 
transcripts are subjected to two different outcomes: their translation can still take place 
and result in the production of aberrant or truncated proteins, some of which would not 
be functional but others displaying dominant functions that can negatively affect the 
cells. Another fate for mis-spliced mRNAs is their direct degradation in nonsense-
mediated decay (NMD) [110]. This mRNA surveillance system in eukaryotes is able to 
detect premature stop codons in newly spliced mRNAs and to induce their rapid 
degradation [111]. 
Different types of pre-mRNA mutations affect the splicing process and can cause 
disease and they can typically be classified in two groups: mutations that affect the 
canonical splice signals, or mutations that affect other important regulatory elements, 
either in cis or in trans.  
 
II. 3. 1. Mutations in the consensus splice signals 
It has been estimated that 60% of all the splicing-associated mutations occur in the 
invariant splice site sequences [112]. Mutations that destroy natural donor splice site (5' 
ss), acceptor splice site (3' ss) or branch point abolish exon recognition and usually 
result in complete exon skipping [109]. The resulting mRNAs often contain premature 
stop codons, which prevent the synthesis of the corresponding protein and therefore 
trigger a disease (Figure 10a). This is the case for a substitution in the 5' splice site of 
exon 20 of I-kappa-B kinase complex associated protein (IKBKAP) gene that induces 
exon 20 skipping and results in familial dysautonomia [113].  
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However, in some cases the inactivation of a consensus splice signal leads to other mis-
splicing events such as the activation of cryptic splice sites, the retention of an intron or 
the inclusion of a pseudoexon. The occurrence of these alternative events depends on 
the local context of the mutation as similar mutations in other contexts can cause exon 
skipping. 
The activation of cryptic splice sites is after exon skipping the most frequent outcome 
that follows the inactivation of strong natural splice site [114]. The use of cryptic sites, 
which are generally weak signals, often leads to the exclusion of an exon or the inclusion 
of an intron, in part or in totality, ultimately inducing a frameshift in the protein coding 
sequence (Figure 10b). A well known example occurs in the β-globin gene after 
mutation of consensus donor or acceptor splice sites and is associated with forms of β-
thalassemia [115-116]. Alternatively, a mutation of a donor splice site can induce 
aberrant intron retention in the transcript, which has been associated with numerous 
mis-splicing diseases such as Leigh syndrome [117] (Figure 10c). Consensus splice site 
mutations can also result in the inclusion of pseudoexons, which are intronic sequences 
that are flanked by consensus splicing signals but are not recognized by the splicing 
machinery and are normally excluded from the mRNA [118]. The splice sites 
surrounding a pseudoexon are generally weak but various mutations can either increase 
the strength of these sites or instead weaken the invariant splice sites of nearby exons, 
increasing the probability of pseudoexon inclusion in the processed mRNA (Figure 
10d). Pseudoexon inclusions often generate premature termination codons and result in 
human diseases. This is the case in some forms of Becker muscular dystrophy where a 
mutation strengthening a potential 3' splice site of an intronic "false exon" in the 
Duchenne muscular dystrophy (DMD) gene triggers the aberrant inclusion of this 
pseudoexon in the mature transcript, which becomes out-of-frame [119]. 
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 Figure 6: mutations affecting the consensus splice signals and consequences 
on the mature transcript  
(a) A mutation of the acceptor splice site at the 3' end of an intron can lead to 
the exclusion of the downstream exon in the mature mRNA; 
(b) The creation of intronic or exonic cryptic splice sites in the premature 
transcript can induce the inclusion of an intron or the exclusion of an exon in 
the mRNA, in part or in totality; 
(c) The inactivation of a donor splice signal leads to the inclusion of intronic 
sequences in the transcript; 
(d) A mutation in an intronic sequence with pre-existing weak splice signals 
can alter one of these sites into consensus signals, leading to the recognition of 
the intronic sequence as pseudoexon and to its inclusion into the mRNA.  
These various events often lead to the creation of premature stop codons in the 
mature mRNA, which prevent the synthesis of the corresponding protein.    
 
 
II. 3. 2. Mutations in the regulatory elements of introns and exons 
The second type of pre-mRNA mutations that affect the splicing process targets the 
variable intronic or exonic splicing motifs. These mutations can lead to aberrantly 
spliced transcripts by weakening or strengthening splicing recognition motifs and are 
associated with a large number of diseases [34].  
A well-described example of mutations in the regulatory elements of exons is a point 
mutation found in the survival of motor neuron (SMN) gene that does not change the 
amino acid code but is associated with spinal muscular atrophy (SMA). In humans, there 
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are two copies of the SMN gene, SMN1 and SMN2, and inactivation of the SMN1 gene 
leads to SMA as the SMN2 isoform is unable to compensate the loss of SMN1. This is 
due to the fact that the SMN2 gene contains a silent C to T substitution in exon 7 that 
disrupts an exonic enhancer (ESE) normally recognized by the splicing activator 
SF2/ASF [120] and enables the activation of a silencer element (ESS) recognized by the 
splicing suppressor hnRNP A1 [121-122]. This mutation significantly alters the splicing 
pattern of the SMN2 pre-mRNA and predominantly induces the skipping of exon 7. An 
average of 80% of SMN2 mRNAs lack exon 7, leading to the production of a truncated 
protein, and the severity of SMA in patients depends on the level of residual functional 
SMN protein. 
Some mutations can also alter the balance of alternatively spliced transcripts. For 
example, the microtubule-associated protein tau (MAPT) gene contains four enhancer 
and three silencer regions in exon 10, which is alternatively spliced in a highly regulated 
manner both spatially and temporally. This alternative splicing event give rise to two 
mRNA isoforms, containing or not the exon 10, and the ratio of the corresponding 
proteins is precisely controlled in the brain. Mutations in MAPT exon 10 can disrupt 
either a silencer or an enhancer region and therefore increase or decrease the frequency 
of exon 10 inclusion in the mRNA. Such mutations alter the ratio of protein isoforms 
generated by alternative splicing and induce various neuropathologies, called 
tauopathies, such as frontotemporal dementia with parkinsonism associated with 
chromosome 17 (FTDP-17) [22, 123]. 
Some diseases can also stem from a change in length of short repeat elements that can 
change the balance of alternative splicing regulation. These short sequence repeats, 
called triplet repeats, are naturally present in exons and enable to increase their 
recognition by certain splicing factors. The number of these repeats varies between 
individuals but can cause disease when they expand beyond a normal threshold. One 
form of Myotonic dystrophy, DM1, is caused by the extension of a CUG repeat in the 
DMPK gene, inducing a gain of function of the transcript. The CUG element normally 
binds to the Muscleblind-like1 (Mbnl1) binding protein but an extension of the repeats 
induces an abnormal sequestration of this protein and reduces its cellular concentration 
(Figure 12). The sequestrated protein is therefore unavailable to modulate the Mbnl1-
dependent alternative splicing of a set of genes, which ultimately leads to aberrant 
splicing and disease [124]. 
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Figure 7: microsatellite expansions in DMPK gene cause MBNL1 protein 
loss-of-function 
In myotonic dystrophy DM1, abnormal expansions of CUG repeats in DMPK 
transcripts induce the sequestration of MBNL1 proteins that become 
unavailable for splicing regulation of various transcripts. 
 
 
II. 3. 3. Mutations in trans-acting splicing factors  
Only few mutations in core elements of the splicing machinery have been described, 
even though the spliceosome is composed of a large number of proteins, which could 
imply that such mutations are often lethal. However, some diseases have been 
associated with mutations in genes encoding pre-mRNA splicing factors. For example, a 
severe autosomal dominant form of retinitis pigmentosa is caused by mutation of the 
splicing factor PRP8 [125], and Frontotemporal lobar dementias develop from the loss 
of TDP43, a member of the heterogeneous nuclear ribonucleoproteins (hnRNP) family 
of proteins [126]. Numerous studies have also demonstrated specific defects in the 
expression of splicing factors that are associated with cancer [23]. For example, an 
overexpression of the SR protein SF2/ASF in several cancers has been shown to 
promote cell transformation by inducing mis-splicing of different genes: SF2/ ASF 
controls alternative splicing of the oncogene Ron by binding to regulatory elements 
within exon 12, and the overexpression of SF2/ASF stimulates the skipping of 
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upstream exon 11 and increases the level of a tumor-associated isoform of Ron, which 
is sufficient to transform cells in culture [127].  
Another example is the modulation of alternative splicing of the Pyruvate Kinase (PK) 
pre-mRNA in tumor cells through the activation of hnRNP splicing repressors. The PK 
gene catalyses the production of Pyruvate in the glycolysis pathway. PK produces two 
mRNA isoforms, PKM1 and PKM2, by alternative splicing of two mutually exclusive 
exons, exons 9 and 10 respectively. In differentiated non-dividing cells, exon 9 is 
predominantly included to produce PKM1 mRNA, which channels Pyruvate towards 
the Krebs cycle. Conversely, in actively replicating cells and tumor cells exon 10 is 
included and high levels of PKM2 species are produced, leading to the degradation of 
Pyruvate into Lactate, which is advantageous for rapidly replicating cells [128]. The 
relative amounts of PKM1 and PKM2 expressed in cells therefore determine the 
metabolic status of the cells, which in turn influence their state of differentiation, 
proliferation and oncogenic transformation. The PK pre-mRNA alternative splicing 
process is regulated by splicing factors interacting with splicing enhancers or inhibitors 
located in exon 9 and 10 [129-130]: in tumor cells the oncogenic transcription factor c-
Myc upregulates the transcription of splicing repressors hnRNP A1, A2 and PTB, which 
then associate with exonic splicing silencers signals located in exon 9, resulting in the 
repression of exon 9 in favour of exon 10 inclusion and in the PKM2-induced 
proliferation and transformation of cancer cell lines [129-130].  
Numerous other splicing factors display an aberrant expression in cancer, it is however 
not clear whether these changes are the cause or consequence of cancer formation and 
tumor progression [131]. Additionally, mutations that affect splicing of tumor 
suppressor genes have been reported as cancers predisposition factors. This is the case 
of the BRCA1 gene where a point mutation disrupting an ESE sequence induces the 
skipping of exon 18, thereby predisposing to breast and ovarian cancer [132].  
Finally, a snoRNA (HBII-52) has been described as a novel trans-acting regulator of 
alternative splicing and shown to influence the splicing of the serotonin receptor 2C 
mRNA by binding to a silencing element in exon Vb [105] (Figure 13). Patients with 
the Prader–Willi syndrome have lost paternal expression of some maternally imprinted 
genes, including the C/D-box snoRNA HBII-52, which triggers the formation of an 
isoform of the serotonine receptor with diminished activity and causes the disease [28]. 
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Figure 8: regulation of alternative splicing by the snoRNA HBII-52 
HBII-52 snoRNA partially blocks a silencer element located in alternative exon 
Vb of human 5-HT2CR receptor and promote its inclusion to produce a 
functional protein. The snoRNA is represented in red in exon Vb. 
P and D indicate the proximal and distal splice sites in exon Vb of 5-HT2CR 
pre-mRNA, and UAA(P) and UAA(D) represent the stop codons resulting from 
their usage. 
 
Numerous defects in a wide array of factors are therefore likely to affect splicing and 
result in various genetic diseases. As this type of diseases present a real challenge for 
conventional therapies, it is becoming more and more important to find strategies that 
can overcome the deleterious effects of these mutations and restore or correct the 
processing of pre-mRNAs.  
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III. Strategies to modulate splicing  
Knowledge of the molecular basis of splicing defects has offered the possibility of 
intervening on mRNA and various strategies have emerged over the years aimed at 
modulating pre-mRNA splicing in order to correct splicing-associated defects. These 
include the use of chemical substances that can act as modulators of alternative splicing 
and influence splice site selection [133]. The mechanisms of action of these substances 
are varied: kinase or phosphatase inhibitors can be used to modulate the state of 
phosphorylation of SR protein domains and alter SR proteins interactions, thereby 
modifying their action on alternative splice sites [103, 134-135]. Some other compounds 
act as histone deacetylases (HDAC) inhibitors and enable to maintain the chromatin in 
an open, transcriptionally active structure, which can allow increasing the transcription 
of genes such as splicing regulatory factors [136-137]. Alternatively, some substances are 
able to induce the readthrough of premature stop codon mutations present in disease-
associated pre-mRNAs through their association with the ribosome. The readthrough of 
stop codons can be beneficial within an in-frame mRNA in order to maintain the 
production of a partly functional protein and this strategy has shown some successes for 
various splicing-associated diseases such as Duchenne muscular dystrophy [138-139]. 
However, the major downside of most of these chemical substances is their lack of 
specificity: their broad mechanism of action implies that genes or transcripts unrelated 
to the disease might also be aberrantly altered, which can have dramatic consequences.  
On the other hand, other splicing modulation strategies present a high degree of 
specificity for the targeted pre-mRNA and seem therefore favoured and more promising 
for the treatment of splicing-associated diseases. Here, we detail the antisense 
oligoribonucleotide technology that is used for the steric blocking of splice signals in 
order to modulate the splicing pattern of mutated pre-mRNAs and recover mature 
transcripts able to produce functional proteins. The development of a targeted 
methylation strategy used to inactivate splice signals through the use of modified small 
nucleolar RNAs is also considered. 
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III. 1. Antisense RNA to modulate gene expression at the post-transcriptional 
level  
The correction of aberrant pre-mRNA splicing can be achieved with the use of 
antisense oligoribonucleotides (AON) [140]. AONs are small synthetic antisense RNA 
molecules that bind to a specific target sequence by Watson-Crick complementarity. 
These antisense sequences can be used to modulate gene expression at the post-
transcriptional level by masking important regulatory sequences in the pre-mRNA; in 
particular they have been extensively used to redirect and correct the splicing of a 
mutated pre-mRNA in order to restore the function of a defective gene [141]. AONs 
designed to mask key splice motifs can alter the splicing pattern of a pre-mRNA by 
preventing spliceosome assembly on the precursor and forcing it to recognize 
alternative signals. This strategy, which was first demonstrated to correct the aberrant 
splicing of β-globin pre-mRNA associated with β-thalassemia [142], presents the 
remarkable advantage of allowing therapeutic intervention on native transcripts within 
their normal regulatory environments. This RNA-based approach has therefore become 
widely used as a tool in molecular genetic studies or in therapeutic approaches to 
counter the deleterious effects of splicing-associated mutations [143]. 
 
III. 1. 1. Antisense RNA: design and chemistry 
- Antisense oligoribonucleotides design 
The design of AONs for therapeutic pre-mRNA processing modulation can prove very 
challenging [144]. Many factors have to be taken into account when conceiving 
antisense sequences against new pre-mRNA targets to ensure a strong and stable 
interaction between the AON and the target and effective splicing modulation [145].  
First, the antisense needs to be able to reach its target for efficient base-pairing, implying 
that the two molecules must co-localize in the cell and that the secondary structure of 
the target transcript must be favourable. The accessibility of the target is a major 
determinant of AONs efficacy and an accurate prediction of the secondary structure of 
the pre-mRNA is therefore really important. Several software programs give an estimate 
of all possible structures of a particular RNA sequence, one of the most widely used 
being the mfold program [146]. AONs are generally unable to target a mRNA region 
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with very stable local structure, such as a stem-loop, and usually show the highest 
activity against targets with the least amount of secondary structure [147]. It has also 
been suggested that AONs that target partially closed (but still accessible) regions could 
be more potent than antisense sequences against unstructured, highly accessible regions. 
This observation implies that, in addition to the steric blocking of regulatory factors, the 
binding of an AONs to its target could also function by disrupting important secondary 
structures [148]. 
The second important factor to take into consideration is the thermodynamic energy of 
the AON-target complex, which depends on AON length, sequence composition and 
the free energy of local structures. To efficiently bind a target sequence, the binding 
energy between the AON and the target must be thermodynamically stable and higher 
than the free energy of the predicted secondary structures of both the target and the 
oligonucleotide [145]. Moreover, the energy of the AON-target mRNA must be high 
enough to effectively compete with the natural binding of splicing factors on the pre-
mRNA. These parameters can be evaluated in silico with the help of various softwares, 
such as OligoWalk that predicts the thermodynamic affinity of complementary 
oligonucleotides to a structured mRNA target [149]. 
It is however difficult to assess and validate all these parameters when designing a new 
antisense molecule and it is not guaranteed that a molecule that finally meets these 
requirements will actually be effective to induce the desired splicing switch. To increase 
the chances of designing a potent AON, various computational algorithms can prove 
very useful. However in practice the efficiency of these molecules needs to be addressed 
by screening many different AONs targeting adjacent sites on a pre-mRNA in order to 
determine the best antisense sequence. 
To add to the complexity of antisense sequences design, one needs to consider the high 
variability in expression of splice variants between individuals. It has indeed been shown 
that up to 30% of splicing events display individual-specific differences [9], and it may 
eventually be important to take into account the effects of genetic variation on the 
splicing code in order to provide efficient personalized therapy. 
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- Antisense oligoribonucleotides chemistry 
Unmodified AONs penetrate through the cell membrane with difficulty and are rapidly 
targeted and degraded by nucleases before being able to act on splicing. Various 
chemical modifications of AONs were therefore developed, enabling to enhance 
nuclease resistance, increase the intracellular stability, improve target affinity and 
enhance cell penetration and nuclear accumulation [145].    
The first generation of AONs contained a phosphorothioate (PS) modification on the 
backbone, which improved the resistance to nuclease activity but also decreased the 
affinity to the target mRNA. A second generation of antisense chemistry was therefore 
designed, which involved the addition of residues at the 2’ position of the ribose in the 
oligonucleotide. 2’-O-Methyl (2’-O-Me) and 2’-O-methoxyethyl (2’-MOE) 
modifications provided a higher nuclease resistance to the AONs and enhanced their 
binding affinity for the target. These carbohydrate modifications are probably the most 
widely used AON chemistries for splicing modulation [150]. Finally, a later generation 
of AONs was fashioned to further improve the characteristics of the molecules. These 
developments involved various chemical modifications of the nucleotide backbone and 
further enhanced the affinity for target sequences and improved biostability and 
resistance to nucleases [151]. Amongst these new-generation AONs, the three most 
studied and used are phosphoroamidate morpholino oligomers (PMO) [152], peptide 
nucleic acids (PNA) [153], and locked nucleic acids (LNA) [154].  
The steric blocking of mutations or splice signals on the premature transcript can have 
different applications (Figure 15): AONs can be used to inactivate cryptic splice sites or 
to block the recognition of pseudoexons, thereby forcing the alternative splicing of the 
pre-mRNA to recover the normal splicing pattern; they can also mask natural splice sites 
to induce the skipping of a mutated exon and recover an in-frame mRNA depleted of 
an exon, or to induce the re-inclusion of aberrantly excluded exons. Finally, a novel 
technology based on the use of bifunctional antisense molecules enables to trigger a 
trans-splicing mechanism, where a sequence exchange between a mutated target pre-
mRNA and a therapeutic tailed antisense molecule occurs. 
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Figure 9: antisense RNA strategies to modulate splicing 
Various splice signals, aberrant or normal, can be masked by AONs in order to 
modulate the splicing of disease-associated pre-mRNAs and restore the 
synthesis of functional proteins. (a) The masking of cryptic splice sites enables 
to recover the correct splicing pattern of the pre-mRNA; (b) blocking aberrant 
intronic splice signals enables to inhibit the inclusion of a pseudoexon; (c) 
masking a natural splice signal can promote the skipping of the downstream 
mutated exon. 
 
III. 1. 2. Cryptic splice sites inactivation 
Successful AON-mediated restoration of correct splicing has been demonstrated for 
various diseases triggered by cryptic sites activation (Figure 15a). A mutation generating 
an aberrant 5’ ss in exon 55 of the Ataxia telangiectasia (ATM) gene causes exon 55 
truncation and generates an out-of-frame transcript. The effect of this mutation was 
countered by blocking the aberrant splice site with PMO oligonucleotides, thereby 
restoring some correctly spliced transcripts [155]. This approach has also been 
successfully used to correct intronic cryptic site activation in the β-globin gene causing 
thalassemia [156] or in the CFTR gene in cystic fibrosis [157]. 
A similar strategy can be used to counter the aberrant inclusion of a pseudoexon in an 
mRNA (Figure 15b). In the same way as for the inactivation of cryptic splice sites, 
AONs can sterically block the abnormal splice site responsible for the pseudoexon 
inclusion and retarget the splicing machinery to the natural sites. This approach has 
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been successfully used to block the recognition of a cryptic donor site generated by a 
point mutation in intron 9 of the NPC1 gene that results in the inclusion of a 
pseudoexon in the mRNA and is associated with Niemann-Pick disease [158]. Similarly, 
an intronic mutation in CEP290 pre-mRNA that creates an aberrant splice donor site 
and results in the inclusion of a cryptic exon has been associated with Leber congenital 
amaurosis (LCA), a severe form of retinal dystrophy. AONs directed against the cryptic 
splice site were successfully used to prevent the inclusion of this aberrant pseudoexon 
and restore the normal splicing pattern of CEP290 pre-mRNA in immortalized 
lymphoblastoid cells or fibroblasts of LCA patients [159-160]. 
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III. 1. 3. Exon re-inclusion 
Antisense oligonucleotides can also block intronic or exonic splicing silencers (ESSs or 
ISSs) and mediate the re-inclusion of aberrantly repressed exons. A classical example of 
this approach is the reintroduction of exon 7 in SMN2 mRNA to restore SMN 
expression, which is developed as a treatment for patients with spinal muscular atrophy 
(SMA). It has been demonstrated that blocking either of two identified ESS elements in 
SMN2 exon 7 with 2’-MOE antisense sequences efficiently induced the inclusion of 
exon 7 in vitro [161]. Alternatively, a 2’-MOE oligonucleotide targeting an intronic 
sequence (ISS) within intron 7 of SMN2 greatly enhanced the inclusion of exon 7 in the 
mRNA, both in vitro and in vivo [162-163].  
Another novel approach to induce the re-inclusion of an exon consists of using 
bifunctional RNAs that are composed of an antisense sequence moiety, responsible for 
binding the complementary target sequence, and a tail effector domain containing a 
splicing regulatory sequence (ESE) for the recruitment of known trans-acting splicing 
factors to mediate activation or silencing of the targeted exon [164] (Figure 17).  This 
strategy, called TOES (targeted oligonucleotide enhancer of splicing) when involving 
the recruitment of splicing enhancer factors such as SR proteins, has been tested for the 
inclusion of SMN2 exon 7 for the treatment of SMA. Tailed 2'-O-methyl antisense 
oligonucleotides carrying an antisense element binding exon 7 and an ESE tail 
successfully triggered the recruitment of SR proteins and promoted exon 7 inclusion in 
SMN2 mRNA, leading to partial recovery of SMN protein in SMA patient fibroblasts 
[164].  
 
Another approach that uses bifunctional reagents to correct aberrant splicing by 
inducing exon inclusion is called ESSENSE (exon-specific splicing enhancement by 
small chimeric effectors). This involves novel hybrid molecules that couple an antisense 
domain for specific sequence targeting with a peptide effector moiety composed of 
arginine-serine (RS) repeats that mimic the effect of authentic SR proteins and therefore 
promote the activation of the targeted exon. These chimeric molecules were proven 
effective at reproducing the functions of SR proteins and restoring correct splicing by 
promoting exon inclusion in BRCA1 or SMN2 pre-mRNAs [165] 
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III. 1. 4. Exon skipping  
Another application of antisense-mediated splicing modulation involves the blocking of 
natural splice sites to induce the skipping of a mutated exon and restore the disrupted 
reading frame of a transcript [166]. By masking key splicing motifs, the spliceosome is 
prevented from recognizing the exon as such and the machinery therefore "skips" to the 
next available set of splice sites on the pre-mRNA, inducing the exclusion of the exon 
along with its surrounding introns (Figure 15c). The requirements for such a strategy 
limit the range of candidate diseases: first the removal of the exon must still allow the 
recovery an in-frame mRNA; secondly the skipped exon must not correspond to a 
crucial region of the protein so that its depletion gives rise to an internally deleted but 
still functional protein. A highly studied example of diseases that can be targeted by this 
mechanism is Duchenne Muscular Dystrophy (DMD), where various missense 
mutations and deletions in the dystrophin gene often result in the generation of 
premature stop codon and absence of functional protein. The dystrophin gene is a good 
candidate for AON-mediated exon skipping as its central region is composed of 
repetitive exons. AONs have been shown to efficiently induce skipping of different 
mutated exons within the repeated region of the gene, leading to the production of a 
truncated protein that still significantly improves the phenotype [167]. This application 
will be further detailed hereafter. 
AON-mediated exon skipping has also been used to disrupt the reading frame of an 
mRNA and silence the expression of disease-associated genes. The blocking of different 
splice sites or ESE sequences within apolipoprotein B (apoB) exon 27 was shown to 
efficiently induce exon 27 skipping and produce a mRNA that is translated into a 
truncated isoform, thereby triggering a downregulation of apoB expression and 
providing a potential way to reduce cholesterol levels for patients with 
hypercholesterolemia [168]. 
As previously mentioned for exon re-inclusion approaches, bifunctional RNAs can also 
be used for exon skipping applications by introducing an ESS sequence into the tail 
effector domain of the chimeric RNA, in which case the method is called TOSS 
(targeted oligonucleotide silencer of splicing). The silencing effector domain thus 
attracts splice silencers such as hnRNP proteins near the exon to be skipped and 
provoke its exclusion [169]. 
48 
 
 III. 1. 5. RNA trans-splicing  
Several mis-splicing defects can also be corrected via an alternative splicing modulation 
approach that involves trans-splicing. This mechanism, which naturally exists in various 
organisms, consists of the mutual splicing of two independent pre-mRNAs to form a 
fused final mRNA [170-171]. This biological process has been derived for therapeutic 
purposes into spliceosome-mediated RNA trans-splicing (SmaRT), a technique that 
enables the splicing machinery to realise a sequence exchange between a mutated target 
pre-mRNA and a repair RNA molecule with functional exons, called pre-trans-splicing 
molecule (PTM) [172]. This molecule contains a binding domain complementary to an 
intronic sequence situated upstream of the targeted defect and a 3' tail composed of a 
branch point, a polypyrimidine tract, the AG dinucleotide acceptor splice site and the 
corrected cDNA 3' end terminated by a poly A site (Figure 19).  
This technique can be applied to correct many mis-splicing diseases, an example being 
the correction of SMN2 splicing in Spinal Muscular Atrophy. In this case the PTM 
molecule targets intron 6 of SMN2 pre-mRNA and contains a replacement SMN1 exon 
7 to be incorporated in the final trans-processed mRNA. To enhance the trans-splicing 
process between the two molecules and repress cis-splicing of the target, an AONs 
targeting the 3' ss of SMN2 exon 8 was co-administered alongside the PTM to block the 
recognition of this exon in cis [173]. The trans-splicing of the two transcripts occurred, 
even if with moderate efficiency, as a mouse model carrying human SMN2 transgenes 
that was administered with this PTM-AON cocktail showed increased levels of SMN 
protein [174]. SmaRT was also designed to correct the mutated CFTR pre-mRNA in 
cells from cystic fibrosis (CF) patients [175]. 
This approach brings the possibility to correct the splicing of a transcript not suitable 
for single exon modulation applications, such as exon skipping or re-inclusion. 
Moreover, a single pre-trans-splicing molecule is able to correct multiple mutations 
located downstream of the hybridization site in a same pre-mRNA. This advantage is 
valuable for mis-splicing diseases treatment as it abolishes the need to design a different 
therapeutic molecule for each different mutation of a given mRNA. For many splicing 
diseases an AON is usually designed to be mutation-specific and has to be considered 
each time as a new drug that require full pre-clinical and clinical studies , which would 
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prove to be very expensive for a drug suitable for only a small number of patients. By 
being able to correct a variety of mutations in a target mRNA with a single therapeutic 
molecule, SmaRT could therefore provide treatment for a larger population of patients 
with one drug. Although very promising, the efficiency of this strategy is however still 
low and could benefit from many improvements. 
 
 
Figure 10: spliceosome-mediated RNA trans-splicing (SmaRT) 
The PTM (pre-trans-splicing molecule) repair construct (purple) contains a 
binding domain complementary to an intronic sequence situated upstream of 
the defect in the target pre-mRNA, and a 3' tail composed of all the necessary 
splice signals: branch point (BP), polypyrimidine tract ((y)n) and the 3' ss 
(AG),  preceding the corrected cDNA 3' end.  
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III. 2. Small nucleolar RNAs as new tools for the modification of pre-mRNA 
splicing 
Another strategy for the modulation of pre-mRNA splicing emerged recently and 
involves the targeted modification of branch point sites to inhibit their recognition by 
the splicing machinery. For this purpose, small nucleolar RNAs (snoRNAs) that 
naturally direct the 2’-O-methylation of various cellular RNAs have been engineered in 
order to re-direct them towards a pre-mRNA and specifically induce the methylation of 
the adenosine branch point, thereby triggering the skipping of the downstream exon. 
 
III. 2. 1. The C/D box small nucleolar RNAs 
The small nucleolar RNAs (snoRNAs) are 60 to 150 nt long non–protein-coding RNAs 
that function mainly in guiding the post-transcriptional modifications of ribosomal 
RNAs (rRNAs) and small nuclear RNAs (snRNAs) [176-177]. The various snoRNAs 
can be classified into two major groups based on their structural features and functions: 
the H/ACA box snoRNAs mediate the pseudo-uridylation of cellular RNAs and the 
C/D box snoRNAs induce the site-specific 2’-O-methylation of ribose on their target 
RNAs by base pairing through the complementary guide sequence of 10-20nt they 
contain [178]. Currently, more than 350 human snoRNAs are referenced in the 
snoRNA-LBME-db database [179], which lists approximately 250 C/D box snoRNAs 
and 80 H/ACA snoRNAs that have been experimentally confirmed. Amongst these 
snoRNAs a great number have no identified target RNA and are referred to as 
“orphan” guides. Moreover, the snoRNA world is a fast growing entity and many novel 
snoRNA-like sequences have been computationally predicted within human introns but 
have not been confirmed experimentally yet [180-182], suggesting that thousands of 
snoRNAs could actually be encoded in the human genome and are yet to be discovered. 
Many snoRNAs are expressed in a tissue-specific manner whilst others can be submitted 
to genomic imprinting, which depicts the complexity associated with these non-coding 
RNAs and the difficulty faced when trying to identify new members of these groups. 
We will focus here on the C/D box snoRNA group. 
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The C/D box snoRNAs are characterized by two short conserved sequence motifs: the 
consensus C Box (RUGAUGA, where R is a purine) and D Box (CUGA) that are 
positioned close to the 5’ and 3’ end, respectively. These two motifs are generally 
brought together through the complementary association of four to five nucleotides 
from each termini to form a 5’-3’ terminal stem structure. Additionally, C/D box 
snoRNAs often contain in their central portion imperfect copies of box C and box D, 
called box C’ and box D' [183]. Finally, the C/D box snoRNAs possess a 10 to 22 nt 
long antisense element located upstream of the D box at the 3’ extremity, sometimes 
complemented by a second antisense sequence upstream of the D’ box.  
These antisense sequences present a perfect complementarity to sequences on their 
target RNAs to which they associate by direct Watson-Crick base pairing, thereby 
positioning the nucleotide to be methylated exactly 5 nt upstream of the conserved D 
(or D’) box. The protein fibrillarin that carries the 2’-O-methyltransferase activity 
specifically recognizes the D box and induces the methylation on the associated RNA at 
this selected nucleotide position. The antisense-snoRNAs therefore act as guides for the 
site-specific methylation of intracellular RNAs, and the antisense sequence together with 
the D/D’ box provide all the information necessary for the selection of the targeted 
nucleotide [184-185]. 
The majority of vertebrate C/D box snoRNAs are encoded within introns of pre-
mRNAs and are co-transcribed with their host genes in the nucleoplasm [187]. A host 
gene can contain one or multiple different snoRNAs within its introns. Many host genes 
are involved in ribosome biogenesis or function, although others have been identified 
that are devoid of protein coding potential and appear to be transcribed by RNAPII 
primarily to express the snoRNA [188-189]. The intron-encoded snoRNAs are excised 
from the spliced and debranched host introns by exonuclease digestion in the 
nucleoplasm [190] (Figure 21). It has been shown that all the necessary signals for 
correct processing of a snoRNA reside within the snoRNA sequence itself as a snoRNA 
artificially placed into a non-natural intron context is accurately processed [191].  
After transcription of the snoRNA-host gene, a snoRNA-specific core of proteins 
composed of the four evolutionarily conserved proteins fibrillarin (Nop1), Nop56, 
Nop58 and Snu13 (15,5K),  assembles on the newly synthesised transcript by 
recognising the conserved C and D boxes and the neighbouring 5’-3’ stem structure 
within the pre-snoRNA sequences, which constitute the signal elements essential for 
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correct processing of the mature snoRNA [192-193]. The assembly of this core of 
proteins is triggered by the splicing of the host pre-mRNA: the proteins are actively 
recruited on the snoRNA by a factor that also associates with splicing factors on the 
pre-mRNA (Figure 21). Intronic snoRNA processing is therefore physically and 
functionally linked to the splicing of the host pre-mRNA intron and these two event 
occur synergistically [194-195]. The position of the snoRNA in the host intron relative 
to consensus splice sites is critical for both pre-mRNA splicing and efficient snoRNA 
synthesis [196-199]. Once the host intron is debranched, exonuclease trimming occurs 
to produce the mature ends of the snoRNA. The core of proteins bound to the pre-
snoRNA therefore define the correct ends of the mature snoRNA and provide a 
protection against over-digestion by exonucleases as well as stability for the snoRNA 
[200]. 
 
Figure 11: biogenesis of intronic C/D box snoRNAs 
During the splicing of the host pre-mRNA, an assembly factor (orange) 
associates with splicing factors (red) bound to the transcript and recruits 4 
core proteins (blue) on the snoRNA. After splicing, the debranched intron 
containing the snoRNA is released and digested by exonucleases to produce the 
mature snoRNP. 
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 The correctly processed mature snoRNA associated with the core proteins is then 
released in the nucleoplasm in the form of a small nucleolar ribonucleoprotein particle 
(snoRNP). Most C/D box snoRNPs then transit into Cajal bodies before accumulating 
in the nucleolus, their final destination and site of action. The conserved C/D box motif 
and its associated core proteins are necessary and required to direct nucleolar 
localization of the mature guide snoRNPs [201-202]. 
 
III. 2. 2. Targeted branch point methylation  
During the splicing process, the 2’-OH of the branch point (BP) adenosine is essential 
as it initiates the first trans-esterification step of the reaction by attacking the phosphate 
of the 5’ splice site. The inactivation of the branch point by eliminating its 2’OH group 
is therefore likely to prevent the reaction and impair the splicing process. It has indeed 
been demonstrated that a 2’-O-methylated BP nucleotide is inactivated and unable to 
pursue the splicing reaction [45]. 
This new concept led several groups to assess the possibility of engineering a C/D box 
snoRNA to specifically target the 2’-O-ribose methylation of a chosen pre-mRNA 
branch point in order to induce the skipping of the downstream exon. The notion that 
C/D box snoRNAs can interact with pre-mRNAs and modulate their processing is 
surprising considering that snoRNAs are thought to be predominantly localised in the 
nucleolus whilst mRNA splicing occurs in the nucleoplasm. It suggests that the sub-
nuclear sites to which the guide snoRNAs accumulate do not necessarily correspond to 
their sites of action. Indeed, several studies have now demonstrated that numerous C/D 
box snoRNA are devoid of complementarity to rRNAs or snRNAs but instead contain 
antisense sequences matching messenger RNAs [203], suggesting that the interaction 
between nucleoplasmic pre-mRNAs and snoRNAs can naturally occur. Accordingly, it 
has been recently shown that the snoRNA MBII-52 could localise in the nucleoplasm, at 
least transiently, and this transit between nucleoplasm and nucleolus enables the 
snoRNA to access the pool of pre-mRNAs in order to function as a regulator of 
splicing [204].  
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Altering the original guide sequence of the snoRNA has been shown to be sufficient to 
re-direct it to the chosen target RNA and to change the specificity of methylation [184]. 
Zhao et al. used this property to design synthetic C/D snoRNAs that specifically target 
the 2′-O-methylation of branch point adenosines in various Saccharomyces cerevisiae pre-
mRNAs in order to block their splicing (Figure 22). They demonstrated that the 
targeted pre-mRNAs became specifically 2’-O-methylated in presence of the modified 
snoRNAs, resulting in efficient splicing inhibition [186].  
 
 
Following this proof-of-concept in yeast cells, this strategy was further investigated for 
its potential to alter the splicing of human genes. An artificial human U24 C/D box 
snoRNA was engineered to guide the 2’-O-methylation of the branch point of the 
human heat-shock cognate protein (HSC8) pre-mRNA and its expression in human 
adenocarcinoma cells induced the exclusion of the exon situated directly downstream of 
the methylated branch point, albeit with a low efficiency of  6 to 10% [205]. This 
approach was also validated in another vertebrate system by injection into Xenopus 
oocytes of an artificial C/D box snoRNA re-directed to the adenovirus pre-mRNA 
branch point. The snoRNA efficiently induced the methylation of the target BP, which 
subsequently resulted in splicing impairment of the region downstream of the 
modification [206].  
 
Figure 12: site-specific 
methylation of pre-mRNA 
using C/D box snoRNA 
The snoRNA antisense 
sequences are modified to 
hybridize a target pre-mRNA, 
perfectly positioning the 
nucleotide to be methylated 5 nt 
upstream of the conserved D 
(and/or D’) box (red circles).  
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Although the proof-of-concept of this snoRNA-mediated pre-mRNA splicing 
modulation strategy has been established in vertebrate systems, the efficiency of this 
approach is low and still needs to be improved. To date, AON-mediated modulation of 
splicing therefore constitutes a more efficient and more promising strategy applicable to 
a wide array of diseases. Significant progress and improvements of the technique have 
been made over the past years and proof-of-concept of AONs efficacy has been 
demonstrated in various diseases. However the use of antisense strategies for clinical 
applications still faces several hurdles: it is currently challenging to express long-term 
therapeutic amounts of antisense sequences in the target tissue as intracellular delivery 
of synthetic oligoribonucleotides induces only a transitory effect and can be rapidly 
degraded in the cells, implying the requirement for repeated re-administration. 
Moreover, the systemic delivery of AONs cannot guarantee a targeted tissue-specific 
expression of the antisense and can result in potential undesirable off-target effects. 
Finally, the in vivo safety of antisense molecules needs to be rigorously investigated and 
controlled as some moderate toxic effects dependent on the AON backbone chemistry 
have been reported [145, 207]. Nevertheless, the potential of AON-mediated therapy 
for mis-splicing defects is becoming more and more evident and is highlighted by the 
onset of clinical trials for various diseases, such as the recent Duchenne muscular 
dystrophy trials that will be detailed later. 
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IV. Vector technologies for expression of exogenous small RNA 
sequences 
The intracellular delivery of synthetic oligoribonucleotides induces only a local and 
transitory effect and repeated administration of high doses of oligonucleotides would be 
needed for the treatment of chronic genetic diseases such as DMD. To circumvent this 
problem, the introduction of antisense sequences in strong expression cassettes that are 
delivered by gene transfer vectors could ensure their stable, targeted and efficient 
expression. One possibility is to use modified small nuclear RNAs (snRNA) as shuttles 
to obtain a sustained intracellular expression of antisense sequences. SnRNAs are 
appealing as antisense vectors since they enable to express the antisense sequence in 
relatively high concentrations from their strong promoters, they induce their 
colocalisation in the same subcellular compartment as the splicing machinery and they 
provide protection of the antisense sequences against intracellular nucleases. The 
validity of this strategy has been established using U1, U2 or U7 snRNAs delivered by 
viral vectors [208-210]. 
IV. 1. The small nuclear RNAs: characteristics and biogenesis 
The small nuclear RNAs are abundant non-coding transcripts that function in the 
nucleoplasm and can be divided into two groups. The Sm-class snRNAs, composed of 
U1, U2, U4, U4atac, U5, U7, U11 and U12 snRNAs, are transcribed by RNA 
polymerase II (RNAPII) and contain a Sm binding site for the recruitment of seven Sm 
proteins, a 5′-trimethylguanosine cap and a 3′ stem–loop (Figure 23). The second 
group, the Lsm-class snRNAs, is composed of U6 and U6atac snRNAs. They are 
produced by RNA polymerase III (RNAPIII) and are characterised by a 3' stretch of 
uridines that constitutes the binding site for Sm-like proteins (termed Lsm proteins), a 
monomethylphosphate cap and a 3′ stem–loop. These Lsm-class snRNAs will not be 
discussed further here. 
All the uridine-rich snRNAs assemble with proteins into small nuclear 
ribonucleoparticles (snRNPs) and form the core component of the spliceosome, except 
the U7snRNA which is non-spliceosomal and functions in histone pre-mRNA 3' 
processing. 
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Figure 13: features of Sm-class snRNA transcripts 
SnRNA transcripts contain a Sm binding site for the recruitment of the Sm 
protein ring (Sm core), a 5′-trimethylguanosine cap and a 3′ stem–loop. The 
general consensus sequence of the Sm binding site and the composition of the 
general Sm core of proteins are represented. 
 
 
The vertebrate Sm-class snRNA genes are ubiquitously and highly expressed and are 
present in multiple copies within genomes, usually in clusters [212]. The structure of 
snRNAs genes is simple: they contain a snRNA-specific core promoter of around 250 
bp that is very active but lacks a TATA box, no intron and no polyadenylation signal. 
The TATA-less promoters contain two elements: a distal sequence element (DSE), 
which behaves like an enhancer and is required for high levels of transcription, and a 
snRNA specific proximal sequence element (PSE) that drives basal levels of 
transcription [213]. The 3' end of snRNAs contains the 3'-box located 9 to 19 nt 
downstream of the snRNA coding region, which is required for correct 3' end 
processing (Figure 24). 
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 Figure 14: structure of Sm-class snRNA genes transcribed by RNAPII  
The promoters of snRNA genes are composed of the proximal (PSE) and distal 
(DSE) sequence elements situated approximately 250 nt and 50 nt upstream of 
the transcription start site (arrow). The 3' box important for snRNA transcript 
processing is located between 9 and 19 nucleotides downstream of the snRNA 
coding region. 
 
IV. 1. 1. Transcription of Sm snRNA genes and coupling with 3'end 
processing 
The transcription of Sm-class snRNA genes starts with the binding of general 
transcription factors on the DSE sequence, such as Oct-1 and Staf that are implicated in 
the transcription of both mRNA and snRNA genes [213]. This interaction triggers the 
recruitment of a complex of transcription factors specific to snRNA genes on the PSE, 
which define the +1 transcription start site [214]. This multisubunit complex called 
SNAPc (snRNA activator protein complex), also known as PTF or PBP, associates with 
the PSE and mediates the recruitment of RNAPII to the promoter [215-216]. The 
transcription of snRNA genes by RNAPII, similarly to mRNA genes, involves the 
general transcription factors TBP, TFIIB, TFIIA, TFIIE, TFIIF and possibly TFIIH 
[217-218]. The downstream AU-rich cis-acting element called the 3' box does not act as 
a termination sequence as the pre-snRNAs produced after transcription are 3' extended 
beyond this element [219], but is instead required for the subsequent 3' processing of 
the newly formed snRNA and marks the upstream cleavage site [220].  
The 3' end processing of snRNAs transcripts is tightly coupled with their transcription 
and the snRNA promoters play a critical role in this process [221]. Indeed, it has been 
demonstrated that the replacement of snRNA promoters with non-snRNA promoters 
abolishes the recognition of the 3' box and causes constitutive misprocessing of the 
snRNA [222-223]. The correct processing of pre-snRNAs therefore depends on a factor 
that requires the presence of the 3' box and of a snRNA-specific promoter, highlighting 
the link between transcription and RNA processing. The factor responsible for snRNA 
processing is a multiprotein complex called Integrator, which contains two subunits 
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(Int9 and Int11) homologous to components of the cleavage and polyadenylation 
specificity factor (CPSF) complex that is essential for the cleavage of mRNA 3′ ends 
[224-225]. The Integrator has been shown to associate with the C-terminal domain 
(CTD) of the largest subunit of RNAPII [224, 226], which is specifically required to be 
phosphorylated on serine 2 and serine 7 for efficient recruitment of the Integrator 
complex and for proper 3' box-dependent 3' end formation [227-228]. Finally, it has also 
been shown that sequences in the terminal 3' stem-loop present within the coding 
region of U7 snRNA are required for Drosophila snRNA processing, although the 
requirement for this stem loop signal has not been demonstrated in vertebrates [223].  
The currently accepted model of the coupling between snRNA transcription and 
processing is that the Integrator complex associates with the phosphorylated CTD of 
RNAPII at the promoter, travels with it along the gene during transcription until it 
recognizes signals in the stem loop of the coding sequence as well as the 3’ box at the 
end of the transcript. The co-recognition of these two elements directs the Integrator to 
the proper cleavage site, approximately 10nt upstream of the 3' box, which then 
mediates the co-transcriptional 3’ processing of the nascent pre-snRNA (Figure 25). 
 
Figure 15: Coupling between snRNA transcription and 3' box-dependent 
processing through the Integrator Complex. 
The Integrator complex is attached to the C-terminal domain of RNAPII, which 
is fixed to the promoter of snRNA genes. The Integrator complex then travels 
along the gene with the polymerase during transcription until it recognises the 
3' box and the stem loop in the newly synthesised transcript. These signals 
direct the Integrator to cleave the nascent transcript approximately 10 nt 
upstream of the 3' box, thereby releasing the pre-snRNA from its template.   
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Once the Sm-class snRNAs are cleaved off the template, a 7-methylguanosine cap is 
added on their 5' end and they are exported from the nucleus to the cytoplasm for 
further maturation. The transport to cytoplasm occurs through the activity of a snRNA-
specific export complex that contains the export adaptor protein PHAX, the export 
receptor chromosome region maintenance-1 (CRM1), the cap-binding complex (CBC) 
and the Ran GTPase [229-230]. 
 
IV. 1. 2. Sm core assembly 
The assembly of snRNAs into stable Sm-core particles (snRNPs) takes place in the 
cytoplasm and is directed by a large assemblyosome called the survival of motor neuron 
(SMN) complex, which is composed of the SMN protein, seven distinct Gemin proteins 
(Gemin 2-8), and several other protein factors [231]. The Sm core proteins (B/B0, D1, 
D2, D3, E, F and G) associate into a stable seven-membered ring around a conserved 
binding sequence called the Sm site (consensus RAUUU/GUUGR) to form the core of 
the snRNP particle [232]. This assembly is facilitated by the SMN complex which binds 
to the snRNA precursors and to the seven Sm proteins and brings them together. As an 
exception, the U7 snRNA contains a non-consensus Sm site that associates with a Sm 
ring of a different composition, which will be detailed later.  
The assembly of the Sm core is required for the completion of the snRNPs maturation 
steps. First, the SMN complex directs the hypermethylation of the snRNA 5' cap to 
form a 2,2,7-trimethylguanosine cap [233]. The 3' extended pre-snRNA is then 
submitted to a nucleolytic trimming, which is also Sm-core dependent, to generate the 
mature length snRNA [234-235]. The Sm core assembly as well as the 3' end trimming 
events are a prerequisite for the nuclear import of the mature snRNA [236]. Once in the 
nucleoplasm, the newly made snRNPs transiently accumulate in Cajal bodies where 
additional modifications steps take place, such as 2'-O-methylation and 
pseudouridylation of the snRNAs, which are essential for the snRNP to be fully 
functional [237-238]. Finally, the Sm particles assemble into di-snRNP or tri-snRNP 
prior to accumulation in nuclear subdomains. 
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IV. 2. Modification of U snRNAs for antisense sequence expression 
 
The small nuclear RNAs can be engineered and used as tools to express antisense 
sequences in the cells in order to modulate mis-splicing defects. As mentioned before, 
the snRNAs are expressed at high level from their strong promoters, are localized in the 
nucleus and interact with their RNA targets by direct base pairing. It is possible to 
replace the natural antisense sequence of a snRNA with an antisense sequence chosen 
to specifically target an mRNA of interest and modulate its splicing, with potentially 
more efficiency than intracellular delivery of AONs alone. Indeed, the use of snRNA 
shuttles to express antisense sequences presents several advantages: the sequences are 
then protected from degradation and produced continuously and at high levels within 
the cell. Moreover, the modified snRNAs are still able to associate with Sm core 
proteins into snRNPs, which provides intracellular stability and induces the nuclear 
localization of the antisense sequence. 
Sm Class snRNAs are therefore ideal candidates as antisense vehicles since the only 
required modification for targeting a desired mRNA is the replacement of their natural 
RNA-binding sequence. It has been shown that U2 snRNA can constitute an antisense 
carrier for splicing modulation purposes [210], but so far U1 snRNA- and U7 snRNA-
based vectors have been the most commonly used for this purpose. 
The 164 bp long human U1 snRNA is transcribed by a strong promoter and is present 
in multiple copies in the genome, allowing the production of approximately 106 U1 
transcripts per cell. This high level of expression has been a strong argument for the use 
of U1snRNA for antisense expression, and chimeric snRNAs targeting various splice 
signals and delivered by viral vectors have demonstrated some efficiency for the 
correction of aberrant splicing in multiple diseases. For example in the context of 
Duchenne Muscular Dystrophy, modified U1 snRNAs redirected towards splice sites of 
the mutated mouse DMD pre-mRNA and systemically delivered by adeno-associated 
virus (AAV) vectors successfully induced a body-wide restoration of Dystrophin in the 
mouse model of the disease [239]. In a more recent study, U1 snRNA also successfully 
induced exon skipping in the human DMD pre-mRNA in primary patient fibroblasts 
[240].  
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Alternatively, modified U1 snRNAs have also been used to correct donor splice site 
mutations in pre-mRNA by compensatory changes. It has been demonstrated that U1 
snRNAs could be engineered into suppressors of donor splice site mutations by 
introducing compensatory substitutions in their 5’ extremities to perfectly match 
mutated splice donors. Such modified U1 snRNAs are then able to promote normal 
splicing at the mutated 5' ss and have shown some efficiency for the correction of 
aberrant splicing in diseases such as β-thalassemia [209], severe factor VII deficiency 
[241-242] or some cases of Bardet-Biedl syndrome [243].A recent study also reported 
the development of modified U1 snRNA designed to hybridize into intronic sequences 
downstream of the donor splice sites of various pre-mRNAs to correct splicing 
impairments [244]. This study showed that some of these U1 variants, termed exon-
specific U1 snRNAs (ExSpeU1), were able to rescue the splicing defects caused by a 
mutated 5' ss, but also to correct the effects of mutations located at the 3′ splice sites or 
in exonic regulatory elements of mutated pre-mRNAs. 
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IV. 3. U7snRNA for antisense sequence delivery 
U7 snRNA is a non-spliceosomal small nuclear RNA that is not involved in pre-mRNA 
splicing, but mediates the 3' end processing of replication-dependent histone pre-
mRNAs by base pairing through its 5’ 18 nucleotides antisense sequence [245-246] 
(Figure 27).  
U7 snRNP is present at only 103 to 104 copies in mammalian cells, much less than the 
spliceosomal snRNPs, but the U7-specific promoter has been shown to be of 
comparable strength to that of the spliceosomal snRNAs [210, 247-248]. The conserved 
U7snRNA transcript is 57–71 nt long depending on the species, and the structure of the 
gene shares structural features with the spliceosomal snRNAs (Figure 27).  
 
 
Figure 16: U7 snRNA and hybridization to replication-dependent histone 
pre-mRNA 
The 239-bp U7-specific promoter contains the DSE and PSE sequences. The 
mouse U7 transcript is composed of a 18-nt antisense element to histone pre-
mRNAs at the 5' end, a non-consensus Sm binding site of 11 nt specific to U7, 
and  a 31-nt long 3'-terminal hairpin structure required for stability. The 3' 
extension present in the premature U7 transcript before nucleolytic trimming 
contains the 15-nt long 3' box located 13 nt downstream of the mature U7 
snRNA 3' end. 
The 100-kDa zinc finger protein (ZFP100) is a component of U7 snRNP that 
interacts with the hairpin binding protein (HBP) associated on the stem-loop of 
the histone H1 pre-mRNA to stimulate histone mRNA processing [249]. 
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As for the spliceosomal snRNAs, the promoter, stem-loop structure and 3’ box element 
are important for the correct processing of the U7 precursor [221, 223, 225]. The 
maturation pathway is also similar, including a cytoplasmic phase where it assembles 
into a snRNP. The main difference resides in the composition of the Sm core of the U7 
snRNP [234]. The non-consensus Sm binding site of the U7 snRNA 
(AAUUUGUCUAG) is responsible for the recruitment of a U7-specific Sm core of 
proteins during the assembly into snRNP. This particular Sm ring is composed of 5 
classical Sm proteins (B/B0, D3, E, F, and G) and of two Sm-like proteins, LSM10 and 
LSM11 that replace D1 and D2 respectively [250-252]. 
 
The assembly of the unique U7 Sm protein core follows several precise requirements. 
First, four nucleotides located within the 3' half of the Sm site are crucial for the 
assembly of an active U7 snRNP and need to be conserved. Furthermore, the position 
and size of the U7 terminal stem-loop structure also affect RNP assembly. Finally, it has 
been shown that the substitution of a particular nucleotide within the U7 Sm site with a 
pseudouridine, which confers structural rigidity on the sugar-phosphate backbone of the 
snRNA, impairs assembly of the U7 Sm core. This highlighted a requirement for 
backbone flexibility at the Sm site for correct assembly of the Sm ring [253]. 
The modification of the non-canonical Sm binding site of U7 snRNA 
(AAUUUGUCUAG) into the consensus sequence derived from spliceosomal snRNPs 
(AAUUUUUGGAG) greatly increases the intracellular U7 RNA expression levels and 
significantly improves the nuclear accumulation of U7 snRNA [254]. Conversely, the 
modification of U1 genes by replacement of their Sm sequence with the U7 Sm binding 
site reduced RNA levels to those of the wild type U7. Altogether, these observations 
demonstrate that the sequence of the Sm binding site strongly influences the level of 
snRNAs in the cell [254]. Moreover, the modification of U7 Sm site into the 
spliceosomal consensus led to the formation of U7snRNPs that are non-functional in 
histone RNA processing [234, 254]. This Sm modification triggers the recruitment of 
the conventional seven-membered Sm core on the U7 snRNA instead of the U7-
specific Lsm10 andLsm11 proteins, which are functionally involved in histone pre-
mRNA 3' processing [250-251], thereby abolishing the natural U7snRNP function. 
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Similarly to the spliceosomal snRNAs, U7snRNA can be modified into a mediator of 
splicing by replacing its original 5' anti-histone sequence with an antisense sequence 
complementary to a pre-mRNA of interest [208, 255] and converting the wild-type Sm-
binding site of U7 snRNA into the canonical Sm sequence (SmOPT). Thereby, the 
U7snRNA shuttle assembles with Sm proteins into a snRNP and associates with the 
spliceosome, facilitating the colocalization of the antisense sequences with the target 
pre-mRNA [256] (Figure 29). Moreover, as the U7-SmOPT transcripts are no longer 
functional in histone pre-mRNA processing, they become fully available to exert their 
new function of splicing modulation [234, 254]. 
 
Figure 17: modification U7 snRNA for antisense sequences delivery 
U7 snRNA is engineered into an antisense carrier by replacing its 18-nt 
antisense sequence and by modifying the U7-specific Sm binding site (Sm WT) 
into the canonical Sm sequence of spliceosomal snRNAs (SmOPT) 
 
 
This U7 snRNA-mediated expression of antisense sequences has proven efficient to alter 
splicing in a variety of mis-splicing diseases. The first U7-induced splicing modulation 
applications demonstrated the successful correction of aberrant β-globin pre-mRNAs in 
cultured cells model of β-thalassemia [208, 257]. Since then, U7 snRNAs were also used to 
induce the correction of SMN2 pre-mRNA splicing in the context of spinal muscular 
atrophy [258-262], to successfully inhibit HIV-1 multiplication through disruption of tat, 
rev or cyclophilin A expression by exon skipping [263-264], and to restore the splicing 
pattern of pre-mRNAs for a range of other disorders (Table 1). One of the most 
promising applications of this strategy is the restoration of dystrophin expression by 
forced exon skipping of the mutated pre-mRNA in Duchenne Muscular Dystrophy. The 
potential of modified U7 snRNAs to successfully induce the skipping of the mutated 
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dystrophin pre-mRNA was first demonstrated in muscular cells of the mdx mouse model 
and resulted in de novo protein synthesis [256]. This study also provided evidence that 
inserting in the U7 cassette two antisense sequences targeting two different sites on the 
pre-mRNA (double-target antisense) allowed a more efficient exon skipping than when a 
single sequence was targeted, as previously demonstrated in the β-globin pre-mRNA [257]. 
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Disorder and 
genetic target 
Genetic therapy using modified U7 
snRNA 
Delivery of U7 snRNA Ref 
 
β-thalassemia 
β-globin gene  
- U7 snRNAs containing antisense 
sequences against cryptic splice sites  
+ Double-target U7 snRNAs 
- Transfection in Hela cells 
expressing the mutated β-globin gene  
- lentiviral vector delivery in 
erythroid progenitor cells of patients  
[208, 
257] 
[265] 
 
 
 
 
 
 
Duchenne 
muscular 
dystrophy 
 
dystrophin gene 
mouse gene: stop mutation in exon 23 
 
Double-target U7 snRNA for mouse 
dystrophin exon 23 skipping 
U7(BP22/5'ss23) 
- Transfection of cultured mdx cells 
- local administration of AAV vectors 
in mdx muscles 
- intravenous injection of self-
complementary AAV in dKO mice  
[256] 
[266] 
 
[267] 
human gene: deletion of exons 49 and 50  
- Bifunctional U7 snRNAs carrying an 
antisense sequence and a splicing silencer 
sequence for exon 51 skipping  
- modified U7 snRNAs for skipping of 
exons 45 to 55 + combination of three 
U7snRNAs into one vector for multiple-
exon skipping of exons 45-47 
 
- lentiviral vectors delivery in human 
DMD myoblasts + intramuscular 
injection of AAV in hDMD mice  
- AAV vectors delivery in DMD 
myoblasts + intramuscular injection 
in hDMD 
 
[268] 
 
 
[269] 
 
canine gene: deletion of exon 7 
Double-target U7 snRNAs directed 
against ESE for double-exon 6-8 skipping  
 
transendocardial delivery of AAV 
vector in GRMD dog 
 
[270-
271] 
Spinal 
muscular 
atrophy 
SMN2 gene 
- U7 snRNA complementary to the 3' 
splice site of exon 8 for exon 7 inclusion  
- bifunctional U7 snRNAs carrying a 
binding sequence for exon 7 and a 
splicing enhancer sequence (ESE) for 
exon 7 inclusion  
Transfection in HeLa cells expressing 
endogenous SMN1 and SMN2. 
- lentiviral vectors delivery in human 
fibroblasts from SMA patients 
- introduction by germline transgenesis 
into SMA mouse model homozygous 
for human SMN2 
[258] 
 
 
[260] 
[259, 
272] 
HIV/AIDS 
cyclophilin A, tat 
and rev genes  
U7 snRNA induced exon skipping to 
impair cyPA, tat or rev pre-mRNAs 
splicing and reduce HIV-1 multiplication 
lentiviral vectors delivery in CEM-SS 
or CEM T-lymphocytes 
[263-
264] 
Dysferlinopathies 
Dysferlin gene 
- double target U7 snRNA against ESE 
sequences to induce exon 32 skipping 
Lentiviral vectors delivery in 
fibroblast-derived myoblasts of patient 
[273] 
cancers 
PTCH1 and 
BRCA1 genes 
U7 snRNAs containing antisense 
sequences against cryptic splice sites  
Transfection in Hela cells containing 
minigene constructs 
[274] 
Myotonic 
dystrophy (DM1) 
DMPK gene 
Human U7-snRNA containing a poly-
CAG antisense for degradation of target 
mRNAs with abnormal CUG expansions  
 Lentiviral vectors delivery in skeletal 
muscle cells from DM1 patients 
[275] 
 Table 1: list of applications using the U7 snRNA-mediated expression of 
antisense sequences to modulate pre-mRNA processing 
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IV. 4. Viral vectors for gene therapy 
The efficient intracellular delivery of antisense-snRNA cassettes requires the use of viral 
vectors, which are able to enter the target cells and to transfer their genetic information 
in the nucleus of infected cells. For safety purposes, these viral vectors are engineered to 
create replication-defective viral particles by replacing the genes required for viral 
replication with an expression cassette containing the antisense gene. Different viruses 
have been modified into antisense delivery vehicles, including retrovirus [210], 
adenovirus [175], lentivirus [265], and adeno-associated virus (AAV) [276].  
Retroviral vectors are unable to infect nondividing cells and their ability to integrate 
their genome into the host DNA has been associated with serious adverse 
consequences, such as the development of T-cell leukemia in children during a clinical 
trial for gene therapy of X-linked SCID [277-279]. The use of adenoviral vectors in 
clinical trials has also raised various concerns such as low efficiency and potential 
adverse effects [280]. Nowadays, the most widely used viral vectors are vectors derived 
from adeno-associated viruses and from lentiviruses. 
 
IV. 4. 1. AAV vectors  
Adeno-associated viruses (AAV) belong to the Parvovirus family and the Dependovirus 
gender. They are dependent on the co-infection of a helper virus, such as an adenovirus, 
to be able to replicate and form viral capsids in the host cell. AAV therefore remain 
quiescent in the absence of a helper virus and so far no human pathology has been 
reported associated to AAV infection.  
AAV viruses contain a small single-stranded DNA genome of approximately 4.7 kb that 
is packaged into an icosahedral, non-enveloped capsid. The genome contains two genes, 
called rep and cap, and two inverted terminal repeat regions (ITR) at the 5' and 3' 
extremities of the genome. The rep gene encodes the four non-structural Rep proteins 
involved in viral genome replication, integration and packaging of AAV genomes into 
preformed empty particles [281-283]. The cap gene encodes three capsid proteins (VP1 
to 3), which are identical in their amino acid sequences except for the N-terminal parts 
[284-285], as well as the assembly-activating protein (AAP), which directs the newly 
synthesized capsid proteins to the nucleolus where AAV capsid morphogenesis occurs 
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and is also implicated in the capsid assembly reaction [286]. Depending on the serotype 
of the AAV virus the amino acid composition of the capsid varies, which results in the 
use of different cell surface receptors for cell entry and provides distinct tissue tropisms 
for each AAV serotype. At the present time, 12 different serotypes and many variants 
have been described. Finally, the ITRs at each end of the genome are folded into a T-
shape through base-pairing between palindromic regions. These secondary structures 
function as origin of replication and are essential for the conversion of the single-
stranded viral DNA into double-stranded DNA prior to expression. The ITRs are also 
important for genome integration of the wild-type AAV into the host DNA [287-288]. 
AAV viruses can be modified into gene transfer vectors by eliminating all the viral genes 
(rep and cap) and replacing them by a transgene, such as a U7-antisense cassette, while 
leaving the ITRs at each end that are required for replication and packaging into viral 
particles. The major inconvenient of using AAV as vectors is the small packaging 
capacity of their genome, which limits the transgene size to a maximum of 4,7 kb.  
During infection by AAV, the presence or absence of a helper virus determine the fate 
of the viral genome: if the helper virus is present, induction of gene expression and 
replication takes place immediately. However in absence of helper virus, the AAV enters 
a latent life cycle and its genome integrates into human chromosome 19 at a specific 
locus known as AAVS1 [290-291]. The expression of the AAV Rep gene is necessary 
for this site-specific integration to occur. Because recombinant AAV (rAAV) vectors 
lack a Rep coding sequences, they are usually not able to integrate their genome in the 
host DNA and persist in an extrachromosomal form, or episome, as either linear or 
circular monomers that can be converted into large concatemers (>12 kb) [292-294].  
Another important point to consider for clinical use of recombinant AAV vectors is the 
potential presence of neutralizing antibodies in humans administered with the vector. It 
has been shown that anti-AAV antibodies can be naturally found in the sera of 
approximately 80% of the human population due to previous exposure from natural 
AAV infections [295], and these specific antibodies can neutralize and impair AAV 
mediated gene transfer. Moreover, repeated vector administration can induce the de novo 
production of neutralizing antibodies even if none were initially detected in the serum, 
which would inhibit the efficacy of the vector in subsequent applications to the same 
patient. One way to circumvent this obstacle is to vary the AAV serotype used in order 
to achieve immune escape from neutralizing antibodies in patients with anti-AAV 
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immunity [296]. Another possibility is to prevent the recognition and action of 
neutralizing antibodies by mutating the relevant capsid epitopes. AAV vectors are 
considered as good tools for transduction of postmitotic cells and Phase I/II clinical 
trials for the treatment of various diseases are currently ongoing [297]. 
 
IV. 4. 2. Lentiviral vectors 
Lentiviruses, which belong to the family of Retroviridae, are RNA viruses that are 
packaged into a capsid enveloped in a lipid membrane. The lentivirus contains a single-
stranded RNA genome that contains its own regulatory elements and is transcribed by 
the transcription apparatus of the host cell. The lentiviral genome features two long 
terminal repeats (LTR) at the 5' and 3' ends flanking the protein-coding regions, and a 
packaging signal located directly downstream of the 5' LTR (ψ). The typical retroviral 
genes, gag, pol, and env, respectively code for the capsid proteins, the reverse 
transcriptase and integrase, and the envelope proteins. Additionally, the lentivirus 
encodes two essential regulatory genes, tat and rev, necessary for the expression of the 
provirus, and some accessory genes (vpr, vpu, vif, and nef) that are essential for 
virulence and infectivity (Figure 31).  
 
 
Figure 18: organisation of the HIV-1 (lentiviral) genome 
The proviral DNA is represented with all the coding sequences. The 5' and 3' 
LTR contain the U3-R-U5 elements in the proviral DNA. 
 
The LTRs flanking the coding sequences consist of three regions: the 3' unique element 
(U3), the repeat element (R), and the 5' unique element (U5), and are important for 
reverse-transcription, integration and expression of the viral genome. Following cell 
entry the RNA viral genome is reverse-transcribed into double-stranded DNA, a 
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process during which the U3-R-U5 Long Terminal Repeats are formed. This double-
stranded DNA genome then enters the nucleus and integrates into the host DNA as a 
provirus (Figure 31), which will then be transmitted to daughter cells upon cell division. 
Lentiviruses such as HIV-1 virus can be engineered into gene delivery vectors with great 
potential for human gene therapy [298]. HIV-based lentivectors have been designed and 
submitted to numerous changes and optimisations over time to minimize the risk 
associated with the pathogenicity of the parental virus and to produce safe and efficient 
gene transfer vectors. The coding regions of the gag, pol and env genes, as well as the 
auxiliary genes (vif, vpr, vpu, env, and nef) and the regulatory genes tat and rev, are 
removed from the vector sequence leaving only a backbone of the 5' and 3' LTRs and 
the packaging signal (ψ). The transgene expression cassette can then be inserted 
between the LTRs to enable its packaging into the new viral particles. The packaging 
functions (gag, pol, and env) and the rev gene necessary for efficient expression of gag 
and pol are then provided in trans in the cell, split into different transcriptional units to 
reduce the possibility of replication-competent virus production through recombination. 
Furthermore, the 5′ LTR is modified by replacing the U3 region, which contains the 
promoter and enhancer elements, with a chosen promoter such as RSV or CMV to 
abolish the transcriptional dependence on tat [299]. Finally, another modification 
present in self-inactivating (SIN) vectors involves a deletion in the U3 region of the 3′ 
LTR, including the TATA box [300]. This deletion is transmitted to the 5' LTR of the 
proviral DNA during reverse transcription, abolishing the transcriptional activity of the 
LTR and the possibility to generate vector genomic RNA in the target cell (Figure 32). 
This deletion also prevents transcriptional interference between the 5’ LTR and either 
host chromosomal genes or internal promoters driving transgene expression.  
 
 
Figure 19: self-inactivating (SIN) lentiviral vector 
SIN vectors contain modifications in the LTR regions: the U3 region in the 5′ 
LTR is replaced by a chosen promoter and a deletion in the U3 region of the 3' 
LTR (ΔU3) abolishes the transcriptional activity of the LTR.   
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V. Exon skipping for Duchenne muscular dystrophy  
V. 1. The Dystrophin gene and the disease  
The human dystrophin gene (DMD) is the largest gene in the human genome, spanning 
2.4 Mb of DNA on the human X chromosome and containing 79 exons [301]. This 
gene encodes a 14 kb, low abundance transcript that is predominantly expressed in 
skeletal and cardiac muscle, and at lower levels in smooth muscle and brain tissue [302]. 
The transcription of the DMD gene, which lasts approximately 16h [78], is activated 
during the process of myoblast differentiation when myoblasts begin to fuse into 
multinucleated myotubes [303]. The large dystrophin protein (427 kDa), located beneath 
the muscle sarcolemna, is a structural protein that plays a major role in the integrity of 
muscular fibres as it links the internal actin cytoskeleton to the extracellular matrix via 
the DAPC, which enables the resistance of the muscular cell against contraction induced 
stress [304].It contains four domains: an actin-binding domain at the N terminus, a 
central flexible rod domain composed of 24 spectrin-like repeats [305], a cysteine rich 
domain, and a C-terminal domain that binds to the dystrophin-associated protein 
complex (DAPC) at the sarcolemma (Figure 33).  
 
 
Figure 20: the dystrophin-associated protein complex links the internal 
cytoskeleton to the extracellular matrix in muscle cells 
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Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disease caused by loss-
of-function mutations in the dystrophin gene. It is the most severe and most common 
form of muscular dystrophies affecting 1 in 3500 males. As the dystrophin is missing 
from the membrane of muscular cells in DMD patients, the DAPC is destabilized and 
the integrity of the muscle fibre is lost during muscle contraction, which leads to 
progressive degeneration and ultimately necrosis of the myofibers [306-307]. The 
cardiac muscle, the vascular smooth muscle and the central nervous system are also 
affected. The onset of the disease usually occurs around 3 to 5 years of age, and 
progresses rapidly: the muscle weakness and degeneration drive the DMD patients to 
use a wheelchair in their early teens, and usually culminates in their death around the age 
of 25 due to cardiac or respiratory failure [304].  
The majority of DMD mutations abolish the dystrophin mRNA reading frame, 
preventing the synthesis of functional dystrophin protein. More than 60% of loss-of-
function DMD mutations are large deletions of one or more exons, usually regrouped in 
a hotspot region between exons 45 and 55. Other mutations are non-sense mutations, 
insertions, or exonic and intronic point mutations causing aberrant splicing [308-309]. A 
milder form of the disease, Becker Muscular Dystrophy (BMD), is caused by in-frame 
mutations in the dystrophin gene that still allow the production of a partially functional 
dystrophin protein, even if in reduced amounts [310]. These BMD mutations mostly 
affect the central domain of the dystrophin constituted of 24 central repeats that 
provide a highly modular structure to the protein. Therefore, truncated proteins where 
one or several of these central domains are missing can still be functional as they 
maintain their essential N and C-terminal domains.  
Animal model of the disease are available for study of the disease pathogenesis and for 
pre-clinical applications. A well-established mouse model of DMD, the mdx mouse, 
presents an out-of-frame mutation in dystrophin exon 23 that prematurely stops the 
protein synthesis [311]. However, the mdx mouse only has a mild phenotype compared 
to the human situation and another mouse model more representative of human DMD 
is available. This model called double-knockout (dKO) is null for both dystrophin and 
another muscle protein, utrophin, and therefore presents a severe phenotype, including 
severe cardiomyopathy [312-313]. Another mouse model, hDMD, carries an integrated 
copy of the full-length human dystrophin gene and therefore allows investigations on 
specific human exons on a small experimental model. However, as the hDMD mice 
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were engineered from a wild-type mouse background and thus still express the 
functional endogenous mouse dystrophin gene, this model can only be used for analysis 
at the RNA level [314]. Besides the murine models, a large animal model has been 
developed: the golden retriever muscular dystrophy (GRMD) dog, which is also 
dystrophin negative due to a point mutation, is an interesting model for preclinical 
studies as it enables to estimate more closely the doses necessary to obtain a particular 
improvement on muscle function before translation to the human situation [315]. 
There is currently no effective therapy for DMD and the current options consist mainly 
in symptomatic treatments to ameliorate the patient's condition. Novel experimental 
strategies are currently being investigated, for which these animal models prove very 
useful and informative. 
 
V. 2. Gene therapy strategies for Duchenne muscular dystrophy 
Various gene therapy strategies for the treatment of DMD are showing promising 
results. Gene replacement therapy aiming at reintroducing a functional version of the 
dystrophin gene using AAV or lentiviral vectors has made significant progress. The 
limited cloning capacity of the recombinant AAV vectors implies that the dystrophin 
gene cannot be delivered in its full-length form and truncated but functional versions of 
the gene must be used. These mini- and micro-dystrophin constructs that lack large 
portions of the central domain of the gene have been designed following the 
observation that some BMD patients with large genomic deletions of dystrophin 
present a very mild phenotype [316] (Figure 35). The feasibility of delivering small 
versions of dystrophin to treat DMD patients has been demonstrated in various animal 
models of DMD. Efficient mini-dystrophin gene transfer has been obtained in mdx mice 
through recombinant AAV injection locally into the muscle [317] or systemically [318] 
and has been shown to ameliorate the pathological phenotypes. Improvements were 
shown by systemic injection in the dKO mice, which led to widespread de novo 
dystrophin expression in skeletal and cardiac muscles [319]. However, although AAV 
vectors do not elicit a cellular immune response in mice, an immune response was 
developed following AAV-mediated gene transfer in the GRMD dog model [320-321], 
as well as in monkeys [322] and in humans [323-324]. Sustained dystrophin expression 
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was however achieved by inducing short-term immunosupression in the dystrophic 
dogs or in non- human primates at the time of treatment [322, 325-326]. 
 
These approaches therefore hold great promises but are still confronted with many 
barriers. First, the use of internally deleted dystrophin constructs can have limited 
biochemical efficacy. Moreover, the long-term transduction of all the different muscles 
of a DMD patient by systemic injection is still a challenge. Finally, there are some 
concerns that the reintroduction of a previously missing dystrophin gene product in 
DMD patients could be immunogenic and trigger a dystrophin-specific reaction, 
hampering the therapeutic benefits of the treatment [328]. 
 
V. 2. 1. exon skipping correction of Duchenne muscular dystrophy 
Many current efforts for the treatment of DMD are focusing on correcting the 
endogenous dystrophic pre-mRNA by antisense-mediated exon skipping instead of 
replacing the gene. The viability of therapeutic exon skipping for DMD was evidenced 
by the observation that "BMD-like" shortened forms of dystrophin protein could still 
be functional. Moreover, the detection in some dystrophic muscles of revertant fibres 
that resume dystrophin protein expression by naturally skipping an exon has laid 
foundation for AON-mediated gene correction in DMD [329-331]. An out-of-frame 
point mutation or deletion located in the central domain of dystrophin could therefore 
be countered by skipping the corresponding or surrounding exon(s) in order to recover 
an in-frame mRNA producing a shorter but functional dystrophin protein, thus 
converting the severe DMD phenotype into a much milder BMD phenotype.  
 
Correction of dystrophin mRNA through splicing modulation presents several 
advantages over classical gene replacement strategies. First, by correcting the 
endogenous gene rather than providing a new truncated copy this strategy highly 
diminishes the issue of a potential immunogenic reaction against the dystrophin 
product. Indeed, the mini-dystrophin constructs used for gene replacement strategies 
are artificial versions that contain fragments of the normal gene joined together at 
abnormal places. The proteins produced from these constructs can therefore present 
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abnormal epitopes and be recognised as new in the treated organism, which is likely to 
trigger an immune response. On the other hand, correcting the endogenous pre-mRNA 
by exon skipping generally aims to skip one or few exons of the normal gene and the 
restored Dystrophin proteins are then very similar to the ones produced in the rare 
revertant fibers found in many DMD patients and should not activate the immune 
system. No immune response against the Dystrophin produced by exon skipping has so 
far been detected, including in patients currently enrolled in clinical trials, and although 
this possibility still needs to be carefully monitored, the likeliness of an immune reaction 
to exon-skipped Dystrophin is low. Furthermore, if the mRNA is efficiently corrected 
through splicing modulation the new truncated product should accumulate for a 
relatively long period of time as the dystrophin protein has been shown to have a long 
half-life [333]. Finally, the small snRNA-based antisense cassettes can be easily packaged 
into AAV vectors, abolishing the difficulties associated with packaging the large 
dystrophin gene in gene replacement strategies. 
Several pre-clinical studies have demonstrated the therapeutic potential of the exon 
skipping strategy for DMD [167] and various observations regarding potential 
improvements of the technique emerged. Efficient restoration of dystrophin expression 
was obtained using various antisense chemistries in the mdx mouse model [334-336], in 
the canine model [337-338] and in DMD patient muscle cells in vitro [339]. It has been 
suggested that exonic splicing sequences may constitute better AON targets than 
introns, and AONs blocking different ESE sites were shown to be more effective in 
inducing the specific skipping of various human dystrophin exons compared to their 
intronic counterparts [340-341]. Furthermore, two AONs targeting different splice sites, 
with similar or different chemistries, can also be combined to induce the exclusion of 
exons. This double targeting strategy has been tested in human DMD pre-mRNA and a 
significant improvement in exon skipping efficiency was observed when two splicing 
regulatory sequences within one exon were simultaneously blocked [342-343].  
The possibility of realising multiple exon skipping on the dystrophin pre-mRNA using a 
cocktail of AONs was also demonstrated, which would enable to increase the 
proportion of patients that could be treated with one same drug, or cocktail, and would 
circumvent the actual need for a personalised medicine for virtually each patient [344]. 
This prospect is interesting since, as mentioned before, a great number of DMD 
mutations are regrouped in a hotspot region between exons 45 and 55. In theory, the 
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simultaneous skipping of exons 45 to 55 could treat over 60% of patients and would 
create a deletion associated with a mild phenotype [345-346]. The validity of this 
approach has been demonstrated using cocktails of synthetic AONs in the dog model of 
DMD to induce the skipping of four exons simultaneously [337]. However skipping up 
to 11 exons simultaneously in human dystrophin is still challenging and has not be 
successful as yet [342, 347]. 
 
These promising results provided the background for two recent phase I/IIa clinical 
trials of antisense-mediated exon skipping in DMD patients. Both selected antisense 
oligonucleotides that target exon 51 of dystrophin pre-mRNA, the skipping of which 
would constitute a suitable therapy for 13% of all DMD patients [348]. 
The first study, carried out by the Dutch consortium from the Leiden University 
medical School in association with the com pany Prosensa, used a 2-′O-MePS AON 
chemistry (PRO051). Four DMD patients treated intramuscularly showed specific exon 
51 skipping and de novo dystrophin expression, associated with the production of 
dystrophin protein at up to 12% of normal levels four weeks after a single injection of 
0.8 mg PRO051 in the tibialis anterior muscle [349]. This encouraging trial led to 
repeated systemic administration studies where four groups of DMD patients received 
escalating doses of PRO051 weekly for 5 weeks. Specific exon 51 skipping was observed 
in patients treated with 2 mg or more per kilogram and novel dystrophin expression was 
detected in muscle fibers of most of the patients to up to 15.6% of the healthy muscle 
[350]. 
The second clinical trial was led by the MDEX consortium in collaboration with AVI 
Biopharma who selected PMO antisense oligonucleotide targeting exon 51 (AVI-4658). 
Seven patients were injected into the extensor digitorum brevis muscles at escalating 
doses and the patients treated with the highest dose of 0.9 mg showed an increased 
dystrophin expression to up to 32% of normal levels [351]. This consortium then 
completed a systemic dose-escalation study where 19 patients received weekly 
intravenous administrations of AVI-4658. Exon 51 skipping was detected in all patients 
and novel protein expression was observed for patients treated with 2 mg per kg and 
above, reaching up to 18% of the protein levels in the normal muscle [352]. 
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These clinical trials constitute the first demonstration that successful restoration of 
dystrophin protein can be achieved by antisense-mediated therapy in patients with 
DMD. However the systemic delivery of AONs faces the issues of poor cellular uptake 
and relatively rapid degradation in the cells, requiring regular re-administration. More 
importantly, the restoration of dystrophin expression in non-skeletal muscle, especially 
in cardiac muscle, is achieved only with low efficiency following systemic delivery of 
AONs. Other approaches using snRNAs to vectorize AONs are therefore being 
investigated to optimize this antisense-mediated strategy. 
 
V. 2. 2. snRNA-mediated exon skipping 
It has been reported that modified U7 or U1 snRNAs packaged into AAV vectors and 
containing a double-target antisense for specific exon 23 skipping in the mdx model 
could efficiently correct the dystrophin transcript and restore high and stable levels of 
functional proteins after a single injection in skeletal muscle [266, 353]. The same 
strategy has been shown to induce sustained production of dystrophin in all the 
muscles, including in the heart, following a single systemic administration of the vector 
in the tail vein of mdx mice  [239, 354] or of dKO mice [267]. The efficacy of chimeric 
snRNAs packaged in AAV vectors was also efficient to rescue dystrophin expression in 
the brain of mdx mice [355], or in the heart of GRMD dogs [270-271] by local 
injections. The proof-of-concept of this snRNA-mediated exon skipping strategy was 
also demonstrated on human sequences since, despite strong sequence homology 
between the human and mouse dystrophin genes, an antisense sequence targeting the 
same pre-mRNA sequence in both species can result in different exon skipping 
efficiencies [356]. Chimeric snRNAs carrying antisense sequences against the 5' and 3' 
splice sites of exon 51 efficiently induced high levels of exon 51 skipping and rescued 
dystrophin synthesis in myoblasts from patient with deletion of exons 48 to 50 [210]. 
 
A downside to the antisense-mediated modulation of pre-mRNA splicing is the need to 
design and validate a new antisense sequence for each different exon to be skipped, 
which require the assessment of several different sequences every time and can be 
fastidious and relatively expensive. An alternative to the conventional modified snRNA 
approach has been proposed to counter this issue, based on the principle of bifunctional 
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oligonucleotides using the TOSS technology. It has been recently shown that tailed U7 
snRNA, carrying a binding sequence for the target dystrophin exon 51 and a splicing 
silencer sequence moiety that is recognized by hnRNP proteins, can be packed into 
lentiviral vectors and induce efficient exon 51 skipping associated with novel dystrophin 
expression in myoblasts from DMD patients, and in vivo in the hDMD mouse using 
AAV vectors [268]. Whilst the binding sequence itself probably plays a role in this 
result, as an antisense oligonucleotide composed of the same sequence targeting the 
same exonic site has previously been reported to induce exon skipping [357], it was also 
apparent that the addition of the splicing silencer sequence to this antisense moiety 
greatly increased the exon skipping efficiency. This observation suggests that the 
splicing silencer tail is sufficient to induce good levels of exon skipping on its own, even 
when the binding sequence of the bifunctional oligonucleotide does not mask an 
important splice signal. This strategy eliminates the need for screening numerous 
sequences when selecting an efficient steric-blocking oligonucleotide since, as long as 
the RNA binding moiety hybridize with the chosen exon, the silencer binding moiety 
will induce the skipping of this exon regardless of the binding site. The design of exon 
skipping AONs is therefore greatly facilitated by this approach, which is easily adaptable 
to many different exons. 
Another difficulty faced by this AAV-based delivery of antisense sequences is the issue 
of personalized medicine for DMD patients: as many different mutations in the 
dystrophin gene can cause DMD, a different AON treatment must be designed for 
virtually every mutation. The adaptation of AAV-mediated delivery to multiexon 
skipping would in theory imply the production and co-administration of numerous viral 
vectors, one for each snRNA-antisense to be used in the cocktail, which is not realistic 
for clinical purposes. However a recent study showed that multiexon-skipping can be 
achieved using multiple U7 snRNA cassettes combined into one single AAV vector. 
Three U7snRNA targeting exons 45, 46, and 47 of human dystrophin were introduced 
sequentially in a AAV vector and hDMD mice injected intramuscularly showed efficient 
skipping of these three exons, with an efficiency almost as high as that of single exon 
skipping [269]. These results are very promising for DMD therapy as they give a proof-
of-concept for AAV-mediated multiexon skipping in vivo, which would enable to 
associate the high-efficiency of AAV vectors for muscle targeting with the possibility of 
optimizing a single drug to treat a high number of patients. 
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The difficulty of targeting all muscles in the body still represents one hurdle that 
prevents AON-directed exon skipping to reach its full potential for the treatment of 
Duchenne muscular dystrophy. In the case of AAV-mediated delivery of antisense 
sequences, it is currently estimated that doses of more than 1013 vector genome per kg 
are required to transduce all the muscles in a mouse model [358], which by extrapolation 
would represent very elevated doses for a DMD boy , likely to trigger an immune 
response. It is therefore of crucial importance to lower the dose of vector necessary to 
obtain sustained therapeutic effects. Identifying the appropriate AAV serotype, such as 
using AAV6, AAV8 or AAV9 that demonstrate natural tropisms for muscle and are the 
most efficient for crossing the blood vessel barrier for systemic gene transfer [318, 358-
359], can help increasing the transduction efficiency of the target tissue and diminish the 
required doses for treatment. The genetic engineering of AAV vectors, including 
modification of their capsid proteins, can provide immune evasion for the vector and 
therefore increase transduction efficiency [359-360]. The work described in this thesis 
focuses on the development of improved vector systems that would enable to maximise 
the amount of antisense sequences delivered to a target tissue and would therefore allow 
a reduction of vector dose.  
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VI. Objectives of the study 
The objective of this project is to find new and improved ways of modulating pre-
mRNA processing and splicing. As mentioned earlier, several studies have now 
demonstrated the efficacy of chimeric snRNAs to induce therapeutic exon skipping in 
animal models of Duchenne Muscular Dystrophy (DMD) or in cells from Duchenne 
patients. The main limitation of this approach for clinical translation remains the large 
amount of snRNA expressing vector which needs to be produced and administered to 
patients in order to restore therapeutic levels of dystrophin protein. These high doses of 
snRNA-carrying AAV vectors are potentially toxic for the patients and are currently 
challenging to produce in vector manufacturing facilities. Improving the therapeutic 
index of these vectors is therefore of critical importance to allow reducing the vector 
dose for clinical application and to avoid the need for re-administration. This can be 
achieved partly by using the appropriate AAV serotype for muscle and heart delivery, 
but also by optimizing the expression level of chimeric snRNA shuttles. 
Here we try to maximize the amount of active antisense sequences delivered to a target 
cell or tissue and obtain robust and long-term levels of expression using more efficient 
and tissue-specific expression cassettes. For this purpose we will explore different 
approaches:  
 - we will first try to optimize the AAV mediated delivery of antisense sequences 
for dystrophin exon skipping by using self-complementary AAV vectors (scAAV), 
which have been demonstrated to present a faster and enhanced transduction efficiency 
compared to their single-stranded counterparts. U7 snRNA cassettes carrying antisense 
sequences for mouse dystrophin exon 23 skipping will be packaged in scAAV vectors 
and the efficiency of this system to increase both the level of antisense sequences readily 
available in the transduced cells and the resulting skipping of the target mRNA will be 
tested in mouse skeletal muscle cells cultures. 
 - Secondly, we will try to increase the level of expression of chimeric U7 snRNA 
cassettes in a tissue-specific manner through the use of enhancer elements. A muscle 
and heart-specific enhancer, MHCK, will be assembled and inserted directly upstream 
of the natural U7 promoter in the snRNA cassette designed for mouse dystrophin exon 
23 skipping. The ability of this strong transcriptional enhancer to drive high-level and 
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tissue-specific expression of modified U7 cassettes will be tested in vitro in mouse 
muscular cells and in vivo in the mdx mouse model. 
 - As a third goal in this study, we aimed to identify improved ways of 
modulating pre-mRNA processing by creating new small RNA cassettes designed for 
splicing alteration. For this purpose, we explored the possibility of using small nucleolar 
RNAs (snoRNAs) as novel molecular platforms for the intracellular delivery of 
antisense sequences. Some C/D box snoRNAs naturally associate with pre-mRNAs and 
regulate their alternative splicing through complementary base pairing. By replacing 
native antisense elements of such snoRNAs with antisense sequences for mouse 
dystrophin exon 23 skipping, we will test the efficiency of this new snoRNA-based 
antisense delivery system to trigger exon 23 skipping when delivered by AAV vectors in 
mouse cultured myotubes. 
 - Finally, the natural property of C/D box snoRNAs to direct the 2’-O-ribose 
methylation of cellular RNAs on precise nucleotides will be investigated as another 
strategy to modulate splicing. A human snoRNA will be engineered to specifically guide 
the 2’-O-ribose methylation of a chosen adenosine branch point in a target pre-mRNA 
in order to inactivate branch point recognition by the splicing machinery and induce the 
skipping of the downstream exon. This approach will first be designed to modulate the 
splicing of an exon skipping reporter construct based on the splicing-dependent 
activation of a luciferase gene, ultimately aiming to apply this approach for dystrophin 
exon skipping.  
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RESULTS 
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I. Optimising the levels of modified U7 snRNA expression to 
improve Dystrophin exon skipping 1 
The delivery of antisense sequences inserted into small nuclear RNA cassettes by viral 
vectors requires further optimisation before being suitable for clinical translation, as 
considerable amounts of vector would still need to be administered to DMD patients in 
order to restore therapeutic levels of Dystrophin protein in all muscular tissues. In an 
attempt to maximise the therapeutic index of such vectors, we first tried to use self-
complementary AAV (scAAV) vectors to deliver antisense-expressing U7 snRNA 
cassettes for dystrophin exon skipping in muscular cells. ScAAV vectors have previously 
demonstrated enhanced transduction efficiencies over single-stranded AAV vectors, and 
this increased efficiency could enable to obtain elevated levels of transgene expression at 
minimal doses of vector, which is a critical property for clinical applications. The small 
size of U7 snRNA cassettes enables their packaging as inverted repeat genome in 
scAAV vectors and we therefore expressed the U7Dtex23 cassette for mouse 
dystrophin exon 23 skipping in such vectors and tested their potential to increase the 
level of antisense sequences readily available in transduced mouse cells for splicing 
modulation and to improve Dystrophin restoration in muscular tissues.  
Another optimisation strategy explored in this chapter consists in using muscle-specific 
enhancer elements to drive the expression of the U7Dtex23 cassette, aiming to increase 
the amount of transcripts produced from a single expression unit. The identification and 
use of such enhancer elements capable of inducing high-level of transgene expression in 
both cardiac and skeletal muscle could enable to maximise the amount of product 
expressed in muscle tissues and to improve the skipping of mouse dystrophin exon 23 
whilst diminishing the vector dose needed to be administered for therapeutic correction 
of dystrophin mRNA splicing.  
  
1 These results have been published in part in 361. Eckenfelder, A, Tordo, J, Babbs, A, Davies, KE, 
Goyenvalle, A and Danos, O, The Cellular Processing Capacity Limits the Amounts of Chimeric 
U7 snRNA Available for Antisense Delivery. Mol Ther Nucleic Acids, 2012. 1: p. e31. This paper is 
shown in Annex 1. 
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I. 1. Assessing the best time point to target dystrophin pre-mRNA for exon 
skipping  
In order to test and compare the efficiency and tissue-specificity of the various 
optimised small RNA-antisense cassettes delivered by AAV vectors, we first needed to 
identify the optimal time to transduce the C2C12 mouse muscle cell line used in this 
study, especially regarding the differentiation state of the cells at the time of 
transduction, in order to target dystrophin pre-mRNA for exon skipping. 
It has not yet been clearly established at what stage of the myogenesis process the 
dystrophin gene (dmd) starts to be transcribed and spliced. Some studies suggest that 
dmd is not expressed in mononucleated myoblasts and that dystrophin transcription is 
only initiated as cultured myoblasts begin to differentiate and fusion into multinucleated 
myotubes [303, 362-363]. Conversely, other studies show that in mouse myogenic cell 
lines such as C2C12, the dystrophin gene is already activated and expressed at the 
myoblastic stage before being strongly up-regulated in the course of in vitro myogenesis, 
increasing to up to 40 times during differentiation into myotubes [364]. Finally it has 
been estimated that approximately 16 h are required for the polymerase to transcribe the 
entire dystrophin gene in myogenic cultures and that the transcripts already start to be 
spliced at the 5’end before transcription is complete [78]. It is therefore really important 
to determine more precisely when the best time point for C2C12 cells transduction is in 
order to achieve efficient dystrophin exon skipping, taking into account the time needed 
for dystrophin to be transcribed and the moment it becomes spliced. 
To determine more precisely the kinetics of dmd gene transcription and to assess when 
the transcript levels reach a steady state in cultured myotubes in the course of in vitro 
myogenesis, we assessed the dystrophin mRNA levels in the C2C12 muscle cell line by 
RQ-PCR (Real-time Quantitative Polymerase Chain Reaction) at different time points 
during myogenesis and differentiation. C2C12 myoblasts were amplified and 
differentiated for up to 14 days and total mRNA was extracted at different time points, 
from 1 day of proliferation (prolif+1d) to 14 days of induced differentiation (diff+14d). 
 A Taqman assay was then performed on reverse-transcribed mRNAs using primers and 
probes specific for the mouse dystrophin mRNA (see Material and Methods), and the 
relative amounts of transcript detected were normalised at each time point with the 
endogenous 18s rRNA expression levels (Figure 39). The 18s ribosomal RNA was 
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considered as a useful endogenous control as the rRNA transcripts are produced by a 
distinct polymerase [365] and are constitutively expressed. Furthermore, it has been 
shown that rRNA expression levels are less likely to vary between different tissues, 
stages of development or in response to variations of treatment conditions than 
mRNAs, such as β-actin or GAPDH that are also traditionally used as internal controls 
[366-367]. 
 
 
Figure 21: kinetics of dmd gene transcription in the course of in vitro 
myogenesis in C2C12 muscle cell line. 
The relative dystrophin transcript levels were normalised to the endogenous 
18s ribosomal RNA and multiplied by a factor of 108 for readability. Each time 
point represents an average of 3 independent experiments. Error bars are 
shown as mean ± SEM  
 
The results presented here suggest that the dystrophin transcript is close to undetectable 
at the myoblastic stage whilst the cells are still proliferating, including after one day of 
induced differentiation. We note that the level of dystrophin mRNA seems to be higher 
after 3 days of proliferation than after one day in differentiation conditions, which 
probably represents an artefact of the experiment as the myoblasts reached a confluent 
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state in culture, inducing them to spontaneously start the differentiation process. We 
observe that the dystrophin transcript begins to be up-regulated after the muscular cells 
experienced 3 days of induced differentiation and started to fuse into myotubes. At later 
time points, the dystrophin levels steadily increase in time until 14 days after 
differentiation, when the transcript production seems to finally slow-down and plateau 
in some of the cultures.  
As we want to target the dystrophin pre-mRNA whilst it is still being transcribed, 
considering that the transcription and splicing of this precursor occur simultaneously, 
we then hypothesised that transducing the myotubes around day 7 of induced 
differentiation, when the dystrophin transcript levels didn't reach a steady state yet, 
should enable us to target and alter the dystrophin pre-mRNA splicing. We therefore 
adapted the transduction protocol of C2C12 muscular cells based on these dystrophin 
kinetics results and decided to transduce the cells at 7 days post-differentiation for our 
subsequent dystrophin exon skipping experiments. 
 
I. 2. Optimal levels of antisense sequences using self-complementary AAV 
vectors 
I. 2. 1. Principle and objective 
Adeno-associated viruses need to convert their single-stranded DNA (ssDNA) genomes 
into double-stranded DNA (dsDNA) prior to expression, which can be achieved either 
by synthesis of the complementary DNA strand [368] or by base pairing of the plus and 
minus strands from two co-infecting viruses into the same cell when the AAV vectors 
are administered at high doses [369]. However, this ssDNA to dsDNA conversion is a 
slow and rate-limiting process during AAV transduction of a target cell, delaying gene 
expression and hindering efficiency of the viruses in many cell types. AAV vectors 
containing a genome of half the size of the wild-type AAV genome are occasionally able 
to package their DNA as dimer molecules that can directly fold into double-stranded 
DNA [370]. These self-complementary AAV vectors (scAAV) circumvent the 
requirement for DNA synthesis or base-pairing between multiple vector genomes and 
therefore present an enhanced transduction efficiency compared to their single-stranded 
counterparts by inducing a faster and higher level of transgene expression.  
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It is therefore possible to produce scAAV vectors simply by decreasing the genome size 
to approximately 2.3 kb or less so that the newly created dimeric inverted repeat DNA 
does not exceed the maximal packaging capacity of 4.7 kb of wild-type AAV. The 
vectors produced through this strategy are however not only composed of dsDNA but 
are usually a combination of ssAAV and dsAAV.  
In order to efficiently and predominantly produce self-complementary particles, two 
different groups have engineered the AAV genome in a way that forced the creation of 
dimeric genomes. A first approach to generate self-complementary rAAV vectors was to 
delete the terminal resolution site (trs) of one ITR , leaving the second ITR intact [372]. 
The second technique involved the deletion of the D-sequence, which constitute the 
packaging signal, along with removal of the trs on one ITR [373] (Figure 41). In both 
cases, the dimer genomes fail to be resolved into monomers and lead to the production 
of a high proportion of scAAV vector. 
 
Figure 22: engineering of scAAV vectors 
Self-complementary vectors are generated through deletion of the terminal 
resolution site (trs) of one ITR, with or without deletion of the packaging signal 
(D) on the same ITR, and leaving the second ITR intact for replication and 
packaging functions. 
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The effect of such mutations is that, when the replication that started at the wild-type 
ITR reaches the mutated ITR, the Rep protein fails to recognize the trs and therefore 
does not cut the genome at this site to form single-stranded DNA. The replication 
instead continues past the mutated ITR without terminal resolution and back across the 
genome to create the dimer DNA until it reaches the initiating wild type ITR. The final 
product of replication is therefore a dimeric inverted repeat genome that contains the 
mutated ITR in the middle and two wild-type ITRs at each end [374]. This self-
complementary molecule can initiate normal rounds of replication from its wild-type 
ITR and generate several hairpin-like dimeric genomes that can fold as dsDNA and can 
be efficiently packaged in the viral particles through their remaining wild-type ITR. 
The counterpart to the increased efficiency of scAAV vectors is that the entire vector 
genome, including the ITRs, has to be smaller than 2.4 kb to meet the requirements for 
efficient AAV packaging. This very limited cloning capacity prevents the use of scAAV 
vectors for many gene replacement approaches. Yet, a number of applications based on 
the use of small transgenes, such as antisense cassettes or small interfering siRNAs can 
benefit from the enhanced transduction efficiency of these vectors. Self-complementary 
vectors have demonstrated increased and faster transduction in a variety of tissues [374]: 
they resulted in more robust and stable transgene expression and more effective DNA 
circularization in mouse liver, brain and muscle [372-373]. The delivery of small 
therapeutic agents, such as ribozymes and siRNAs, has also shown improved efficacy 
using scAAV [375-376]. The systemic administration of scAAV vectors carrying a mini-
human factor IX (hFIX) transgene in mice induced a 20-fold increase in hFIX 
expression in liver compared to conventional ssAAV vectors [377]. The same construct 
also efficiently transduced the liver of nonhuman primates after systemic injection and 
allowed the restoration of therapeutic levels of hFIX at a much lower dose than usually 
needed with ssAAV [377-378]. Finally, a self-complementary AAV vector was recently 
used to systemically deliver U7snRNA cassettes designed for mouse dystrophin exon 23 
skipping and successfully induced the restoration of high levels of dystrophin protein in 
the severe dKO mouse model [267].  
Considering the small size of antisense-expressing U7 snRNA cassettes, it is possible to 
package them as an inverted repeat genome in scAAV vectors and we therefore decided 
to use this type of vector in our study, aiming to increase the level of antisense sequence 
readily available in the transduced cells for splicing modulation.   
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I. 2. 2. Self-complementary AAV vector to express the U7Dtex23 cassette 
and improve transduction of myotubes 
 
The read-out in this study is the efficiency of dystrophin exon 23 skipping in mouse 
skeletal muscle cells as a result of modified U7 snRNA expression. The snRNA cassette 
used, U7Dtex23, is designed to induce exon 23 skipping in mouse DMD pre-mRNA by 
specifically recognising two different target sequences: the donor splice site of intron 23 
and the branch point of intron 22 [266]. The U7Dtex23 cassette, containing its own 
promoter and terminator sequences, was amplified by polymerase chain reaction (PCR) 
and introduced between the inverted terminal repeat sequences of a self-complementary 
AAV vector (Figure 42, and see material and methods). The construct, termed AAV-
sc-U7Dtex23 was verified and validated by restriction enzymes digestion and 
sequencing and the efficiency of this system to express high levels of antisense 
sequences and to increase the correction of the dystrophin transcript compared to 
ssAAV was tested in mouse skeletal muscle cells cultures. 
 
 
 
Figure 23: AAV-sc-U7Dtex23 vector for mouse dystrophin exon 23 skipping 
U7Dtex23 snRNA contains the optimised SmOPT sequence and a double target 
antisense sequence directed against the branch point of intron 22 (BP22) and 
the splice donor of exon 23 (SD23) on the mouse dystrophin pre-mRNA [266]. 
The U7Dtex23 snRNA cassette, represented here from 3' to 5' and containing 
the U7-specific promoter and 3'box at each end, is inserted between the ITR of 
a self-complementary AAV vector, where the 3' ITR is deleted of the terminal 
resolution site (trs) sequence. 
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We first compared different AAV serotypes, AAV2/8 and AAV2/5, for their efficiency 
to transduce C2C12 muscular cells in culture and observed that the AAV2/5 viral 
serotype was more efficient at expressing a GFP transgene in differentiated myotubes 
when administered at 7 days after differentiation and at a MOI of 104 vg/cell (data not 
shown). We therefore selected this serotype for all the in vitro AAV transduction 
experiments in this study. We then produced AAV2/5-sc-U7Dtex23 and conventional 
AAV2/5-U7Dtex23 viral vectors by triple transfection of 293T cells and purified the 
harvested viral particles by affinity chromatography on an AVB sepharose column. The 
viral titer of these vectors assayed by quantitative PCR enabled to estimate a multiplicity 
of infection (MOI), corresponding to the number of viral genomes administered per 
cell, with which to transduce the cells. Cultured C2C12 cells were then transduced at 7 
days post-differentiation, according to the results of the kinetics experiment, with either 
of the AAV2/5 viral preparations at MOI 105 or 106 particles per cell.  
We also included a control self-complementary AAV vector expressing a non-relevant 
sequence to assess if the mere transduction of C2C12 cells with such vectors would 
impair the dystrophin splicing. We chose the wild-type (wt) U7 snRNA carrying the 
natural U7 antisense, and inserted it in the scAAV vector to produce AAV2/5 particles. 
C2C12 cells were transduced with this vector in parallel with the other transduction 
experiments. Total RNAs were extracted from transduced cells at 7 days post-
transduction and we compared the efficiency of scAAV and conventional AAV vectors 
to express the U7Dtex23 cassette and to induce dystrophin exon skipping. 
 
- Northern blot analysis of U7Dtex23 expression in transduced cells 
We first assessed the RNA extracts from the transduced cells for U7Dtex23 expression 
by Northern blot in order to match the amount of snRNA actually expressed in the cells 
with the exon skipping efficiency observed. Total RNAs were loaded on denaturating 
gels and the resulting blots were hybridized with a probe specific for the Dtex23 
antisense sequence expressed in the U7 cassette. An additional probe specific for the 
endogenous U2 snRNA was used in order to normalise the signals obtained (Figure 
43). 
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 Figure 24: northern blot analysis of U7Dtex23 snRNA expressed in 
transduced mouse C2C12 cells 
The U7Dtex23 chimera is 86 nucleotides long and the wild-type U2 snRNA is 
detected at 187 nt. A schematic representation of the U7Dtex23 cassette is 
shown on the right hand side, indicating the approximate position of the 32P 
end-labeled probe recognizing the Dtex23 antisense sequence in the U7 snRNA. 
A second band of approximately 65 nt also reacts with the Dtex23 probe 
(bottom question mark), as well as some high molecular weight species (top 
question mark). NT represents non-transduced cells. A 15% TBE-Urea gel was 
used. 
 
The U7Dtex23 transcript was readily detected at 86 nt in all the transduced samples. As 
expected, the transcript was absent from the sample corresponding to the non-
transduced cells (NT). The endogenous U2 snRNA signal indicated that approximately 
the same amounts of RNAs were loaded for each condition. A dose-response could be 
observed of the amount of U7Dtex23 transcript expressed in the cells depending on the 
dose of viral vector used as we could see a slightly stronger U7Dtex23 signal for the 
cells transduced at MOI 106 compared to that of the cells transduced at MOI 105. This 
difference of signal representative of the transcript expression was however not 
dramatic and suggested that saturating levels of U7 cassette could have been expressed 
in the cells following treatment at such high doses, thereby hampering the distinction of 
signal strength on the Northern blot. 
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It was not clear from this analysis whether the use of the self-complementary vector 
induced a stronger expression of the transgene than the normal AAV vector at 
comparable doses. At the highest dose of vectors administered (MOI 106), the 
U7Dtex23 signal obtained at 86 nt from each vectors seemed to be saturated and 
therefore prevented a comparison of the vectors efficiency. However, at lower dose the 
self-complementary vector seemed to increase the amount of U7Dtex23 expressed 
compared to the one observed with the conventional AAV vector (compare lanes 2 and 
4). We could also detect a second band on the Northern blot, around 20 nucleotides 
shorter than the expected U7Dtex23 transcript, that also reacted with the U7Dtex23-
specific probe. Furthermore, high molecular weight (HMW) species that seemingly 
increased with the dose were detected. These phenomena have to our knowledge not 
been described or explained before and will therefore be further investigated in this 
study (see results sections I. 3. and I. 5) 
 
- Analysis of exon 23 skipping in mouse Dmd mRNA by nested PCR 
In order to analyze the exon 23 skipping obtained on mouse dystrophin mRNA after 
transduction of AAV2/5-sc-U7Dtex23 or AAV2/5-U7Dtex23 viral vectors, the RNA 
extracts from these cells were reverse-transcribed and used in a nested PCR reaction, 
where two successive rounds of PCRs enabled to specifically amplify and detect the 
dystrophin transcript from exons 20 to 26, thereby differentiating mRNAs still 
containing exon 23 with mRNAs efficiently depleted of it (Figure 44). 
The full-length dystrophin transcript containing exon 23 and amplified from exon 20 to 
exon 26 produces a 901 bp fragment, as illustrated on the right hand side of figure 44a. 
The non-transduced cells (NT), as expected, showed only a 901bp band corresponding 
to the complete dystrophin transcript from exon 20 to 26. Furthermore, the negative 
control AAV2/5-sc-U7wt displayed only a 901 bp product. 
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 Figure 25: exon 23 skipping analysis in transduced mouse muscular cells 
(a) Reverse transcription and nested PCR detection of dystrophin exon 23 
skipping after transduction of C2C12 cells with AAV2/5-sc-U7DTex23 or 
AAV2/5-U7DTex23 at various MOI. A schematic representation of the PCR 
primers and products is shown on the right hand side. AAV2/5-sc-U7wt is 
included as a negative control of skipping. NT represents non-transduced cells 
and RT- is a control without reverse transcriptase. The native dystrophin 
mRNA is detected at 901 bp (yellow star) and the skipped mRNA yields a 688 
bp product (double yellow star). A third product is detected on the gel (white 
star). (b and c) Sequencing of the 688 bp band (double yellow star) and of the 
third band (white star) extracted from gel (a), respectively. The exons are 
inversed on the chromatograms as the sequences were produced from a reverse 
primer.  
 
In the samples transduced with AAV2/5 viral vectors specific for dystrophin mRNA we 
observed a band of 688 bp that corresponds to the dystrophin transcript depleted of 
exon 23 (double yellow star, Figure 44a). Gel extraction of the 688 bp band and 
sequencing confirmed that exon 23 was successfully skipped in these RNA species, 
creating a correct junction between exon22 and 24 (Figure 44b). 
A smaller band was also observed on the gel in the samples where exon 23 skipping was 
induced by U7 snRNA expression (white star, Figure 44a). The sequencing of this band 
indicated that these RNA species are 542 bp long and correspond to a double exon 
skipping event where dystrophin mRNA lacks both exons 22 and 23, creating a clean 
junction between exons 21 and 24 (Figure 44c). Similar additional amplification 
products of ~542 bp have been reported previously [256] and their appearance seem to 
correlate with the advanced age of the culture. These mRNA species are out of frame 
and cannot yield a functional dystrophin protein. 
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We observed a good dose-response of the amount of skipped dystrophin transcript 
depending on the amount of viral vector administered on the cells. This was consistent 
with the amount of U7Dtex23 transcript expressed in the cells (Figure 43).  
This experiment suggests that the use of self-complementary AAV vectors enabled to 
increase the amount of antisense sequences expressed in the cells and the associated 
level of dystrophin exon skipping compared to the use of a normal AAV vector. To 
determine more stringently the potential beneficial effects of the self-complementary 
AAV vector we sought to obtain more quantitative data.  
 
- Analysis of exon 23 skipping in mouse Dmd mRNA by quantitative 
real-time PCR 
The proportion of skipped dystrophin transcripts obtained in each condition was 
quantified using a Real-Time Quantitative PCR (RQ-PCR) assay in order to compare 
the efficiency of each vector.  
A Taqman assay for dystrophin exon skipping was designed, where a set of primers and 
probe specific for exon 22-24 junction enables to specifically estimate the amount of 
transcripts depleted of exon 23. Another set of primers/probe specific for exon 22-23 
junction detects full-length dystrophin transcripts containing exon 23 (see material and 
methods and Figure 45, right hand pannel). RNA extracts obtained from C2C12 cells 
transduced with AAV2/5-sc-U7DTex23 or AAV2/5-U7DTex23 at MOI 105 or 106 
were reverse-transcribed and analysed by Taqman RQ-PCR.  
In this assay the emission of a fluorescent signal is directly proportional to the amount 
of product formed at each PCR cycle and the Ct (cycle threshold) is defined as the 
number of cycles required for the fluorescent signal to cross the threshold level. A 
comparative CT quantitative analysis of exon 22-24 junctions (skipped dystrophin) and 
exon 22-23 junctions (non-skipped dystrophin) was performed on each sample, which 
involved the subtraction of the Cts for the 22-23 assay from the CTs for the 22-24 assay 
to obtain a delta Ct value for each condition. The delta Ct can then be used to calculate 
the relative amounts of skipped dystrophin RNA species relative to full length species 
(Figure 45). 
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 Figure 26: analysis of mouse exon 23 skipping by RQ-PCR 
The graph represents the ratio between the exon 22–24 junction (skipped 
mRNA species) and the exon 22–23 junction (full-length mRNA species). 
Quantification was performed on mRNA extracts from C2C12 cells transduced 
with AAV2/5-sc-U7DTex23 (scU7) or AAV2/5-U7DTex23 (U7) at the indicated 
MOI and harvested at 7 days post-transduction. A schematic representation of 
the RQ-PCR primers and probe used is shown on the right hand side. Each 
condition represents an average of 5 independent experiments. No significant 
difference was observed between the various conditions, according to Student’s 
t-test (P value > 0.05). Error bars are shown as mean ± SEM.  
 
We could observe that the delivery of the U7Dtex23 cassette by a self-complementary 
AAV vector seemed to produce a slight increase in the proportion of skipped transcripts 
relative to full-length dystrophin species compared to that obtained from the use of 
conventional AAV vectors. Of note, we could observe that the ratios between skipped 
and non-skipped dystrophin species obtained by this Taqman assay seem much higher 
than those evaluated from the nested PCR realised previously on the same samples 
(Figure 44). Although we could not explain this observation, the moderate increase in 
skipped dystrophin mRNAs obtained with the scAAV vector was also detected by the 
nested PCR analysis. This beneficial effect of the self-complementary vector was 
however very moderate according to the RQ-PCR results and the difference in exon 
skipping efficiency was not statistically different. Moreover, the important error bars 
showed on each histogram, especially at the highest dose of virus, indicate that this 
experiment presents a relatively low reproducibility and that the efficiency of exon 
skipping can vary from one sample to another. We hypothesised that in order to assess 
the efficiency of the self-complementary AAV vectors to induce an accelerated 
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transduction compared to conventional single stranded AAV vectors it would be 
interesting to compare the exon skipping efficiency obtained from each vector at an 
earlier time-point after transduction.  
 
- Analysis of scAAV kinetics of transgene expression and resulting 
exon 23 skipping by RQ-PCR 
We therefore transduced more differentiated C2C12 mouse myotubes with AAV5-sc-
U7Dtex23 and AAV2/5-U7Dtex23 viral vectors at a dose of 105 particles per cell. The 
cells were harvested at 4 days or at 8 days after transduction and we compared the level 
of exon skipping obtained in each condition by Taqman RQ-PCR on the various RNA 
extracts (Figure 46). This experiment aimed at assessing if, at 4 days after transduction, 
the scAAV vector enables to induce higher levels of dystrophin exon skipping than 
normal AAV vectors, reflecting their ability to improve transduction by accelerating the 
expression of the transgene in host cells. 
 
 
Figure 27: analysis of scAAV transgene expression rapidity reflected by 
induction of dystrophin exon 23 skipping  
The graph represents the ratio between exon 22–24 junction and exon 22–23 
junction in dystrophin mRNA species extracted from C2C12 cells transduced 
with AAV2/5-sc-U7DTex23 (scU7) or AAV2/5-U7DTex23 (U7) at MOI 105. The 
cells were harvested at 4 days or at 8 days post-transduction. Each condition 
represents an average of 3 independent experiments. No significant difference 
was observed between the various conditions, according to Student’s t-test (P 
value > 0.05). Error bars are shown as mean ± SEM.  
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 This result indicated that, at 8 days after transduction, the exon skipping efficiency 
obtained with the scAAV vector could be considered equivalent to the one obtained 
with the single-stranded AAV (ssAAV) according to the error bars, which reflected a 
comparable level of U7Dtex23 transgene expression in the host cells. However, at 4 
days after transduction the scAAV vector importantly increased the ratio of skipped 
against non-skipped dystrophin transcripts, bringing the proportion of skipped species 
approximately two times higher than the one recorded with the regular AAV vector (left 
hand side histograms). Moreover, four days only after transduction the scAAV vector 
already generated a proportion of skipped mRNA species equivalent to the one 
obtained at 8 days post-transduction with the same vector or with the ssAAV vector, 
indicating that the levels of U7Dtex23 expressed in the transduced cells after 4 days was 
already at its highest. On the other hand, the ratio of corrected transcripts compared to 
full-length transcripts obtained from the conventional AAV vector only reached similar 
levels after 8 days of incubation, implying a slower rate of transgene expression. These 
data demonstrate that the rate of transgene production is accelerated with the use of 
scAAV vectors, inducing a high level of dystrophin exon 23 skipping early after 
transduction and much faster than that obtained form ssAAV vectors. 
We further wanted to assess the efficiency of the self-complementary AAV vectors to 
induce an increase in transgene expression compared to conventional single stranded 
AAV vectors by comparing the exon skipping efficiency obtained from each vector at a 
lower dose. It is possible that the scAAV efficiency over the single-stranded vector is 
mostly noticeable at lower doses as the high amount of antisense sequence expressed at 
such high doses (MOI 105) could have reached a saturating level, which could trigger the 
antisense sequences to naturally associate two by two and form double-stranded 
structures spontaneously, hiding the potential effect of the self-complementary vector.  
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- Analysis of scAAV increase of transgene expression illustrated by 
dystrophin exon 23 skipping  
To ascertain the potential beneficial effect of the self-complementary vector in 
increasing the amount of U7 snRNA transgene expression at a given vector dose, we 
transduced C2C12 muscular cells at a lower MOI, 103 viral genome per cell, to limit the 
number of available antisense sequences in each cells and prevent the spontaneous 
formation of double-stranded sequences. The cells were harvested and RNAs extracted 
at 4 days after transduction and a Taqman RQ-PCR quantitifying of the proportion of 
skipped transcripts against non-skipped dystrophin mRNA was realised (Figure 47).  
 
The delivery of U7Dtex23 cassettes by scAAV vectors induced a dramatic increase in 
the proportion of skipped dystrophin transcripts compared to the use of ssAAV 
vectors. This improvement was highlighted here by the use of lower doses of vectors 
and the difference between the samples treated with AAV-sc-U7DTex23 and the 
samples treated with AAV-U7DTex23 was statistically significant according to the 
Student’s t-test (P value <0.05). This result illustrates the potential of scAAV vectors to 
increase transgene expression. We could observe that, for the same dose of vector, the 
scAAV is able to readily express higher amount of U7 snRNA cassette than the ssAAV, 
thereby inducing a three to four fold increase in the resulting proportion of exon 23 
skipped dystrophin mRNA. This observation suggests that the use of self 
Figure 28: analysis of scAAV levels of 
transgene expression illustrated by 
induction of dystrophin exon 23 skipping 
The graph represents the ratio between 
exon 22–24 junction and exon 22–23 
junction in dystrophin mRNA species 
extracted from C2C12 cells transduced 
with AAV2/5-sc-U7DTex23 (scU7) or 
AAV2/5-U7DTex23 (U7) at MOI 103. The 
cells were harvested at 4 days post-
transduction. Each condition represents an 
average of 5 independent experiments. A 
significant difference is observed as shown 
by the P value (P = 0.023), according to 
Student’s t-test. Error bars are shown as 
mean ± SEM.  
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complementary vectors could enable to decrease the dose necessary to obtain significant 
levels of exon skipping, which is of utmost interest in the context of DMD where high 
doses of vector are so far deemed necessary for therapeutic benefits. The self-
complementary AAV vectors therefore constitute a very promising tool to express U7 
snRNA cassettes for dystrophin exon skipping as they enable a faster and increased 
expression of chimeric snRNAs, resulting in a greater efficiency of exon 23 skipping in 
the mouse dystrophin mRNA in the C2C12 cell line. 
 
I. 3. Analysing the origin of the extra-processed U7Dtex23 sub-products 
On the Northern blots for U7Dtex23 transcripts detection after transduction of 
muscular cells we observed the generation of a second smaller transcript, about 20 
nucleotides shorter than the expected U7Dtex23 size, that also reacted with the 
U7Dtex23-specific probe (Figure 43, bottom question mark). This surprising 
observation compelled us to investigate the origin and cause of this hyper-processing of 
the U7 snRNA cassette.  
- Effect of the size of the transcript on U7 snRNA cassettes processing 
Our first hypothesis was that this shortening could be triggered by the increased size of 
the U7 transcript when modifying its antisense sequence, as the U7Dtex23 is 86 
nucleotides long, more than 20 nucleotides longer than the original mouse U7 snRNA 
transcript of 62 nucleotides. It is therefore possible that the intracellular processing 
machinery further process the modified U7 cassette to shorten the U7 transcript back to 
its natural size. To assess this hypothesis, the M23D(+07-18) antisense sequence 
targeting the donor splice site of dystrophin exon 23 [379] was inserted in the U7 
snRNA cassette by fusion PCR to replace the Dtex23 antisense sequence in the scAAV 
vector (see Material and Methods). This U7-M23D cassette produces a U7 transcript 
that is 66bp long, close to the original U7 wt size, and therefore provides a good way to 
assess if the extra-shortening of chimeric U7 snRNAs is size-dependent. We transduced 
C2C12 myotubes with self-complementary AAV2/5 vectors expressing the U7M23D or 
the U7Dtex23 constructs at MOI 104 to 106 and harvested the cells at 7 days post-
transduction. The extracted RNAs were used in a Northern blot assay using the Dtex23 
probe and the M23D probe for U7M23D transcripts detection (Figure 48). 
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Figure 29: northern blot analysis of U7Dtex23 and U7M23D snRNAs 
expressed in transduced mouse C2C12 cells 
(a) The 86 nt U7Dtex23 and the 66 nt U7M23D snRNA cassettes are 
represented, along with the position of the 32P end-labeled Dtex23 and M23D 
probes for their respective detection. (b) The U7Dtex23 is detected at 86 nt and 
a second band of approximately 65 nt also reacts with the Dtex23 probe (red 
star). The U7M23D is detected at 66 nt and a second band approximately 20 
nucleotides shorter is also observed (double red star). NT represents non-
transduced cells. A 15% TBE-Urea gel was used. 
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Regarding the samples obtained from the transduction of C2C12 cells with AAV2/5-sc-
U7Dtex23 vectors (lanes 1 to 3), the Northern blot indicated that the expected full-
length U7Dtex23 transcript is produced in the transduced cells in a dose-dependent 
manner. The additional extra-processed transcripts of approximately 65 nt were 
detected in these samples, similarly to the former Northern blot experiment (Figure 
43), and their production also depended on the dose of vector administered. 
Interestingly, in the AAV2/5-sc-U7M23 samples a second 20 nt-shorter band was also 
observed along with the 66 nt band corresponding to the U7M23D transcript, indicating 
that the U7M23D mRNA was also submitted to an additional processing event in the 
transduced cells. This observation proved that this additional processing is independent 
of the size of the U7snRNA cassette, thereby ruling out our first hypothesis. Since the 
probe used to detect the U7M23D transcript hybridizes on the 5’ end of the snRNA, 
this experiment also indicated that the additional processing event occurs on the 3’ side 
of the transcript, somewhere along the stem-loop structure, thereby shortening the 3' 
end of the transcript of approximately 20 nucleotides. 
Further analysis were therefore needed to determine if this phenomenon also occurs on 
the endogenous U7 transcript or if it affects only the exogenous modified U7 expression 
cassettes.  
 
- Analysis of endogenous U7 snRNA transcripts in human and mouse 
cell cultures 
To detect the endogenous U7snRNA in human 293T cells and mouse C2C12 cells by 
Northern blot a probe specifically hybridizing in the natural antisense sequence present 
in the U7 wild-type mRNA was designed. The U7 snRNA is well-conserved between 
mice and humans and the antisense sequence against histone H1 is identical in both 
species (Figure 49a), therefore a single probe (U7wt) could be designed to detect the 
U7 transcript in both the human and the mouse cell lines by Northern blot (Figure 
49b). 
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We could detect the U7 snRNA in both cells lines at the expected 62 nt and 63 nt sizes 
for mouse and human transcripts, respectively. The additional 20 nt-shorter band 
previously observed on the Northern blot detection for U7Dtex23 and U7M23D 
transcripts could however not be observed, indicating that the wild-type U7 snRNAs are 
not naturally submitted to an extra-processing event. This observation suggested that 
the 3' shortening of U7 chimeras is a result of modifications realised on the U7 snRNAs 
to engineer it into an antisense shuttle. The cause of this phenomenon must be either 
the modifications of the Sm binding site into the consensus SmOPT sequence made to 
the U7 shuttles or could stem from the antisense sequence introduced in the cassette. 
Alternatively, the generation of these shortened species could be the result of the AAV-
mediated delivery of U7 snRNAs and the transduction process. 
  
Figure 30: northern blot analysis of 
endogenous U7 snRNA transcripts in 
mouse C2C12 and human 293T cells 
(a) Nucleotide alignment of human and 
mouse U7 snRNAs. The nucleotides 
labelled in red are non-conserved. The 
conserved histone H1 antisense 
sequence, corresponding to the position 
of the U7wt probe for Northern blot 
detection, is underlined. (b) Northern 
blot analysis of endogenous U7 snRNA 
transcripts in mouse C2C12 and human 
293T cells. The murine and human 
transcripts are detected at 62 and 63 nt, 
respectively. The 187 nt U2 snRNA is 
used as a control. 15% TBE-Urea gel 
104 
 
 - Analysing the effect of the SmOPT sequence on the U7Dtex23 
processing  
 
In order to analyse whether the SmOPT sequence present in the modified U7 snRNA 
cassettes plays a role in the additional processing of U7 transcripts, different variants of 
the U7snRNA cassette were analyzed. We first modified the Sm sequence of the wild-
type U7 snRNA, which retains its natural 5′ sequences targeting Histone H1 mRNA, 
into the consensus SmOPT site by site-directed mutagenesis. Alternatively, it was 
envisaged that the antisense sequence itself could trigger this processing event in a 
sequence specific manner. To assess this later hypothesis we also altered the U7Dtex23 
cassette by reverting the SmOPT sequence to the Sm sequence present in U7 snRNAs.  
These constructs were transfected in human 293T cells and a Northern blot was realised 
on extracted RNAs (Figure 50). 
The data indicate that an additional 3' shorten transcript was generated only in the 
presence of the SmOPT mutations (Figure 50b). The transfected wild-type U7 cassette 
was only detected at the expected 62 nt and no shorter transcripts reacted with the 
probe. Additionally, the U7Dtex23 cassette was detected at 86 nt and further shortened 
to around 65 nt only when containing the SmOPT sequence. In contrast, the U7Dtex23 
construct containing the natural U7 Sm site was not processed into shorter transcripts 
but only detected at 86 nt, indicating that the antisense sequence itself does not 
contribute to this extra-processing event. This experiment also indicated that the 
generation of these shortened U7 species is not due to AAV gene transfer as we could 
also observe their production after cell transfection. 
105 
 
 Figure 31: northern blot analysis of the effect of the SmOPT sequence on U7 
snRNA processing  
(a) Left panel: representation of the U7wt-Sm or -SmOPT constructs and the 
U7wt probe used in b. Right panel: the U7Dtex23-Sm or -SmOPT constructs 
and the Dtex23 probe used in c. (b) Northern blot detection of mouse U7 
snRNAs transfected in 293T cells. The U7 snRNAs contain the wild-type 
antisense sequence against histone H1 mRNA (U7 wt) and either the U7 Sm site 
(Sm) or the optimised SmOPT sequence (SmOPT). U7 snRNA is detected at 62 
nt using the U7wt probe. An additional band is detected in the sample 
containing the U7wt-SmOPT transcripts. The endogenous 63 nt human U7 
snRNA is detected in the non-transfected 293T cells (NT). (c) Northern blot 
detection of U7Dtex23 transcripts transfected in 293T cells. U7Dtex23 contain 
the Dtex23 antisense sequence and either the U7 Sm site or the optimised 
SmOPT sequence. U7Dtex23 is detected at 86 nt using the Dtex23 probe. An 
additional band is detected in the sample containing the U7-SmOPT 
transcripts, but not in the U7-Sm transcripts. NT: non-transfected 293T cells. 
The 187 nt U2 snRNA is used as a control. 15% TBE-Urea gels were used. 
 
Altogether, these data demonstrate that the optimised SmOPT sequence is responsible 
for an extra-processing of chimeric U7 snRNA cassettes on the 3' hairpin side of the 
transcripts, however the relevance of this phenomenon for the function of U7 cassettes 
as antisense carriers is unknown. It is not clear whether the 3' processed U7 species are 
also able to target pre-mRNAs for exon skipping and whether the SmOPT sequence is 
crucial or dispensable for this function. 
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- The SmOPT sequences induce an additional processing of the 
U7snRNA cassette but increase chimeric U7snRNA expression in 
cultured myotubes 
U7 cassettes with or without the SmOPT mutations were compared in AAV2/5 
transductions of C2C12 myoblasts. The U7Dtex23 expression levels obtained were 
determined by Northern blot, and the exon skipping efficiency obtained from each 
vector was assessed by nested PCR (Figure 51). 
 
Figure 32: analysis of the effect of SmOPT mutations on the expression of 
chimeric U7snRNAs and on exon skipping efficiency in cultured myotubes 
Northern blot analysis of U7DTex23 transcripts expressed in C2C12 cells 
transduced with AAV2/5 vectors (15% TBE-Urea gel). U7Dtex23 contains the 
Dtex23 antisense sequence for dystrophin exon skipping and either the natural 
U7 Sm binding site (Sm) or the SmOPT sequence (SmOPT). U7Dtex23 is 
detected at 86 nt using the Dtex23 probe. An additional band of approximately 
65 nt is detected in the sample containing the U7Dtex23-SmOPT transcripts, 
but not in the U7Dtex23-Sm transcripts. NT: non-transduced C2C12 cells. The 
187 nt U2 snRNA is used as a control. The right hand side panel represents the 
quantification by densitometry of the 86 nt band intensity for each sample, 
expressed as a percentage relative to the expression of U7Dtex23 (86 nt) 
obtained from the sample SmOPT 105. The lower panel presents the analysis of 
exon 23 skipping performed in the same RNA samples. The native dystrophin 
mRNA containing exon 23 is detected as a 901-bp fragment and the skipped 
mRNA yields a 688-bp product. 
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 As expected, the presence of the SmOPT mutation in the U7Dtex23 cassette induced 
an additional 3' end shortening of the transcripts which was not detected in the 
U7Dtex23-Sm sample confirming that the SmOPT mutations determine this 
modification. The presence of the SmOPT sequence also yielded higher levels of 
expression of chimeric U7 cassettes, as the amounts of U7Dtex23 full-length transcripts 
(86 nt) obtained with the SmOPT construct were more than two fold higher than that 
obtained with the Sm-containing transcripts for the same dose of vector administered, 
according to the quantification by densitometry of the Northern blot. Consistent with 
this observation, analysis of dystrophin mRNA skipping resulting from the expression 
of each construct showed that the U7Dtex23-SmOPT cassette induced a strong exon 23 
skipping whereas the same quantity of AAV expressing the U7Dtex23-Sm construct was 
almost inactive. 
These data show that the shortened U7snRNA transcripts correspond to 3’ processed 
species whose presence depends on the SmOPT modification and that this optimisation 
highly increases the U7snRNA transcript levels in vitro, leading to a several fold increase 
in dystrophin exon skipping in the transduced cells. It remains unclear whether the 
additionally-processed U7 species are also active in targeting dystrophin pre-mRNA for 
exon skipping, and the mechanism behind this 3' processing is not elucidated. However, 
the inclusion of the SmOPT mutation in chimeric U7 cassettes appears critical for the 
efficiency of U7 cassettes expression. Of note, we could again observe on the Northern 
blot the presence of high molecular weight RNA species that reacted with the Dtex23 
probe and are produced in a dose-dependent manner. This observation could 
correspond to unprocessed RNA species accumulating at high doses of vector and are 
further investigated in section I. 5. 
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I. 4. Optimal levels of antisense sequences using a muscle and heart specific 
enhancer to drive the expression of U7 snRNA cassettes 
I. 4. 1. Principle and objective 
As an alternative optimization strategy, we tried to increase the level of expression of 
the U7 cassette in muscular and cardiac tissues using a transcriptional enhancer.  
The non-conventional structure of snRNA genes and the coupling between their 
transcription and 3' processing via the Integrator complex imply that the presence of a 
snRNA-specific promoter is necessary for their proper expression. Replacing the 
snRNA promoter with an mRNA promoter, such as an entire muscle-specific promoter, 
would impair the expression of the snRNA cassette by preventing the correct 3' end 
processing of the transcript. It is however possible to stimulate an snRNA promoter 
through the use of an enhancer, as shown by Brun et al. who inserted an MCK enhancer 
element upstream of the U7 snRNA promoter [256].  
The MCK promoter and its 206 bp enhancer have been thoroughly studied [380-381] 
and various synthetic versions of these elements have shown strong potential to drive 
the expression of transgenes in the skeletal muscle [382]. The MCK enhancer promotes 
tissue-specific expression in fast-twitch myofibers preferentially, but expression activity 
in the cardiac muscle is limited [382]. Yet, achieving robust transgene expression in the 
cardiac muscle is paramount for the treatment of DMD where heart failures are 
frequent. It is therefore important to identify enhancer/promoter elements capable of 
inducing high-level of transgene expression in both cardiac and skeletal muscle.  
Such regulatory cassettes have been previously engineered by fusing enhancer and 
promoter elements from the α-Myosin Heavy Chain (α-MHC) and the Muscle Creatin 
Kinase (MCK) genes [383]. The best enhancer, MHCK7, is composed of a fusion 
between the α-MHC enhancer and an optimised MCK placed upstream of the 358 bp 
MCK promoter (Figure 52). The 188 bp α-Myosin Heavy Chain (α-MHC) enhancer 
present in this construct is known to promote strong cardiac muscle-specific expression 
of downstream genes, even in the context of a heterologous promoter [384]. As the α-
MHC enhancer is a short element, its introduction in the MHCK7 cassette enabled to 
obtain high-level of transgene transcription in the heart muscle, in addition to the MCK-
promoted activity in the skeletal muscle, without hampering the requirement for a small 
size enhancer cassette for introduction in rAAV vectors.  
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The MHCK7 element can be shortened by deleting 63 bp sequence in the MCK 
enhancer, thereby moving the right E-box closer to the MEF2 binding sites (Figure 
52). This modification constitutes an important optimisation as various myogenic 
regulatory factors binding to the E-box, such as MyoD, are known to interact and to 
synergize with transcription factors associating with the MEF2 site of the MCK 
enhancer [385]. Bringing together the E-box and MEF2 sites through the modification 
in the MCK enhancer therefore facilitates interactions between the regulatory factors 
binding on both sites, which then cooperatively activate transcription in a more efficient 
fashion. The final 770 bp MHCK7 regulatory cassette induces a robust and mostly 
tissue-specific enhancement of gene expression in both skeletal and cardiac muscles 
when delivered via AAV vectors [383]. 
In order to drive high-level and tissue-specific expression of U7Dtex23 cassettes in 
skeletal and heart muscles we have assembled a similar enhancer, MHCK, by 
reproducing the synthetic fusion between the MCK and the α- MHC enhancers 
described in the MHCK7 hybrid cassette. The MCK promoter initially present in the 
cassette was omitted and the MHCK element was inserted directly upstream of the 
natural U7 promoter in the U7Dtex23 cassette (Figure 53).  
 
Figure 33: the MHCK-U7Dtex23 construct 
The enhancer moiety from the MHCK7 cassette [383], containing the α- MHC 
enhancer fused to a 63 bp-deleted MCK enhancer, was inserted upstream of the 
U7 promoter in the U7Dtex23 cassette for mouse dystrophin exon 23 skipping. 
 
AAV vectors containing the MHCK-U7Dtex23 transgene were tested in myoblast 
cultures and administered intramuscularly in mdx mice and their efficiency to promote 
dystrophin exon 23 skipping was compared to that of the conventional AAV vector 
without muscle-specific enhancer. 
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 I. 4. 2. Design and validation of the MHCK enhancer sequence 
We assembled a strong muscle-specific hybrid enhancer, MHCK, composed of elements 
from the α-Myosin Heavy Chain (α-MHC) and the Muscle Creatin Kinase (MCK) 
enhancers similar to the one described by Salva et al. [383] (see materials and methods). 
The ability of this enhancer to increase the expression of a transgene in muscular cells 
was first validated in murine C2C12 myotubes by assessing its activity when placed 
upstream of the human PGK promoter driving the expression of the green fluorescent 
protein (GFP) gene. AAV vectors carrying the PGK-GFP construct with or without 
MHCK enhancer were transduced in mouse myotubes and the resulting expression of 
GFP protein recorded by Western Blot showed that the MHCK enhancer induces an 
increase of GFP expression in myogenic cells, which was more than two fold higher 
than that obtained from the vector without enhancer (Figure 54). 
 
Figure 34: the MHCK enhancer increases GFP expression in myogenic 
cells. 
(a) Western blot to detect GFP expression obtained from protein extracts of 
C2C12 cells transduced with self complementary AAV2/5 vectors expressing 
the PGK-GFP or the MHCK-PGK-GFP cassettes (MOI = 104 vg /cell). The 
non-transduced cells (NT) and the endogenous control β-actin are shown. (b) 
Representation of GFP expression levels relative to β-actin in the transduced 
cells. The quantification was performed from the western blot presented in (a). 
The membrane was converted to a numerical picture and band intensities were 
analysed by densitometry using the GeneTools analysis software (Syngene, 
UK). GFP levels are expressed as a percentage compared with β-actin levels. 
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I. 4. 3. Analysis of the expression of the MHCK-driven U7Dtex23 and on 
the resulting exon 23 skipping in muscular cultures 
With the goal of testing the efficiency of the MHCK enhancer in the skeletal muscle of 
mdx mice, we then introduced it upstream of the U7DTex23 cassette designed for exon 
23 skipping in the mouse dystrophin pre-mRNA (Figure 55a). AAV2/5 vectors 
carrying the U7Dtex23 cassette construct with or without the MHCK enhancer were 
produced and C2C12 myotubes were transduced at various MOI. Total RNAs extracted 
from the transduced cells were used in a Northern blot assay to detect the levels of 
U7Dtex23 expression resulting from each condition (Figure 55b). 
The full-length 86 nt U7Dtex23 snRNA was detected in all samples, along with the 3' 
end processed species of around 66 nt, and expressed in a dose-dependent manner. We 
could observe that, from the same quantity of vector transduced, the expression of 
U7Dtex23 transcripts was increased in the presence of the MHCK enhancer (Figure 
55b). This enhancement was mainly noticeable at the lower dose of vector (105 vg/ml), 
where the expression of chimeric U7 snRNAs was increased by approximately 1.5 fold 
when driven by the MHCK enhancer according to quantification by densitometry. At 
higher dose of vector the effect of the enhancer was almost negligible, potentially 
reflecting a saturation of transcript amounts in the cells when administering such high 
quantities of AAV vector. In agreement with this idea, the presence of high molecular 
weight RNA species reacting with the probe proportionally to the amount of vector 
further suggested an accumulation of unprocessed species when the quantity of U7 
snRNAs produced in the cells reached a saturated level.  
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 Figure 35: enhancement of U7Dtex23 snRNAs expression in C2C12 cells. 
(a) The sequence of the U7DTex23 transcript is shown, including two antisense 
sequences (underlined) that encompass the donor splice site of exon 23 (SD23, 
shown in italics) and the branch point of intron 22 (BP22) on the murine DMD 
pre-mRNA. The optimized Sm binding sequence (SmOPT) is shown in bold. The 
probe used for the Northern blot analysis in (b) is underlined in bold. 
 (b) Northern blot analysis of U7DTex23 transcripts expressed in C2C12 cells 
transduced with AAV2/5-U7DTex23 (-MHCK) or AAV2/5-MHCK-U7DTex23 
(+MHCK) at different MOI (105 or 106 viral genome per cell). NT: non-
transduced cells. The blot was hybridized with two 32P end-labeled probes 
recognizing the U2 snRNA and the U7DTex23 chimera (underlined in bold in 
(a)), respectively. U2 snRNA shows up as a 187 nt band. Two bands of 86nt and 
approximately 66 nt react with the U7DTex23 probe. 
 
The RNAs from the same transduced myotubes were further used to analyse the 
dystrophin exon 23 skipping obtained from each condition by nested PCR and Taqman 
RQ-PCR (Figure 56).  
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 Figure 36: U7-mediated exon 23 skipping on the DMD pre-mRNA.  
(a) Reverse Transcription and nested PCR detection of DMD exon 23 skipping 
after transduction of C2C12 cells with AAV2/5-U7DTex23 (-MHCK) or 
AAV2/5-MHCK-U7DTex23 (+MHCK) with different MOI (105 or 106 viral 
genome per cell). Controls include non-transduced cells (NT) and no reverse 
transcriptase (RT-). The native murine DMD mRNA containing exon 23 is 
detected as a 901bp fragment and the skipped mRNA yields a 688bp product. 
Results are representative of at least three independent transductions. 
(b) Analysis of mouse exon 23 skipping by quantitative PCR. The graph 
represents the ratio between the exon 22-24 junction (skipped mRNA species) 
and the exon 22-23 junction (full-length mRNA species). Quantification was 
performed on mRNA extract from C2C12 cells transduced with AAV2/5-
U7DTex23 or AAV2/5-MHCK-U7DTex23 at the indicated MOI. A significant 
difference is observed at MOI 105 as shown by the p value (p = 0,023), 
according to Student’s t-test. Error bars are shown as mean ± SEM (n = 6). 
 
Exon 23 skipping was achieved on the dystrophin pre-mRNA from all conditions and 
the proportion of skipped mRNA detected at 688 bp was consistent with the levels of 
U7Dtex23 transcripts detected on the Northern Blot in figure 55b. The proportion of 
skipped dystrophin transcripts compared to the non-skipped ones assessed by RQ-PCR 
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indicated that the MHCK enhancer induces an increase in dystrophin exon 23 skipping 
in muscular cells, especially at the lower dose of vector administered where the 
difference between the samples with or without the enhancer was statistically significant 
(p value < 0.05 in the Student's t test). Furthermore, we could notice that the proportion 
of skipped dystrophin mRNA obtained in presence of the enhancer was almost 
equivalent to the one achieved with a 10 fold higher dose of vector without enhancer. 
This observation is of importance as the main goal of this strategy is to enable to reduce 
the dose of AAV vector to be administered in order to restore therapeutic levels of 
dystrophin. 
 
I. 4. 4. Evaluation of MHCK-U7Dtex23 in the skeletal muscle of mdx mice 
AAV2/8 vectors carrying U7Dtex23 cassettes with or without the enhancer were 
produced and administered intra-muscularly in the tibialis anterior of mdx mice at doses 
of 5x109, 1010 or 1011 vg per muscle. Total RNAs were extracted from the injected 
muscle sections one month after injection and were analysed by Northern Blot, nested 
PCR and Taqman RQ-PCR. 
The nested PCR analysis indicated that a moderate increase in dystrophin exon 23 
skipping was obtained in the presence of the MHCK enhancer, consistent with the 
increased expression of the U7Dtex23 cassette, approximately 1.5 fold, as seen on the 
Northern blot (Figure 57a). Of note, although hyper-processed U7 snRNA species 
were also present in each sample on the Northern blot, no high molecular weight RNAs 
could however be detected, even at the highest dose of AAV injected. The slight 
beneficial effect of the MHCK enhancer for dystrophin exon skipping in vivo could be 
observed by Taqman RQ-PCR quantifying of the proportion of skipped against non-
skipped dystrophin transcripts. Although the highest dose of vector was too strong to 
clearly see an effect of the enhancer, the intermediate dose indicated an improvement in 
exon skipping efficiency (Figure 57b).  
115 
 
 Figure 37: MHCK enhances U7DTex23-mediated exon skipping on the 
DMD pre-mRNA in the muscle of mdx mice. 
(a) Northern blot analysis of U7DTex23 transcripts expressed in mdx mice 
muscles treated with AAV2/8-U7DTex23 (-MHCK) or AAV2/8-MHCK-
U7DTex23 (+MHCK). Total injected vector doses in vector genomes are 
indicated on top. The blot was hybridized with two 32P end-labeled probes 
recognizing the U2 snRNA and the U7DTex23 chimera, respectively. U2 
snRNA shows up as a 187 nt band. Two bands of 86 nt and approximately 66 nt 
react with the U7DTex23 probe. The lower panel presents the analysis of exon 
23 skipping performed in the same RNA samples. The native murine DMD 
mRNA containing exon 23 is detected as a 901bp fragment and the skipped 
mRNA yields a 688bp product. NT, non-transduced muscle. RT-, no reverse 
transcriptase. Results are representative of at least three independent 
transductions. 
 (b) Quantitative PCR analysis of exon 23 skipping in RNA samples prepared 
from injected muscles. The graph represents the ratio between the exon 22-24 
junction (skipped mRNA species) and the exon 22-23 junction (full length 
mRNA species). No statistically significant difference could be observed 
between the groups (Student’s t-test, P > 0.05). Error bars are shown as mean 
± SEM (n = 3 per cohort). 
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This improvement was more visible when analysing Dystrophin protein rescue by 
Western blot in the same treated muscles. In the presence of the MHCK enhancer a 
three- to five-fold increase of de novo dystrophin protein production was obtained 
compared with the AAV-U7Dtex23 vector (Figure 58). At the highest dose of vector 
administered, the levels of dystrophin protein restored in treated muscles reached 
approximately 60% of the levels in wild-type tissue according to quantification by 
densitometry of the band intensities on the Western Blot. Furthermore, the amount of 
protein rescue obtained with a dose of 2.1010 vg per muscle was higher than the one 
obtained with a 5-fold higher dose of vector, again demonstrating that the MHCK 
enhancer can enable to reduce the vector dose needed for therapeutic exon skipping. 
 
Figure 38: MHCK-mediated enhancement of DMD exon skipping in mdx 
mice leads to an increased rescue of Dystrophin protein in treated muscles. 
Western blot analysis of Dystrophin levels in muscles of mdx mice treated with 
AAV2/8-U7DTex23 (-MHCK) or AAV2/8-MHCK-U7DTex23 (+MHCK), at 
doses of 2x1010 or 1x1011 vg / muscle. Samples from two different animals are 
analysed for each condition. The wild type C57 mouse Dystrophin is shown as 
a positive control and the endogenous α-Actinin is detected for normalization. 
 
Altogether, these results consistently indicated that the MHCK sequence enhances 
U7DTex23-mediated exon skipping on the dystrophin pre-mRNA in the muscle of mdx 
mice, thereby leading to an increased rescue of Dystrophin protein in treated muscles. 
Furthermore, the efficiency of this strategy was also demonstrated in a human context, 
as a MHCK-driven chimeric U7snRNA containing antisense sequences for exons 51 
and 52 skipping on the human dystrophin pre-mRNA and delivered by lentiviral 
vectors, induced an enhancement of dystrophin exon skipping in human CHQ 
myoblasts, readily visible at lower doses (Figure 59). 
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 Figure 39: MHCK enhances U7ex51-mediated exon skipping on the DMD 
pre-mRNA in cultured human myotubes. 
(a) U7ex51 expression is driven by the U7 promoter containing Distal and 
Proximal Sequence Elements (DSE and PSE respectively, shaded boxes). The 
MHCK enhancer [21] has been placed upstream. The rightward arrowhead 
indicates the site of transcription initiation and the downward arrowhead is the 
site of 3’ processing, activated by recognition of the 3’box (shaded). The 
sequence of the U7ex51 transcript is shown, including an antisense sequence 
(underlined) that corresponds to  an exonic splicing enhancer (ESE) in exon 51 
of the human DMD pre-mRNA (h51AON1: 5′-
UCAAGGAAGAUGGCAUUUCU-3′) [22]. The optimized Sm binding sequence 
(SmOPT) is shown in bold.  
 (b) Reverse Transcription and nested PCR detection of DMD exon 51 skipping 
after transduction of human CHQ cells with lentiviral vectors containing the 
U7ex51 (upper panel) or the MHCK-U7ex51 (lower panel) cassettes, at 
increasing multiplicities of infection (MOI) Controls include non-transduced 
cells (0) and no reverse transcriptase (RT-). The native human DMD mRNA 
containing exon 51 is detected as a 886bp fragment and the skipped mRNA 
yields a 653bp product.  
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I. 5. Analysis of the high molecular weight species of the U7Dtex23 
transcript. 
We have observed a dose-dependent accumulation of high molecular weight (hMW) 
species during U7 snRNAs detection on Northern blots (Figures 3, 8, 11 and annex 2 
Figure 2b). To further analyse these additional hMW species, a Northern blot 
membrane containing U7Dtex23 transcripts produced with or without the MHCK 
enhancer and at different doses, corresponding to figure 2b from annex 1, was stripped 
and hybridized with a new 32P-end labelled probe that specifically recognises the 3' box 
of U7 transcripts localised at the processed 3' end, thereby only detecting the non-
processed primary U7 transcripts (Figure 60a).  
 
Figure 40: dose-dependent accumulation of readthrough U7 transcripts  
(a) Representation of the primary U7 transcript and position of the Dtex23 
probe (black arrow) and U7unprocess probe (red arrow) used for the Northern 
Blot detection in (b) and (c), respectively. (b) Northern blot analysis of 
U7DTex23 transcripts expressed from C2C12 cells transduced with AAV2/5-
U7DTex23 or AAV2/5-MHCK-U7DTex23 at 105 or 106 vg per cell. The samples 
were detected using the Dtex23 probe that reacts with the full-length U7Dtex23 
(86 nt), the 3' end processed U7Dtex23 (~66nt) and some HMW species. (c) 
The membrane from (b) was stripped and hybridized with a probe 
complementary to the U7 3' box for the detection of unprocessed primary U7 
transcripts only. NT: non-transduced cells. 10% TBE-Urea gels were used. 
119 
 
 
The Northern Blot indicated that the hMW species detected earlier contain the U7 3' 
box that is normally removed during the processing of the mature U7 snRNA (Figure 
60b). These species could therefore correspond to unprocessed primary U7 RNAs 
transcribed from tandem or circle copies of the AAV vector genome [294]. We also 
noticed a difference in size between the HMW species expressed from the AAV-
U7Dtex23 and the ones expressed from the AAV-MHCK-U7Dtex23. This difference 
could correspond to the size of the MHCK enhancer itself present in the HMW species 
expressed from the later vector, and further analysis using a MHCK-specific probe 
indicated that the MHCK sequence was present in these HMW species (Figure 61). 
 
Figure 41: the readthrough U7 RNAs transcripts generated from MHCK-
U7Dtex23 AAV vectors contain the MHCK sequence 
The left panel corresponds to the Northern Blot from figure 12c where the 
U7unprocess probe for detection of U7 3' end was used. The approximate sizes 
of each band are indicated, calculated from the distances of migration. Right 
panel: Northern blot analysis of HMW U7 species expressed from C2C12 cells 
transduced with AAV2/5-U7DTex23 or AAV2/5-MHCK-U7DTex23 at 105 or 
106 viral genomes per cell. The membrane used in figure 54c was stripped and 
a probe specific for MHCK sequences was used to detect MHCK-containing 
primary transcripts, as represented on the top panel. 10% TBE-Urea gels were 
used. 
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We calculated the expected sizes of the unprocessed transcripts, with or without 
enhancer, based on the idea that they were generated from circle copies of the AAV 
vector genome. Such transcripts should therefore contain: the U7 transcript, the 3' 
unprocessed extremity, the ITR region of the AAV vector, the U7 promoter region 
(with or without MHCK), and another U7 transcript and 3' box. We thereby estimated 
the size of the unprocessed U7 snRNA without enhancer to be around 920 nucleotides, 
and around 1100 nucleotides for the enhancer-containing transcript. The second main 
hMW bands observed in each sample, of higher size than the former, could correspond 
to dimers of unprocessed U7 transcripts produced from circle copies of AAV. In this 
case, the expected sizes of the bands should be approximately 1800 and 2300 
nucleotides for the transcripts without or with enhancer, respectively. We further 
confirmed these measurements by estimating on a semi-logarythmic graph the 
approximate size of the hMW bands depending on their migration distances on the gel.  
Altogether these data indicated that the high molecular weight RNA species observed 
during detection of U7 transcripts by Northern blot are consistent with readthrough 
primary transcripts, monomers and dimers generated from AAV vector genome 
concatemers or circles, containing both promoter and 3' untranslated regions and 
accumulating in a dose-dependent manner. This accumulation of unprocessed 
readthrough U7 species at high doses of AAV vector suggests that a saturation of the 
U7 3’ end processing machinery takes place: it is possible that the integrator-mediated 
formation of U7 snRNA 3’ end is saturated when the primary transcript is present in 
too many copies in the cells, thereby limiting the amount of mature U7 transcripts 
available that can be produced intracellularly.  
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I. 6. Coupling the effects of MHCK enhancer and self-complementary vectors 
We next asked whether the benefits of the MHCK enhancer and scAAV could be used 
in synergy. We introduced the MHCK-U7Dtex23 cassette into a self-complementary 
AAV vector and AAV2/5-sc-MHCK-U7Dtex23 particles were produced and used to 
transduce C2C12 myotubes at 103 vg/cell. This low dose of AAV vector was chosen in 
order to avoid a potential saturation of the U7 3’ end processing machinery when high 
amounts of U7 snRNA cassettes are expressed in the cells, which would prevent the 
comparison of exon-skipping efficiencies obtained from each vector. Total RNAs 
harvested at 4 days after transduction were analysed by Taqman RQ-PCR to determine 
the efficiency of dystrophin exon 23 skipping compared with the ones obtained 
following transduction with AAV-U7Dtex23, AAV-MHCK-U7Dtex23 and AAV-sc-
U7Dtex23 vectors (Figure 62). 
 
Figure 42: analysis of mouse dystrophin exon 23 skipping obtained from 
various U7Dtex23 vectors by RQ-PCR 
The graph represents the ratio between the exon 22–24 junction (skipped 
mRNA species) and the exon 22–23 junction (full-length mRNA species). 
Quantification was performed on mRNA extracts from C2C12 cells transduced 
with AAV2/5-sc-MHCK-U7Dtex23 (scMU7), AAV2/5-MHCK-U7Dtex23 
(MU7), AAV2/5-sc-U7Dtex23 (scU7) or AAV2/5-U7Dtex23 (U7) at MOI 103 
vg/cell and harvested at 4 days post-transduction. Each condition represents an 
average of 5 independent experiments. The data shown for the scU7 and U7 
samples was already represented in figure 47. Significant differences are 
observed as shown by the P value (P < 0.05), according to the Student’s t-test. 
Error bars are shown as mean ± SEM.  
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Consistent with our previous experiments, the use of the MHCK enhancer to express 
U7Dtex23 cassettes, as well as their delivery by scAAV vectors, both increased the 
amounts of skipped dystrophin transcripts (compare MU7 or scU7 with U7). More 
importantly, we could observe that the use of a self-complementary AAV vector to 
deliver the MHCK-driven U7Dtex23 cassette enabled to increase the amount of U7 
transcripts expressed in the transduced cells as a significant improvement in exon 23 
skipping efficiency was recorded when using AAV-sc-MHCK-U7Dtex23 compared to 
single-stranded AAV-MHCK-U7Dtex23 vectors (compare scMU7 and MU7). 
Surprisingly, the proportion of skipped dystrophin obtained with scMU7 was not 
improved relative to scU7. The exon skipping efficiency obtained from both scAAV 
vectors was identical independently of the presence of an enhancer sequence, indicating 
that these two optimisation strategies do not act synergistically. 
  
123 
 
I. 7. Conclusion 
 
In this chapter we tried to maximise the amount of antisense-expressing U7snRNA 
cassettes expressed in muscular cells for dystrophin exon skipping for a minimal dose of 
AAV vector administered. For this purpose two different optimisation strategies were 
tested. Here we show that the use of self-complementary AAV vectors to deliver U7 
snRNA cassettes for mouse dystrophin exon skipping induce a faster and better 
transduction efficiency and enable to increase the proportion of exon 23 skipped 
dystrophin mRNA in mouse muscular cells compared to the same dose of single-
stranded AAV vector. Furthermore, we show that using the heart and muscle-specific 
MHCK enhancer to promote the transcription of U7Dtex23 snRNA cassettes in 
muscular cells induces an increase in dystrophin exon 23 skipping both in vitro and in vivo 
and highly improves Dystrophin expression in transduced muscles of mdx mice. 
Both the use of self-complementary AAV vectors or of muscular-specific enhancer 
elements therefore constitute promising tools to express U7 snRNA cassettes for 
dystrophin exon skipping as both strategies independently demonstrated a potential for 
decreasing the dose of vector necessary to obtain significant levels of dystrophin exon 
skipping, which is of utmost interest in the context of DMD where high doses of vector 
are so far deemed necessary for therapeutic benefits. Of note, we also observed the 
generation of high molecular weight (hMW) U7 RNA species accumulating at high 
doses of AAV vector and in a dose-dependent manner in transduced muscular cells. 
This accumulation of unprocessed readthrough U7 species at high doses of AAV vector 
pointed at a possible saturation of the U7 snRNA 3’ end processing machinery when 
the primary U7 transcript is expressed in too many copies in the cells. This suggests that 
the potential for maximising the amounts of mature U7 transcripts that can be produced 
in muscular cells is limited by the cellular machinery capacity. Accordingly, further 
improvement of U7Dtex23 cassettes expression and dystrophin exon 23 skipping was 
not observed following the combination of both scAAV and MHCK strategies, 
probably owing to saturating levels of primary U7 transcripts produced.  
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II. Small nucleolar RNAs as new molecular platforms for the 
modification of pre-mRNA splicing 
 
Another line of investigation explored in this study involved the creation new small 
RNA cassettes designed for the modulation of pre-mRNA processing. By using 
different carriers and methods for specific splicing alteration we hoped to identify more 
efficient and regulatable ways to modulate pre-mRNA processing.   
We first explored the possibility of using small nucleolar RNAs (snoRNAs) as novel 
molecular platforms for the intracellular delivery of antisense sequences, aiming to alter 
dystrophin pre-mRNA splicing with potentially more efficiency than with the original 
U7snRNA shuttles. The natural presence of antisense elements in C/D box snoRNAs 
that present perfect complementarities to various cellular RNAs pointed at the feasibility 
of engineering snoRNAs as antisense carriers through the alteration of their natural 
antisense sequence. As snoRNAs are encoded within introns of RNA polymerase II 
transcripts, their concomitant synthesis would allow an antisense-expressing snoRNA to 
be transcribed from strong and regulatable promoters, allowing for tissue-specificity 
control and high levels of expression. We therefore derived a C/D box snoRNA into an 
antisense sequence carrier by replacing its original guide sequence with the Dtex23 
antisense sequence for mouse dystrophin exon 23 skipping, and we tested the efficiency 
of this new system to modulate pre-mRNA splicing. 
As an alternative strategy, snoRNAs were modified to specifically target the methylation 
of intronic adenosine branch points in order to inhibit their recognition by the splicing 
machinery. This pre-mRNA splicing modulation strategy still displays very low 
efficiency to-date and our aim was to reproduce and potentially improve this technique 
in order to obtain effective splicing inhibition in a human cell culture context. We re-
directed a human C/D box snoRNA towards the branch point of an exon-skipping 
reporter construct, based on the splicing dependent activation of a luciferase gene, 
aiming to first validate this approach before ultimately trying to optimise it for 
dystrophin exon skipping application.  
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II. 1. Modified snoRNAs for the intracellular delivery of antisense sequences  
II. 1. 1. The snoRNA MBII-52: characteristics and engineering into an 
antisense carrier  
As mentioned earlier, some C/D box snoRNA are devoid of any complementarity to an 
rRNA or snRNA, suggesting a potential for functions other than 2'-O-methylation and 
for the targeting of other classes of RNAs. One of them in particular, the human HBII-
52 C/D box snoRNA, naturally contains an 18-nt antisense element complementary to 
a brain-specific mRNA [203] and therefore constitutes a potential good tool for the 
delivery of antisense sequences designed to target pre-mRNAs. 
The HBII-52 snoRNA is an 82 nt long brain-specific snoRNA located in a maternally 
imprinted region on human chromosome 15q11-13, and a loss of expression of this 
locus from the paternal allele has been associated with the Prader–Willi syndrome 
(PWS) [28, 386]. In addition to containing several other snoRNAs, this region contains 
47 almost-identical copies of HBII-52 separated by poorly conserved non-protein 
coding exons [203]. The mouse RNA orthologue MBII-52, which is also exclusively 
brain-specific, is 79 nt long and is present in 130 tandemly repeated copies. HBII-52 as 
well as the murine MBII-52 contain a perfect antisense element complementary to the 
alternatively spliced exon Vb of the serotonin receptor 5-HT2CR pre-mRNA in a region 
subjected to site-specific A-to-I RNA editing [387]. It has been shown that HBII-52 
regulates the 5-HT2C mRNA alternative splicing by base pairing through its 18nt 
antisense and can promote the inclusion of alternative exon Vb, potentially by masking 
an exonic silencer in 5-HT2C receptor pre-mRNA [105, 203].  
In addition to the MBII-52 capacity to modulate the alternative splicing of the HT2CR 
mRNA, it has been suggested that the mouse MBII-52 gene could also generate shorter 
RNA species, exonuclease processing products of the full-length snoRNA termed 
psnoRNAs and involved in the splicing of other transcripts [106]. These shortened 
snoRNA species would not form conventional snoRNPs but could instead associate 
with proteins involved in splice site selection such as hnRNPs [106, 204], and their 
expression was suggested to modulate the alternative splicing of five additional 
endogenous pre-mRNAs by interfering with the splicing machinery [106].  These so-
called psnoRNAs and the experimental procedure used for their identification have 
however been recently refuted in a study by Bortolin-Cavaillé et al. [388], but the role of 
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the full-length MBII-52 snoRNA in the regulation of HT2CR mRNA splicing has 
however not been questioned. The MBII-52 snoRNA is not an isolated case as another 
C/D snoRNA, HBII-180C, has also recently been implicated in the regulation of 
alternative splicing of various pre-mRNAs including FGFR3 [389]. 
It seems therefore possible to engineer snoRNAs into shuttles for the expression of 
antisense sequences through the alteration of their natural antisense sequence in order 
to target pre-mRNAs and modify their splicing pattern. In line with this hypothesis, a 
recent study showed that a new group of C/D box snoRNAs containing, in addition to 
the methylation guide sequence, a 21 nt sequence complementary to a pre-mRNA 
termed the M box could be engineered as a tool for the targeted knockdown of protein 
expression by replacing the natural M box sequence with a sequence complementary to 
a target mRNA [390]. This new vector technology called snoMEN (snoRNA modulator 
of gene expressioN) provides further evidence that natural functions of snoRNAs can 
be redirected towards a target mRNA in order to influence its expression.  
Designing snoRNAs to transform them into antisense sequences carriers for the 
modulation of splicing presents the advantage that a snoRNA cassette encoded within 
introns of RNA polymerase II transcripts could be efficiently expressed from strong 
and regulatable promoters. This system may therefore allow more expression of 
antisense sequences than the original U7snRNA shuttles.  
To test this snoRNA-based approach we replaced the original guide sequence of the 
mouse snoRNA MBII-52 with the Dtex23 antisense sequence able to induce the 
skipping of dystrophin exon 23 (Figure 64). We compared the efficiency of the new 
snoRNA-based antisense delivery system to the one obtained with U7snRNA by 
assessing the exon 23 skipping observed in C2C12 myotubes as a result of the Dtex23 
antisense expression. 
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 Figure 43: the chimeric MBII52-Dtex23 snoRNA 
The original antisense sequence contained in the snoRNA MBII52 was replaced 
by the Dtex23 antisense for mouse dystrophin exon 23 skipping. The modified 
MBII52-Dtex23 cassette is included in the original MBII52 host gene, between 
the bipartite exon G (G1 and G2) of the ipw gene, and placed under the control 
of the CMV promoter 
 
 
II. 1. 2.  AAV vectors delivery of modified MBII-52-Dtex23 snoRNAs for 
mouse dystrophin exon 23 skipping 
The original guide sequence of the mouse snoRNA MBII-52 directed against the 
serotonin receptor 5-HT2CR pre-mRNA was replaced with the Dtex23 antisense 
sequence for mouse dystrophin exon 23 skipping by fusion PCR (see material and 
methods). MBII52 snoRNA is naturally located in an intron of the ipw (imprinted 
Prader-Willi) gene, between the bipartite exon G (G1 and G2) [203], and this context 
was therefore conserved for the MBII52-Dtex23 construct in order to ensure correct 
synthesis and processing of the snoRNA cassette. The MBII52-Dtex23 product 
enclosed between exons G1 and G2 of ipw gene was then placed under the control of 
the CMV promoter and introduced into a scAAV vector. This vector was first assessed 
by transfection into 293T cells in order to ensure that the final construct could produce 
correctly processed MBII52-Dtex23 snoRNAs (Figure 65). 
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 Figure 44: AAV-sc-MBII52-Dtex23 construct 
The modified snoRNA MBII52 containing the Dtex23 antisense for mouse 
dystrophin exon 23 skipping is included in the original MBII52 context, 
between the bipartite exon G (G1 and G2) of the ipw gene, and placed under 
the control of the CMV promoter. The construct is inserted between the ITRs of 
a self-complementary vector where the 3' ITR is depleted of the terminal 
resolution site (Δtrs). Right panel: Northern blot to detect MBII52-Dtex23 
transcripts in 293T cells transfected with the AAV-sc-MBII52-Dtex23 plasmid. 
The transcripts are detected at 105 nt using the 32P-end labelled MBII52-
Dtex23 probe (see figure 60a, right panel). A 15% TBE-urea gel was used. 
 
 
The AAV-sc-MBII52-Dtex23 construct generated correctly processed chimeric 
snoRNAs of 105 nucleotides that could be specifically detected by Northern blot. We 
therefore produced AAV2/5-sc-MBII52-Dtex23 viral vectors and transduced mouse 
C2C12 myotubes at MOI 104 to 106 viral genomes per cell. The RNA extracts were first 
analysed by Northern blot to assess the levels of MBII52-Dtex23 transcripts actually 
genereated in the transduced cells, and a nested PCR was then realised to record the 
efficiency of dystrophin exon 23 skipping obtained with this construct (Figure 66). 
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 Figure 45: analysis of AAV-mediated snoRNA MBII-52-Dtex23 expression 
and of dystrophin exon 23 skipping in C2C12 myotubes   
(a) Northern blot analysis of MBII52-Dtex23 transcripts expressed in C2C12 
myotubes transduced with AAV2/5-sc-MBII52-Dtex23 vectors at MOI 104 to 
106. A control of MBII52-Dtex23 transcripts expressed in transfected 293T 
cells is shown (ctrl TFX 293T). The MBII52-Dtex23 snoRNA is detected at 105 
nt. The endogenous control MBII52 is detected at 79 nt. NT: non transduced 
cells. 15% TBE-Urea gel. Right panel: representation of MBII52-Dtex23 and 
MBII52 wt snoRNAs and the respective probes used for Northern Blot 
detection. (b) Reverse transcription and nested PCR detection of dystrophin 
exon 23 skipping in C2C12 cells transduced with AAV2/5-sc-MBII52-Dtex23 at 
various MOI. A schematic representation of the PCR primers and products is 
shown on the right hand side. NT represents non-transduced cells and RT- is a 
control without reverse transcriptase. The native dystrophin mRNA is detected 
at 901 bp (yellow star) and the skipped mRNA at 688 bp (double yellow star). 
 
We could detect some 105 nt MBII52-Dtex23 transcripts on the Northern blot only in 
the cells transduced with the highest doses of AAV2/5 vectors (Figure 66a). The 
general level of expression of the modified snoRNAs was surprisingly low considering 
the amount of AAV vector administered and compared to the endogenous MBII52 
snoRNA levels. The fact that we could detect the endogenous MBII52 transcript in 
C2C12 muscular cells is startling considering that its expression is supposed to be 
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exclusively brain-restricted in mice and humans [203]. This observation might be 
explained by the fact that the C2C12 cell line does not actually correspond to muscle 
tissue but correspond instead to transformed cells. We could also detect a strong signal 
at high molecular weight on the Northern blot that seemed to accumulate in a dose-
dependent manner. This signal could represent non-processed MBII52-Dtex23 
transcripts still surrounded by their host intron, thereby suggesting a potential problem 
in the processing of the pre-snoRNA from the debranched intron. Alternatively, it has 
been demonstrated that the MBII52 snoRNA is naturally processed into several shorter 
RNAs by exonuclease trimming [106]. It could be envisaged that the expected MBII52-
Dtex23 form is under-represented in the RNA species produced from the MBII52 
region and that, as most of the transcripts are further processed into short RNAs, we 
could only detect few full-length MBII52-Dtex23 species on the Northern blot. 
Consistent with this observation, we could detect some dystrophin exon 23 skipping in 
the transduced myotubes but only at very low efficiency, reflecting the low amount of 
antisense cassettes correctly expressed and active in the cells (Figure 66b). Nonetheless, 
although this result proved relatively difficult to replicate, some dystrophin exon 
skipping events could be observed in different independent experiments, which 
demonstrated that the snoRNA-mediated delivery of antisense sequences is feasible, if 
imperfect. 
 
In order to thoroughly compare the efficiency of the new snoRNA-based antisense 
delivery system to the one obtained with U7snRNA, C2C12 myotubes were transduced 
with AAV2/5 self-complementary vectors containing either the MBII52-Dtex23 
cassette or the U7Dtex23 cassette at MOI 105 and 106 vg/cell. We assessed the amounts 
of Dtex23 antisense-containing cassettes expressed from each vector by Northern blot 
and analysed the resulting exon 23 skipping obtained on dystrophin mRNA by nested 
PCR and Taqman RQ-PCR (Figure 67). 
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 Figure 46: comparison of U7snRNA and MBII52 snoRNA cassettes for 
intracellular expression of antisense sequences and dystrophin exon skipping  
(a) Northern blot analysis of U7Dtex23 and MBII52-Dtex23 transcripts 
expressed in C2C12 myotubes transduced with AAV2/5-sc-U7Dtex23 or 
AAV2/5-sc-MBII52-Dtex23 vectors at various MOI. The MBII52-Dtex23 and 
the U7Dtex23 transcripts are detected at 105 nt and 86 nt, respectively, using 
the Dtex23 probe. U2 snRNA is used as an endogenous control. NT: non 
transduced C2C12 cells. 15% TBE-Urea gel. (b) Reverse transcription and 
nested PCR detection of dystrophin exon 23 skipping after transduction of 
C2C12 cells with AAV2/5-sc-U7Dtex23 or AAV2/5-sc-MBII52-Dtex23 vectors 
at MOI 106. NT: non transduced C2C12 cells. (c) Taqman RQ-PCR to quantify 
the ratio between exon 22–24 junction and exon 22–23 junction in dystrophin 
mRNA species obtained from RNA samples visualised in (b).  
 
It was clear from these experiments that, for a similar dose of AAV vector administered, 
the amount of MBII52-Dtex23 transcripts actually expressed in the cells are much lower 
than the levels of U7Dtex23 snRNAs (Figure 67a). Consistently, we observed that the 
snoRNA construct was much less efficient than the U7 cassette to inhibit the splicing of 
dystrophin exon 23, as seen on the nested PCR analysis and on the quantitative PCR 
assay (Figure 67b and c). 
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 Overall these data indicated that the snoRNA-based delivery of antisense sequences to 
target pre-mRNAs is not an efficient system compared to the U7snRNA approach. The 
general shortage of MBII52-Dtex23 expression in AAV transduced cells could reflect a 
problem in the cassette expression or in the processing of the snoRNA from the 
transgene. In order to assess if the concatemerisation of AAV genomes in transduced 
cells could be a limiting factor for the correct synthesis of the MBII52 transcripts we 
decided to test this system in the context of lentiviral vectors as the integration of the 
vector DNA in the genome of host cells could potentially provide a better environment 
for the splicing of the transgene and the subsequent processing of the snoRNA cassette. 
 
II. 1. 3.  Lentiviral vectors delivery of snoRNA MBII-52-Dtex23 cassettes 
in mouse myotubes for dystrophin exon skipping 
We wanted to assess if the snoRNA system for intracellular antisense sequences delivery 
could be improved through the use of lentiviral vectors, which could enable to express 
the snoRNA cassettes more steadily and therefore increase their efficiency for 
dystrophin exon skipping. We therefore subcloned the CMV-MBII52-Dtex23 sequence 
into the pRRL-PGK-GFP lentiviral vector, thereby obtaining a bicistronic vector that 
also expresses GFP as a control of transduction (Figure 68a). Lentiviral particles were 
produced by calcium phosphate transfection of HEK293T cells and C2C12 myoblasts 
were transduced with pRRL-MBII52-Dtex23-GFP viral particles at MOI of 30 or 40 
infectious particles per cells. The cells were allowed to proliferate for 3 days and then 
induced to differentiate for 3 additional days before GFP observation and RNA 
extraction for analysis (see material and methods). A reverse transcription and nested 
PCR was realised on the RNA extracts to detect potential dystrophin exon 23 skipping 
events obtained with this vector (Figure 68b). 
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 Figure 47: pRRL-MBII52-Dtex23-GFP construct and analysis of exon 23 
skipping in transduced myotubes by nested PCR 
(a) The modified snoRNA MBII52-Dtex23, containing the Dtex23 antisense for 
mouse dystrophin exon 23 skipping and surrounded by exons G1 and G2 of the 
ipw gene, is placed under the control of the CMV promoter and inserted 
between the LTR of a pRRL-PGK-GFP vector. (b) Reverse transcription and 
nested PCR detection of dystrophin exon 23 skipping after transduction of 
C2C12 cells with the pRRL-MBII52-Dtex23-GFP lentiviral vector at MOI 30 or 
40 infectious particles per cell. NT: non transduced C2C12 cells. RT-: control 
without reverse transcriptase. Right panel: Fluorescent microscopy image of 
C2C12 myotubes transduced with pRRL-MBII52-Dtex23-GFP vector at MOI 
40. The cells were observed after 3 days of induced differentiation, 6 days in 
total after transduction, at a magnitude of 10x. 
 
From the nested PCR assay we could observe that, although a reasonable amount of 
vector seemed to have integrated in the transduced cells as reflected by the expression 
of GFP, no skipped dystrophin species could be obtained as only a 901 bp band 
corresponding to the full-length cDNA could be visualised on the gel (Figure 68b). 
This observation was further confirmed by RQ-PCR (data not shown). This somewhat 
surprising result might indicate that such doses of lentiviral vector did not allow the 
expression of enough copies of MBII52-Dtex23 transcript in the transduced cells to 
target the dystrophin pre-mRNA. Accordingly, on a Northern blot realised from the 
same samples we failed to observe a signal corresponding to the MBII52-Dtex23 
transcripts (data not shown), suggesting that the modified snoRNAs were expressed in 
too low amounts, if expressed at all, from the pRRL-MBII52-Dtex23-GFP vector. 
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To increase the probability of observing an effect with the lentiviral construct we 
decided to sort and isolate the GFP-positive cells obtained after transduction of 
myoblasts with the pRRL-MBII52-Dtex23-GFP vector, in order to expand only the 
cells that integrated the lentiviral genome in their DNA. By doing that, every single cell 
should contain at least one MBII52-Dtex23 sequence stably integrated in their genome 
and readily available to express antisense sequences for dystrophin exon skipping after 
differentiation. The sorted GFP-expressing cells, termed C2C12-sno+, were induced to 
differentiate for 14 days before harvest and RNA extraction. We then analysed the 
proportion of dystrophin exon skipping obtained by nested PCR (Figure 69). 
 
 
Figure 48: analysis of dystrophin exon 23 skipping in C2C12 cells stably 
expressing the MBII52-Dtex23 cassette by nested PCR 
Top: Fluorescent microscopy pictures of C2C12-sno+ cells transduced with the 
pRRL-MBII52-Dtex23-GFP vector. The isolated GFP-positive myoblasts were 
expanded to reach confluence (top left, 20x) and induced to differentiate for 14 
days (top right, 10x). Bottom: Reverse transcription and nested PCR detection 
of dystrophin exon 23 skipping in C2C12-sno+ sorted and differentiated cells. 
NT: non transduced cells. RT-: control without reverse transcriptase. Only a 
901 bp band is detected, corresponding to the non-skipped dystrophin cDNA. 
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This experiment confirmed that, although all the analysed cells should contain the 
snoRNA construct stably integrated in their genome, no dystrophin exon skipping could 
be obtained using lentiviral vectors to deliver the MBII52-Dtex23 cassette. The most 
likely explanation for this lack of efficiency is a too low amount of antisense sequences 
expressed in the cells: it has been previously shown that to achieve some level of exon 
skipping a very high dose of antisense-expressing vector must be administered. This was 
achieved by using AAV vectors where the number of viral genome copies per cell used 
was up to 106 copies, leading to some exon skipping events. However in this experiment 
the number of antisense-expressing cassettes per C2C12-sno+ cell could be as little as 
one copy per cell, which was probably not enough to alter the dystrophin transcripts. 
 
We therefore concluded that the delivery of snoRNA MBII52-Dtex23 construct by 
lentiviral vectors is inefficient to induce dystrophin exon 23 skipping in cultured 
muscular cells. Furthermore, although the use of AAV vectors seemed more suited for 
this snoRNA-antisense strategy as some skipping could actually be achieved through 
AAV delivery of high doses of transgene, the overall efficiency of this approach did not 
meet expectations. The use of snoRNAs as shuttles to express antisense sequences is 
therefore not a promising tool for dystrophin splicing modulation and the high 
efficiency of U7snRNA cassettes should be privileged for this purpose over the use of a 
snoRNA cassette. This strategy was thus not investigated further in this study. 
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II. 2. A human C/D box snoRNA to target the 2’-O- methylation of branch 
point adenosine as a new strategy for exon skipping 
The engineering of C/D box snoRNAs to specifically target the 2’-O-ribose methylation 
of pre-mRNA branch points for exon skippimg has shown some moderate success in 
vertebrate systems previously, but the efficiency of this approach is still very limited. 
Here we tried to reproduce and improve this technique and to obtain effective splicing 
inhibition in cultured human cells, ultimately aiming to apply this approach to 
dystrophin exon skipping. 
II. 2. 1. The U24 snoRNA: characteristics and modifications for directed 
2’-O-ribose methylation of a pre-mRNA branch point  
A modified U24snoRNA previously showed some efficiency in inducing the skipping of 
a downstream exon by targeted methylation of the branch point [205] and we therefore 
decided to derive the same human U24 snoRNA to induce the methylation of our target 
branch site and trigger exon skipping. 
The human U24 snoRNA is a 76 nt long phylogenetically conserved C/D box snoRNA 
encoded in the second intron of the RPL7A (ribosomal protein L7a) gene and present at 
approximately 14 000 molecules per human cell. U24 contains two target recognition 
sequences of 12 nucleotides each situated upstream of the consensus D and D’ boxes, 
which naturally guide the 2’-O-ribose methylation of two adjacent residues in 28S rRNA 
exactly 5 nucleotides upstream of the D/D' motif [391] (Figure 70).  
 
Figure 49: the human U24 snoRNA 
The human U24 C/D box snoRNAs represented at the bottom contains two 
antisense sequences of 12 nt each situated upstream of the D and D' boxes 
(CUGA). These antisense sequences recognize the human 28s rRNA (top) to 
target the 2’ O-methylation of nucleotides located 5 nt upstream of each CUGA 
motif (black dot). 
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The initial aim of this project was to modify the original guide sequences of human U24 
snoRNA to perfectly match the branch point of intron 22 (BP22) of mouse dystrophin 
pre-mRNA, precisely positioning the adenosine for 2’-O-methylation, in order to target 
the exclusion of dystrophin exon 23. However, to first ensure that the BP methylation 
strategy would induce exon skipping the use of a reporter system rather than the 
endogenous dystrophin pre-mRNA seemed more informative and easily interpretable. 
The βglobin gene constitute a good candidate to use as a reporter system in this study as 
the splicing of this pre-mRNA has been extensively studied and the important splice 
signals such as the branching point are well-described [60, 392-398]. A reporter system 
based on the βglobin sequence and the splicing dependent activation of a luciferase gene 
was therefore created in order to facilitate the read-out in this study. 
 
II. 2. 2.  Design and validation of an exon skipping reporter construct  
The reporter construct designed to test the branch point methylation strategy for pre-
mRNA splicing modulation consists of the human βglobin sequence, composed of three 
exons and two introns, fused to an out-of-frame luciferase reporter gene and placed 
under the control of the CMV promoter. We first isolated the human βglobin gene by 
PCR and removed the termination codon at the 3' end of the third exon. The codon 
optimized X12-Luciferase gene [399], deleted of its ATG initiation codon, was then 
amplified and fused to the βglobin gene by fusion PCR, placing the X12-Luciferase in-
frame with the βglobin gene to enable the production of a luciferase fusion protein 
through the ATG initiation codon of the βglobin mRNA (pCMV-βglobinN-Luciferase 
construct). Finally, a 2-base pair deletion in βglobin exon 3 was induced by mutagenesis 
in order to disrupt the reading frame of the mRNA and to generate a stop codon 
downstream of the mutation in βglobin exon 3, thereby placing the fused luciferase 
transcript out-of-frame and enable to be expressed. The skipping of βglobin exon 2 
would however restore the correct reading frame of the construct and allow the 
production of Luciferase, and the resulting expression of luciferase recorded would 
therefore reflect the proportion of exon skipping obtained (Figure 71). This reporter 
plasmid, named pCMV-βglobin-Luciferase, was verified by sequencing. 
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Figure 50: βglobin-Luciferase exon skipping reporter system 
The pCMV-βglobin-Luciferase construct contains a GT dinucleotide deletion in 
βglobin exon2 and is fused to an out of frame luciferase gene. The luciferase 
mRNA becomes in frame and expressed only if exon 2 of the beta-globin gene is 
skipped. 
 
To confirm that the construct is valid and does not spontaneously express the luciferase 
gene we first transfected the pCMV-βglobin-Luciferase construct into 293T cells and 
recorded the light signal obtained in the cell extracts after 48 hours by luciferase assay. 
The initial in-frame βglobin-Luciferase construct obtained before deletion of two base 
pairs in βglobin exon 3, named pCMV-βglobinN-Luciferase, should express high levels 
of luciferase and was therefore transfected in parallel as a positive control. The raw light 
units (RLU) obtained were normalised to the total amount of proteins present in each 
sample, which were quantified by BCA assay (see material and methods) (Figure 72).  
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 Figure 51: validation of the pCMV-βglobin-Luciferase reporter construct by 
luciferase assay 
Luciferase assay realised on cellular extracts from 293T transfected with the 
out-of-frame pCMV-βglobin-Luciferase (βglob-Luc) construct or the in-frame 
pCMV-βglobinN-Luciferase (βglobN-Luc). The average RLU recorded was 
normalised by the total amount of protein present in each sample. NT 
corresponds to non-transfected 293T cells. 
 
 
As expected, the pCMV-βglobinN-Luciferase (βglobN-Luc) control plasmid emitted a 
good light signal indicating that the βglobin-Luciferase fusion protein generated from 
this construct was successfully expressed in the transfected cells. On the other hand, the 
reporter construct pCMV-βglobin-Luciferase (βglob-Luc) was not able to generate any 
light signal in the transfected cells, which demonstrated that the luciferase sequence 
placed out of frame in the construct was not able to produce a luciferase protein 
spontaneously, thereby validating the system. We could therefore use the pCMV-
βglobin-Luciferase reporter to test the branch point methylation strategy as a new 
approach for splicing alteration. 
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II. 2. 3. The chimeric U24met-βglobin for targeted methylation of the 
reporter construct and exon skipping 
To target the 2'-O-methylation of the βglobin exon 2 adenosine branch point in the 
pCMV-βglobin-Luciferase reporter construct we engineered the human U24 snoRNA 
to specifically hybridize in intron 1 of βglobin pre-mRNA at the precise position to 
target the nucleotide to be modified. In order to insure the proper processing of the 
synthetic U24 snoRNA we decided to maintain it within its natural host introns context, 
between exons 2 and 3 of the human RPL7A gene. A RPL7A gene fragment from exon 
2 to 3 was first isolated by PCR and inserted downstream of the CMV promoter to 
create the pCMV-U24 plasmid (Figure 73a). After verification of the construct by 
sequencing, we transfected it in NIH3T3 mouse fibroblasts to ensure that the human 
U24 snoRNA was correctly processed and expressed from this construct and we 
analysed the extracted RNAs by Northern blot (Figure 73b).  
 
Figure 52: pCMV-U24 construct and detection by Northern blot 
(a) Representation of the pCMV-U24 construct containing the human U24 
snoRNA enclosed between exon 2 and 3 of the RPL7A gene, under the control 
of the CMV promoter. (b) Northern blot analysis of U24 snoRNAs in NIH3T3 
cells transfected with the pCMV-U24 plasmid. The U24noRNA transcript is 
detected at 75 nt. The human-specific U24snoRNA probe hybridizes the 
transfected U24 in NIH3T3 mouse cells and the endogenous U24 in 293T cells. 
A second band of approximately 170 nt (yellow star) also reacts with the probe 
in the samples expressing U24 snoRNA. NT: non-transfected cells. 15% TBE-
Urea gel. (c) Representation of the human U24 snoRNA containing two 
antisense elements against 28S rRNA (green). The red capital letters show the 
hybridization positions of the nucleotides to be methylated in the target RNAs. 
The probe used for U24 detection by Northern blot is indicated. 
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 The U24 snoRNA was successfully detected at 79 nt on the Northern blot, both from 
transfected or endogenous source, indicating that its synthesis and processing was 
correctly achieved from the synthetic construct. We could also observe on the Northern 
blot the presence of a second band of higher molecular weight than the expected U24 in 
the samples expressing U24 snoRNA (Figure 73b, yellow star). This second transcript, 
of approximately 170 nucleotides, was present in both transfected 3T3 cells and non-
transfected 293T cells but not detected in non-transfected mouse cells, suggesting that 
these RNA species are also present endogenously in cells naturally expressing the U24 
snoRNA and could therefore represent premature U24 transcripts that are still attached 
to parts of their host introns before processing. As good amounts of correctly processed 
U24 snoRNAs were detected at the expected size after cell transfection, we therefore 
further used this construct to realise the modifications necessary to retarget U24 
snoRNA to the chosen pre-mRNA.  
We replaced the original U24 antisense sequences in the pCMV-U24 plasmid with 
sequences targeting βglobin intron 1 in the reporter construct, precisely positioning the 
branch point adenosine for 2’-O-methylation in order to trigger βglobin exon 2 
skipping. The branch point adenosine residue to target has been well-described in the 
literature [393-394] and has been located 37 nucleotides upstream of the 3’ splice site in 
βglobin intron 1, which we further confirmed using the software ESEfinder [56]. As the 
U24 snoRNA naturally contains two antisense sequences, both able to direct the 2'-O-
methylation of target nucleotides, we decided to insert the branch point-specific 
sequence in the antisense box situated at the 3' side of the snoRNA. The 5' antisense 
sequence was designed to hybridize the βglobin pre-mRNA downstream of the first 
hybridization site, thereby strengthening the association between the modified U24 and 
its target (Figure 74). The pCMV-U24metβglob construct obtained was verified by 
sequencing.  
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 Figure 53: the modified U24metβglob snoRNA to target the adenosine 
branch point of βglobin intron 1 in the exon skipping reporter construct 
The U24metβglob snoRNA contains two antisense sequences (red) directed 
against βglobin intron 1. The antisense sequence on the 3' side of the snoRNA 
specifically targets the branch point adenosine of the reporter construct and 
precisely positions it 5 nucleotides upstream of the D box for site-specific 2’-0-
methylation. The C and D boxes of the snoRNA are represented in green and 
orange, respectively. 
 
In order to test the efficiency of the pCMV-U24metβglob construct to trigger the 
skipping of βglobin exon 2 in the reporter construct by specifically targeting the branch 
point, the pCMV-U24metβglob plasmid was co-transfected with the luciferase reporter 
construct in 293T cells. To increase the probability of successfully targeting the βglobin 
sequence, the constructs were transfected following a 5:1 (U24:reporter) molecular ratio. 
The cell extracts were analysed 48 hours later by luciferase assay to assess the exon 
skipping potentially obtained in the transfected cells depending on the intensity of the 
light signal detected. Furthermore, to insure that the U24metβglob transcript was 
efficiently expressed in the transfected cells we realised a Northern blot on the RNA 
extracted from these samples (Figure 75). 
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 Figure 54: analysis of pCMV-U24metβglob expression and induction of exon 
skipping in the reporter construct by co-transfection in 293T cells 
(a) Luciferase assay realised on cellular extracts from 293T transfected with 
the pCMV-βglobin-Luciferase (βglob-Luc) construct and either the pCMV-
U24metβglob or the pCMV-U24 (U24endog) constructs. The βglob-Luc 
transfected alone was used as a negative control and the βglobN-Luc 
constitutes the positive control. The average RLU recorded was normalised 
with the total amount of proteins. Each condition represents an average of 3 
independent experiments. Error bars are shown as mean ± SEM. (b) Left: 
Northern blot analysis of U24metβglob snoRNAs expressed in transfected 293T 
cells, corresponding to samples in (a). The U24metβglob snoRNA is detected at 
75 nt. 15% TBE-Urea gel. Right: representation of the U24metβglob containing 
the C/C' boxes (blue), the D/D' boxes (orange), and two antisense elements 
against βglobin intron 1 (red). The capital letters correspond to the position of 
the methylated nucleotides in the target RNA. The probe used for U24metβglob 
snoRNA detection by Northern blot is indicated. 
 
The luciferase assay showed that no significant increase of luciferase signal was recorded 
when the reporter construct was co-expressed with the U24metβglob snoRNA 
compared to the signal obtained with the reporter construct alone or co-transfected 
with the non-modified U24 snoRNA (U24 endog). This result indicated that no exon 
skipping could be obtained in this system, at least not at detectable levels. The 
inefficiency of the strategy was however not due to a lack of expression of the U24 
cassette in the transfected cells as good amounts of U24metβglob transcripts could be 
observed at the right size on the Northern blot from these samples (Figure 75b).  
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These data suggested that this exon skipping strategy was greatly inefficient in this 
system, which could be due to various factors. It is possible that, even if a base-pairing 
occurs between the U24metβglob and the reporter construct at the right position, the 
modified U24 is not able to efficiently target the methylation of the intronic branch 
point of the reporter construct and cannot trigger the skipping of the downstream exon. 
Alternatively, by inactivating the major branch point of intron 1 of the reporter 
construct through targeted methylation, it is highly possible that a cryptic branch point 
could be activated to restore the normal splicing pattern [395]. To eliminate this 
possibility, the exon skipping reporter construct would need to be stringently examined 
in order to identify and mutate all the putative cryptic splice sites that could favour 
alternative splicing events or restore the splicing pattern even after successful alteration 
of the pre-mRNA. This strategy could therefore be further investigated and optimised.  
Of note, in an attempt to validate the βglobin-luciferase reporter system used in this 
assay, we also tried to induce the skipping of exon 2 through the use of antisense 
oligonucleotides in order to assess if an expression of Luciferase could effectively be 
recovered. The second exon of βglobin pre-mRNA contains three well-characterised 
exonic splicing enhancers (ESE) that are activated by SR proteins, each of them 
independently able to induce the splicing of an heterologous pre-mRNA [60]. We 
therefore designed 2’-O-Methyl oligonucleotides directed against each of these ESE and 
tested them by co-transfection with the reporter construct. However, no expression of 
Luciferase could be detected as a result of AON expression, administered one by one or 
simultaneously (data not shown), demonstrating that antisense-mediated exon skipping 
was inefficient to modulate the splicing of this reporter construct. This observation 
could mean that the steric blocking of these ESE sequences was not sufficient to alter 
the splicing pattern and inhibit the splicing of this exon. Accordingly, it has been 
suggested that additional splicing enhancers sequences could be present in βglobin exon 
2 [60], which could promote the splicing of this exon even when the three main 
characterised ESE have been inactivated.  
The BP methylation strategy for splicing modulation, as well as the exon-skipping 
reporter construct designed in this study, therefore need to be further investigated and 
potentially optimised before considering further applications. 
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II. 3. Conclusion 
Here we tried to design and improve different methods for splicing alteration by 
deriving small nucleolar RNAs to specifically target pre-mRNAs and induce exon 
skipping. We first tried to use snoRNAs as an alternative antisense delivery system for 
exon skipping application, and we also considered the property of C/D box snoRNAs 
to direct site-specific methylation of cellular RNAs as a mean to target the branch point 
of pre-mRNAs and inhibit the splicing of the downstream exon. 
Overall these data indicated that the newly designed snoRNA-based delivery of 
antisense sequences to target mouse dystrophin exon 23 skipping is not an efficient 
system compared to the U7snRNA approach. Although some dystrophin exon skipping 
events could be observed in different experiments through AAV-mediated delivery of 
high doses of transgene, demonstrating that the modification of snoRNAs for antisense 
sequences delivery is feasible, the overall efficiency of this approach did not meet 
expectations.  
Furthermore, the use of modified C/D box snoRNAs to direct the methylation of a 
branch point (BP) adenosine and inhibit the splicing of the downstream exon in a target 
pre-mRNA prove to be highly inefficient. No significant increase of luciferase signal 
was recorded when the modified U24 snoRNA was co-expressed with the luciferase 
reporter construct, indicating that no exon skipping could be obtained in the target pre-
mRNA through this system.  
Altogether, although both the snoRNA-based delivery of antisense sequences and the 
BP methylation strategy could benefit from further analysis and optimisations, the very 
poor exon skipping efficiencies obtained with these strategies suggest that the use of 
snoRNAs as new molecular platforms to modulate pre-mRNA processing presents little 
potential for an application to disease treatment by exon skipping.  
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DISCUSSION 
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Antisense oligonucleotide-mediated therapy for the treatment of splicing-associated 
diseases has been extensively studied over the past ten years and many efforts have been 
focused on correcting the mutated dystrophin transcript by exon skipping for the 
treatment of Duchenne muscular dystrophy [400]. However, the delivery of antisense 
sequences inserted into small nuclear RNA cassettes by viral vectors still faces some 
hurdles before being considered for clinical translation as large amounts of vector would 
still need to be administered to patients in order to stably restore therapeutic levels of 
dystrophin protein in all myofibers. In an attempt to maximise the therapeutic index of 
such vectors, different approaches were investigated in this study. Here we discuss the 
efficiency and limitations of the small RNA-antisense cassettes designed and optimised 
in this study, U7 snRNA- or snoRNA-based, and analyse their potential for clinical 
applications.  
 
I. Limitations of the U7snRNA cassettes  
I. 1. Cassette design and optimisation  
During this study we have used the U7 snRNA to deliver antisense sequences for 
specific exon 23 skipping in the mouse dystrophin pre-mRNA. The choice of this 
snRNA over the other frequently used U1 snRNA was based on various observations. 
The endogenous U1 snRNP is detected in cells at much higher levels than the U7 
snRNP due to its higher gene copy number and to a more efficient assembly into 
snRNP, which could lead us to favour its use over the U7 snRNA to shuttle antisense 
sequences. However, the modification of the Sm binding site into the consensus 
SmOPT sequence in the U7 gene leads to levels of expression equivalent to that of the 
U1 gene [254]. Accordingly, it has been demonstrated that modified U1 snRNA carrying 
antisense sequences were not more efficient than the engineered U7-SmOPT cassettes 
to alter the splicing of pre-mRNAs, and replacing the U7 promoter with the U1 
counterpart to drive U7 snRNA transcription did not result in increased snRNA levels 
[209-210]. Based on these observations, the U7 snRNA seemed as good a candidate for 
the intracellular delivery of antisense sequences and was then chosen in our study to 
target the skipping of exon 23 in the murine dystrophin transcript. 
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Furthermore, a new regulatory role for U1 snRNA aside from its implication in pre-
mRNA splicing has recently been brought to evidence, providing an explanation to the 
presence of such high levels of U1 transcripts in cells. The spliceosomal U1 snRNA has 
been shown to recognize and associate with cryptic polyadenylation signals that can 
occur at different positions along the transcript and to inhibit the premature cleavage 
and polyadenylation (PCPA) process, thereby ensuring the integrity of the mRNA [401]. 
This U1-mediated regulation of PCPA, termed telescripting, therefore protects pre-
mRNAs from premature termination but also constitutes a mechanism to regulate gene 
expression. This novel function of U1 snRNA makes its use as an antisense carrier less 
attractive as it is not clear to what extent the overexpression of exogenous modified U1 
could impair the PCPA-mediated regulation of gene expression.  
 
I. 1. 1. scAAV vectors for U7 snRNA cassettes expression 
The first optimisation tested in this study was the use of self-complementary AAV 
vectors to deliver the U7Dtex23 cassette in muscular cells, which have previously 
demonstrated enhanced transduction efficiencies over single-stranded counterparts. Our 
initial experiments did not show any significant increase of U7Dtex23 expression or of 
dystrophin exon 23 skipping compared to that obtained with conventional AAV vectors 
(Figure 45). This could be due to a spontaneous two-by-two association of small 
transgenes such as U7 snRNAs when high doses of ssAAV vector are administered. In 
such a situation, the snRNA cassettes would readily be present as dimer molecules in the 
transduced cells, thereby abolishing the need for double-strand synthesis of vector 
genome and mimicking the potential benefit obtained from self-complementary vectors. 
Accordingly, when lower doses were used, the delivery of U7Dtex23 cassettes by 
scAAV vectors induced a three-to four-folds increase in the proportion of exon 23-
skipped dystrophin mRNAs compared to the same dose of ssAAV (Figure 47).  
Moreover, we observed that the rate of transgene synthesis was accelerated with the use 
of scAAV vectors, inducing a high level of dystrophin exon 23 skipping early after 
transduction and much faster than that obtained from ssAAV vectors (Figure 46). 
Altogether these data suggested that the use of self complementary vectors to express 
chimeric U7-antisense cassettes could enable to decrease the dose of vector necessary to 
obtain significant levels of dystrophin exon skipping, which presents an obvious interest 
for the treatment of DMD where high doses of vector are so far still needed. 
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These encouraging data are however to be taken precociously as various technical issues 
could have led to a mis-interpretation of the results. Firstly, it must be noted that the 
choice of Taqman probes and primers used for the quantification of dystrophin exon 23 
skipping was probably not optimal. By only quantifying the transcripts containing exons 
22-23 junctions and exons 22-24 junctions, we failed to consider the double exon 
skipping events leading to dystrophin transcripts lacking both exons 22 and 23 that are 
detected on agarose gel by nested PCR (Figure 44). We therefore did not determine the 
total amount of dystrophin transcripts expressed in the treated cells and the total 
percentage of exon 23-skipped mRNAs is only approximate. It would have been helpful 
to include in the assay a third pair of primers/probe in distant exons not affected by the 
antisense in order to quantify the total amount of dystrophin transcripts.  
A second technical issue potentially hindering the correct interpretation of data 
concerns the quantitative PCR method used to assess the viral titer of an AAV 
preparation. This method is of limited reliability as the result obtained gives an 
estimation of the number of copies of viral genome present in the sample but does not 
relate to the number of capsid proteins and does not actually indicate the proportion of 
infectious viral particles. It is therefore possible that two AAV preparations quantified 
as containing comparable amounts of viral genomes could actually present important 
differences in transduction efficiencies. Furthermore, it has been recently demonstrated 
that the quantification of vector genomes in a self-complementary AAV preparation by 
qPCR can lead to an underestimation of the viral titer. The scAAV genomes have been 
shown to rapidly self anneal into the hairpin structure immediately after the PCR 
denaturation step, thereby inhibiting primer annealing and preventing the amplification 
of proximal amplicons [402]. This phenomenon often results in an underestimation of 
the copy number of vector genomes present in a scAAV preparation. The authors show 
that, depending on the position of the pair of primers used relative to the mutated ITR, 
the measured titer of an AAV preparation by conventional qPCR can be up to 10-fold 
lower than the actual viral genome content of the sample and could therefore lead to the 
administration of a 10-fold higher dose of scAAV vector than initially thought. To 
counter this effect, a method based on the cleavage of scAAV genomes by 
endonuclease digestion close to the terminal hairpin was designed in order to separate 
the two amplicons prior to the qPCR reaction and to enable an accurate quantification 
of vector genomes[402]. 
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Considering this observation, it is possible that the improved transduction efficiency 
that we observed with the scAAV vectors was due to a higher dose of vector 
administered, leading to an overestimation of the benefit obtained. It would therefore 
be important to reiterate the titration of the scAAV preparations used in our study by 
realising the endonuclease digestion of terminal hairpins mentioned above [402]. 
Alternatively, the titration of vector genome by Southern blot or by dot blot assay could 
be accomplished as both techniques seem to be unaffected by the structure of the 
scAAV genome [372-373] 
Nonetheless, our results suggested that the delivery of U7Dtex23 cassettes for 
dystrophin exon 23 skipping in mouse muscular cells was improved by the use of self-
complementary AAV vectors. Accordingly, this benefit was recently demonstrated in 
vivo using the same U7Dtex23 cassette to correct the dystrophin transcript in the severe 
dKO mouse model [267]. In this study, a single systemic injection of 1013 vg of self-
complementary AAV9 vector encoding the modified U7 snRNA cassette induced long-
term restoration of Dystrophin protein in all muscles of the body, including the heart. 
Whilst this study did not directly compare the efficiency of scAAV over ssAAV vectors, 
the particularly high levels of dystrophin exon 23 skipping obtained following a single 
injection of scAAV9, ranging from 20% to 50% of total dystrophin transcripts 
depending on the muscle types, demonstrated that the delivery of U7Dtex23 cassettes 
by scAAV vectors was a very efficient strategy to transduce muscular tissues and stably 
correct the mouse dystrophin transcript. 
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I. 1. 2. The MHCK enhancer for increased U7Dtex23 expression 
We further tried to optimise the expression of the U7Dtex23 cassette in cultured muscle 
cells by using muscle-specific enhancer elements, aiming to improve the skipping of 
mouse dystrophin exon 23 at a minimal dose of AAV vector administered. The MHCK 
enhancer used in our study was based on previous work where a synthetic fusion 
between the α-MHC enhancer and regions of the MCK enhancer and promoter induced 
high levels of transgene expression in muscular cells in vitro and in vivo [383]. We 
observed that the MHCK element placed upstream of the U7 promoter increased the 
levels of modified U7Dtex23 snRNAs expression by approximately 1.5-folds in cultured 
myotubes and resulted in a two-fold increase in the proportion of exon 23-skipped 
dystrophin transcripts, reaching equivalent levels than that achieved at a 10-fold higher 
dose of vector without enhancer (Figure 55 and 56). This improvement seems however 
weaker than the one reported in the original study, where the MHCK7 cassette, which 
consists of the same MHCK fusion enhancer coupled to a modified MCK promoter, 
induced a up to 10-fold increase in transgene activity in transfected mouse muscle cells 
compared to the native mouse MCK enhancer and promoter (CK1 cassette) [383]. The 
U7 snRNA promoter is however very active and of comparable strength to the 
spliceosomal snRNAs promoters [247, 254], which themselves are similar in activity to 
the CMV viral promoter [403]. It can therefore be expected that an enhancer element 
placed upstream of such an active promoter would only produce a moderate effect.  
We could also obtain a beneficial effect in vivo when AAV vectors encoding the MHCK-
driven U7Dtex23 cassette were administered in the tibilias anterior muscle of mdx mice. 
A moderate increase in the proportion of skipped dystrophin transcripts was observed 
in the presence of the MHCK enhancer, correlating with an increase of around 1.5-fold 
in U7DTex23 transcript expression (Figure 57). This enhancement in exon 23 skipping 
resulted in a three-to-five fold increase in Dystrophin protein expression and enabled to 
obtain levels of protein rescue equivalent to the ones obtained with a five-fold higher 
dose of vector without enhancer (Figure 58). Interestingly, we observed that the 
beneficial effect obtained with the MHCK cassette was mostly noticeable at 
intermediate doses of vector but that no significant improvement could be obtained at 
higher doses, which suggested that saturating levels of transcripts had been reached in 
the transduced cells. Nonetheless, our results consistently pointed at a positive effect of 
the MHCK sequence on U7Dtex23 expression, which could allow decreasing the 
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amount of vector administered to reach satisfactory amounts of dystrophin exon 23 
skipping and protein rescue in treated muscular tissues. 
We also observed the loss of tissue specificity of the MHCK-driven U7 snRNA cassette, 
demonstrated by the increase in U7Dtex23 expression in non-muscular cells in the 
presence of the enhancer (Annex 1, Figure S4). In contrast, the MHCK7 cassette 
originally reported allowed high-level of transgene expression in muscles whilst 
presenting an highly reduced activity in non-muscular tissues [383]. Yet, this MHCK7 
element contains the MCK promoter which contributes to the muscle-specific activity 
of the cassette, whereas in our design the MHCK enhancer was fused to the ubiquitous 
U7 promoter. This is in line with the previously reported loss of tissue specificity of 
both MCK and MHC enhancers when coupled with constitutive promoters [404]. 
However, even if the expression of the U7Dtex23 cassette is augmented in all tissues in 
the situation of a systemic injection of vector, the tissue-specificity is dictated by the 
expression of the dystrophin transcript and therefore the U7Dtex23 can have no effect 
in non-muscular tissues that do not express dystrophin.  
The MHCK enhancer-U7 hybrid promoter presents improved transcriptional activity of 
the antisense cassette in muscular tissues and therefore constitutes a promising tool to 
allow reducing the vector dose needed for therapeutic dystrophin exon skipping. It 
would now be interesting to assess the activity of this enhancer sequence in cardiac 
muscle after systemic injection of AAV vectors in mdx mice to assess if an increase in 
U7Dtex23 expression and in dystrophin exon 23 skipping could be obtained in this 
tissue, in agreement with the very high activity of the MHCK7 element reported in the 
heart muscle [383]. 
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I. 2. Consequences of the engineering of U7 snRNA cassettes on their 
efficiency and processing. 
I. 2. 1. Effects of the SmOPT modification  
A surprising phenomenon was brought to light during our study as we observed the 
generation of smaller U7 snRNA species, about 20 nucleotides shorter than the 
expected U7Dtex23 size, following transfection or AAV transduction of mouse 
myocytes. Such shortened species issued from modified U7 snRNA cassettes have 
already been observed previously but the origin of this phenomenon was not further 
investigated [210]. This extra-processing of U7 transcripts was identified to occur on the 
3' side of the snRNA, somewhere along the stem-loop structure, and we show that the 
formation of these 3’ processed species is dependent on the presence of the SmOPT 
modification in the U7 snRNAs (Figures 48-50). Furthermore, we observed that the 
SmOPT sequence highly increases the expression levels of the U7Dtex23 transcripts in 
vitro, thereby greatly improving their efficiency as shuttles for antisense delivery and 
leading to a more efficient dystrophin exon skipping in the transduced cells (Figure 51). 
This observation has been described earlier by Grimm et al. who showed that modifying 
the U7-specific Sm sequence into the consensus SmOPT sequence redirected U7 
transcripts into snRNPs containing the canonical Sm proteins, which led to a dramatic 
increase in U7 snRNA levels and a higher accumulation in the nucleus [254]. We 
concluded that, although the SmOPT mutation results in the formation of additional 3’ 
processed U7 snRNA species, its presence is critical to achieve a maximum efficiency of 
antisense expression. 
The mechanism involved in this SmOPT-dependent 3' processing of the U7 snRNA 
cassettes is however still unclear. By modifying the U7 binding site into the canonical 
SmOPT sequence the U7snRNA assembles into a particle whose behavior mimics the 
spliceosomal snRNPs. We could therefore speculate that the misprocessing is caused by 
an absence of correct cis-acting sequence on the U7snRNA that are important for the 
proper 3’ processing of spliceosomal snRNAs. Yet, this explanation is not very likely as 
the U7snRNA-SmOPT cassette used in this study contains the native U7 3’ box 
downstream of the mature 3’ end and a snRNA-specific promoter, which are the critical 
signals for correct processing of a precursor snRNA [221, 225]. It was recently 
demonstrated that a cis-acting element present in the 3' stem-loop of Drosophila U7 
snRNA is required for snRNA processing by the Integrator complex [223]. It is 
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therefore possible that the artificial packaging of U7-SmOPT into a spliceosomal 
snRNP with Sm proteins alters the secondary structure of the snRNA and exposes a 
cryptic nucleolytic site in the stem loop, which would trigger a partial cleavage of the 
snRNA during particle maturation and generate 3' shortened species. 
It has also been shown that the SmOPT modification, in addition to increasing  U7 
transcript levels, also modifies the exonucleolitic trimming that takes place after 
assembly of the Sm particle and before re-entry into the nucleus [234, 253]. The 
endogenous U7snRNA transcript detected in the nucleus is 1 to 2 nucleotides shorter 
than the cytoplasmic transcript. On the other hand, the SmOPT-containing U7 
transcript is shortened by 3 to 4 nt instead of 1 or 2, which indicates that the presence 
of the SmOPT binding site affects the processing of the U7 snRNA by promoting a 3' 
shortening reaction [254]. We could then hypothesize that the exonucleolitic trimming 
occuring before nuclear import could play a role in the generation of 20-nt shorter 
U7SmOPT transcripts. 
More studies are therefore needed to understand this phenomenon as well as the factors 
responsible for this additional processing of the U7SmOPT transcript. It still remains 
unclear whether the shortened U7 species, which still carry the introduced antisense 
sequences, are also able to induce exon skipping or whether this 3' shortening along the 
stem-loop alters the secondary structure of the snRNAs and therefore destabilises and 
inactivates the transcripts. Nonetheless, the inclusion of the SmOPT mutation in 
chimeric U7 snRNAs appears critical for their efficiency and should therefore be 
conserved in the design of snRNA-based antisense cassettes. 
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I. 2. 2. The rate-limiting effect of the snRNA processing machinery  
Another observation of interest in our study relates to the presence of high molecular 
weight (hMW) U7 RNA species accumulating at high doses of AAV vector and in a 
dose-dependent manner in transduced muscular cells. These hMW species may 
correspond to readthrough primary U7 transcripts containing both promoter and 3' 
untranslated regions, generated from tandem or circular copies of the vector genome 
known to form at high doses of AAV vector [294] (Figure 60 and 61).   
We further noticed that by replacing the SmOPT sequence with the wild-type Sm 
sequence in the U7 snRNAs a diminution of the amount of non-processed hMW 
transcripts was detected (Figure 51). The proportion of hMW species observed could 
therefore be dependent on the presence of the SmOPT sequence. Considering that the 
SmOPT mutation enables the recruitment of Sm proteins to form a complex with the 
modified U7 snRNAs and to stabilize them after their 3' processing, it seems possible 
that the 3' extended transcripts containing the SmOPT consensus are also transported 
to the cytoplasm and stabilized by Sm proteins. This could explain the increased 
proportion of unprocessed transcripts observed in the presence of the SmOPT 
sequence as their association into canonical snRNPs would make them more stable than 
the ones containing the U7-specific Sm sequence. 
We could also speculate that the presence of the SmOPT mutation directly affects the 
co-transcriptional 3' processing of U7 snRNAs by somehow preventing Integrator to 
cleave at the 3' end of the nascent transcript. This hypothesis is consistent with a 
previous study reporting that the formation of the correct 3’end of U1 snRNA is Sm 
site-dependent and that a mutation in this sequence causes misprocessing of the 
U1snRNA precursor, leading to accumulation of 3’ extended species [235]. The SmOPT 
modification could have the same consequences and lead to a defect in 3’ end 
formation. However, we also observed the generation of unprocessed hMW forms in 
the presence of the wild-type U7 Sm site, albeit in much lower quantities (Figure 51), 
suggesting that the misprocessing observed is not directly induced by the SmOPT 
sequence. Instead, it seems more likely that the accumulation of 3' unprocessed species 
depends on the amount of primary U7 transcript produced and reflects a saturation of 
transcript amounts in the cells when administering such high quantities of AAV vector. 
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Based on this idea, we could think that the SmOPT sequence directly activates the 
transcription and triggers the production of higher amounts of primary U7 transcript. In 
this situation, the Integrator complex that normally associates with the CTD of RNAPII 
during the transcription of U7 genes to induce their 3' end processing is then not 
present in sufficient amounts in the cells and is unable to associate on all the nascent 
transcripts, thereby leaving many U7 snRNAs in an unprocessed state. This 
accumulation of unprocessed readthrough U7 species at high doses of AAV vector 
therefore points at a saturation of the U7 3’ end processing machinery when the primary 
transcript is produced in too many copies in the cells, which would limit the amount of 
mature U7 transcripts that can be produced intracellularly. Such accumulation of 
precursor U7 transcripts have been observed following injection of U7-SmOPT 
constructs in xenopus oocytes and have been suggested to result from a saturation of 
the processing machinery [247, 254]. Consistent with this hypothesis, a similar 
accumulation of primary U1 and U2 transcripts is observed after depletion of some sub-
units of Integrator, suggesting that a shortage of Integrator complex available for the 
primary transcripts in the cells results in a defect in the processing of the snRNA 3' ends 
[224]. 
 Further analysis are therefore needed to understand the origin of the high molecular 
weight RNA species generated when high levels of U7 snRNAs are transcribed in the 
cells. Understanding the molecular basis of this phenomenon could enable to modulate 
this effect and maybe increase the amount of mature U7 transcripts that can be 
produced in the cells. We could design an experiment where high doses of U7 snRNA-
carrying AAV vectors are administered in the context of an overexpression of the 
Integrator complex’s sub-unit Int11. If the amount of hMW species diminishes when 
Integrator is overexpressed, we could deduce that the appearance of unprocessed 
transcript is attributable to a saturation of the 3' end processing machinery and can be 
reversed by increasing the Integrator-to-primary transcripts ratio. Alternatively, we could 
use a previously described U7snRNA-GFP reporter system where the U7 snRNA gene, 
including its 3' processing signal, is fused to an in-frame GFP gene that is followed by a 
polyadenylation site [223]. In this system, aberrant 3' end formation of snRNA resulting 
in read-through transcription leads to a gain of GFP expression in the transduced cells. 
We could derive the same system with the mouse U7 snRNA gene containing the wild-
type Sm or the SmOPT sequence and fused to the GFP gene, and deliver it to cultured 
cells with AAV vectors. If the U7 snRNA is properly processed in the cells no 
157 
 
expression of GFP should be detected. On the other hand, any detection of GFP 
expression would correspond to transcriptional readthrough past the U7 processing site 
and would therefore demonstrate an impairment of the processing machinery. By 
comparing the results obtained with or without the SmOPT sequence and at high or 
low, non-saturating doses of AAV vector administered, we  could determine whether 
the misprocessing of U7 transcripts is function of the amount of primary U7 snRNAs 
produced, which would trigger increasing amounts of GFP being expressed with 
increasing doses of vector, or if the failure to process U7 snRNA 3' ends directly results 
from the presence of the SmOPT site itself, thereby generating a GFP signal even under 
non-saturating levels of vector. 
This saturation hypothesis also explains the results obtained when trying to couple the 
effects of the self-complementary AAV vector delivery with the use of the muscle-
specific enhancer MHCK. We have observed that the proportion of skipped dystrophin 
transcripts obtained with the scAAV vector was not improved by the enhancer (Figure 
62). This is also consistent with the saturation hypothesis and it would be interesting to 
further establish this point in dose-response experiments, in which the minimal dose 
required to achieve comparable effects could be determined. It is however conceivable 
that these elements function sequentially, the scAAV vector providing early expression 
of high levels of U7 transcripts and the MHCK enhancer ensuring high levels of 
expression at later time points. A careful kinetic study is thefore also needed in order to 
assess the benefit of the self-complementary vector containing the MHCK- U7.  
Altogether, these observations highlight the limitations faced when trying to maximise 
the expression of antisense-containing U7 cassettes in a tissue: the potential saturation 
of the cellular machinery implies that the processing of these transcripts can only occur 
at a certain rate and up to a certain level in the cells, leaving little room for optimisation 
of U7 snRNA shuttles expression. Of note, no high molecular weight RNA species was 
detected after local administration of U7Dtex23-containing AAV vectors in mdx mice 
muscles, even for the highest dose of vector injected. Differences in the cellular 
environment provided by myocytes in culture versus differentiated mdx muscle may 
account for this and it is therefore possible that saturation does not occur in vivo.  
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II. New strategies for exon skipping and the use of small nucleolar 
RNAs 
II. 1. The snoRNA MBII-52 to express antisense sequences 
II. 1. 1. Rationale for the study and choice of the MBII-52 snoRNA 
We have tried to derive snoRNAs into antisense sequences carriers to target dystrophin 
exon 23 skipping, aiming to find new and potentially more efficient tools to modulate 
the splicing of this transcript. As snoRNAs are encoded within introns of RNA 
polymerase II transcripts, their concomitant synthesis allow the snoRNA to be 
transcribed by strong and regulatable mRNA promoters, which theoretically present an 
advantage over the U7 snRNA genes that specifically require snRNA-specific promoters 
for their transcription and processing. The natural presence of antisense elements in 
C/D box snoRNAs that present perfect complementarities to various cellular RNAs 
further deepened our argument for the feasibility of engineering snoRNAs as antisense 
carriers. Finally, it has been demonstrated that certain C/D box snoRNAs could be 
engineered as a tool for the targeted knockdown of protein expression by replacing the 
natural M box sequence with a sequence complementary to a target mRNA, providing 
further evidence that some snoRNAs can be redirected towards a target mRNA in order 
to influence its expression [390]. Following this line of reasoning, it seemed therefore 
possible to design a snoRNA to induce the skipping of dystrophin exon 23. 
We chose to use the MBII-52 C/D box snoRNA to deliver antisense sequences for 
dystrophin splicing modulation as this snoRNA naturally associates with a messenger 
RNA, the HT2CR mRNA, to modulate its alternative splicing through its antisense 
element [203]. Furthermore, the several copies of the MBII-52 snoRNA present in the 
mouse genome display different sequence variations in their antisense sequences 
compared to the 18 nt consensus, and it has been recently suggested that these variants 
could associate with five additional mouse pre-mRNA targets and modulate their 
pattern of alternative splicing [106]. It seemed therefore fairly straightforward to derive 
such an mRNA-specific snoRNA to redirect it towards another pre-mRNA for splicing 
alteration. 
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II. 1. 2.  low efficiency of the strategy and potential optimisations 
The modification of the MBII-52 snoRNA into a Dtex23 antisense sequence delivery 
tool for mouse dystrophin exon 23 skipping did not prove to be an efficient system. 
The expression of MBII52-Dtex23 transcripts delivered by AAV vectors in muscular 
cells was detectable only at the highest dose of vector administered, and the overall 
mature transcript level was strikingly low for such high doses of vector (Figure 66). 
Accordingly, the skipping of dystrophin exon 23 occurred with very limited efficiency in 
transduced myotubes, and at levels much lower than that obtained with the same dose 
of U7Dtex23-containing AAV vectors (Figure 67). Furthermore, we observed that the 
delivery of MBII52-Dtex23 snoRNAs by lentiviral vectors was inefficient to induce 
dystrophin exon 23 skipping in cultured muscular cells (Figures 68 and 69). We 
concluded that, although the snoRNA-mediated delivery of antisense sequences to 
target pre-mRNAs is feasible in an AAV context and only at high doses, the general 
efficiency of this approach was very low and did not meet expectations. This lack of 
efficiency could stem from several issues related to the design of the system 
 
- Problem of intracellular localisation 
It is possible that the MBII52-Dtex23 transcript could not act on the dystrophin 
transcript because of different sub-nuclear localisations. The snoRNAs are 
predominantly localised in the nucleolus whilst mRNA splicing occurs in the 
nucleoplasm and, although it has been shown that endogenous MBII-52 snoRNAs 
could transiently localise in the nucleoplasm to modulate the alternative splicing of 
HT2CR pre-mRNA [204], this transit into the pre-mRNA compartment might be too 
transitory to allow splicing alteration of long dystrophin transcripts. Indeed, considering 
that the splicing of dystrophin pre-mRNA occurs co-transcriptionaly and that its 
transcription last approximately 16 hours, it is possible that the brief passage of the 
snoRNA in the nucleoplasm does not occur at all or at the right timing and for long 
enough to inhibit exon 23 splicing. 
 To assess this issue we could imagine a way to detect and localise the modified 
snoRNAs in live cells to gain information on their real-time sub-cellular trafficking as 
well as the abundance of mature molecules produced for a set amount of vector 
administered. The development of RNA-based probes that contain two aptamer 
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modules to specifically recognize small molecules and generate a fluorescent signal when 
bound to the targets could be envisaged for our purpose [405]. Such aptamer probes are 
composed of a detector moiety that bind to the small molecule to be detected and of a 
second aptamer domain that can bind to a dye such as malachite green. When the 
targeted ligand binds to the detector domain of the probe, a change of conformation of 
the probe occurs so that the dye that is added in the cell culture media can associate 
with the second aptamer moiety. By doing so, the malachite green that is not naturally 
fluorescent is submitted to a change of conformation that induces it to become 
fluorescent. The specificity of the technique is such that a fluorescent signal is emitted 
only when the targeted ligand binds to the detector module. As the probe is constituted 
entirely of RNA it can be easily produced through genetic encoding inside the cells and 
could be adapted to detect intracellular nucleic acids, such as snoRNAs [406].  
It would be interesting to track the spatiotemporal localisation of transduced snoRNAs 
in the muscular cells using this type of approach to assess if they are able to localise in 
the nucleoplasm with the dystrophin pre-mRNA and if this potential co-localisation 
lasts long enough to act on the splicing of these transcripts. In order to discriminate 
multiple RNAs simultaneously., we could use an aptamer probe specific for the 
snoRNA and able to bind the malchite green dye, and a second aptamer probe for 
dystrophin transcript detection binding a different dye, such as the SRB dye described 
elsewhere [407]. In the case where the snoRNA is not able to transit through the 
nucleoplasm or at least not long enough, we could try to further modify the chimeric 
MBII52 molecule to force this localisation. It has been demonstrated that the conserved 
C/D box motif of the snoRNAs is necessary to induce nucleolar accumulation of the 
mature snoRNPs [201-202]. It could be envisaged to alter these C/D boxes in a way 
that would prevent the retention of the snoRNA in the nucleolus and would enable to 
redirect it towards the nucleoplasm, thereby promoting its co-localisation with target 
pre-mRNAs. 
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- Problem associated with the antisense sequence 
The very low efficiency of the snoRNA cassette could be related to the size or the 
composition of the Dtex23 antisense sequence itself. The 44-nucleotide long Dtex23 
antisense is more than twice larger than the original 18-nt HT2CR complementary 
sequence present in the endogenous MBII-52 snoRNA. The replacement of this natural 
antisense by the double-target Dtex23 sequence could therefore destabilise the 
transcript and lead to a disruption of the snoRNA secondary structure, thereby 
preventing the association of the transcript into a stable snoRNP and leading to its 
global inactivation and inability to associate with the target pre-mRNA. Instead of the 
long double-target Dtex23 antisense sequence we could therefore insert in the snoRNA 
construct a single-target antisense sequence that would be closer in size to the original 
MBII-52 antisense sequence. For example, a sequence directed against the 5' splice site 
of exon 23 alone and introduced into a U7snRNA cassette was reported to allow 
dystrophin exon 23 skipping in mouse mdx cells, albeit with less efficiency than the 
double-target construct [256]. This 24-nucleotide sequence inserted in the snoRNA 
cassette could be tested for its ability to induce exon 23 skipping, thereby deciphering 
whether the size of the antisense sequence plays a determining role in the efficiency of 
the snoRNA-based approach for dystrophin splicing modulation. 
Alternatively, snoRNAs have also been derived as carriers to express ribozymes and 
target the cleavage of precise transcripts in trans [408]. In this study, a shortened version 
of the U3 C/D box snoRNA was modified by replacing its original 5' single stranded 
sequence involved in ribosomal RNA binding by the chosen hammerhead ribozyme 
sequence. This so-called "snorbozyme" was able to induce specific cleavage of the 
targeted transcript. To introduce the ribozyme into the U3 snoRNA construct, a 54-
nucleotide segment of the 5' snoRNA extremity was replaced by the 46-nt catalytic 
portion of the ribozyme. This demonstrates that a large RNA sequence can be inserted 
into the U3 snoRNA without hampering its metabolic stability and whilst still 
maintaining the ability to direct the modification of cellular RNAs. We could therefore 
consider using this described mini-U3 snoRNA as a carrier to express the large 44-nt 
Dtex23 antisense sequence and assess if this approach enables to alter the splicing of 
mouse dystrophin transcript with more efficiency than the use of the MBII-52 snoRNA. 
Another option would be to introduce the antisense into a snoRNA that naturally 
contains two complementary sequences directed against a cellular RNA. The U24 C/D 
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box snoRNA for example naturally contains two target recognition sequences of 12 
nucleotides each to guide the methylation of two residues in the 28S rRNA [391]. We 
could therefore split the double-target Dtex23 sequence into the two sequences 
complementary to the branch point of intron 22 and the donor splice site of exon 23 of 
the mouse dystrophin pre-mRNA and insert each of these antisenses into each of the 
natural antisense boxes of U24. We could then assess if this strategy enables to form 
more stable snoRNPs and to induce the inhibition of exon 23 splicing more efficiently 
than the use of the MBII-52 snoRNA. 
 
- Problem associated with the processing of the snoRNAs 
The very low efficiency of the snoRNA-based delivery of antisense sequences for 
dystrophin exon skipping might also stem from inaccurate processing of the modified 
snoRNA. We observed in our experiments that only very low levels of mature MBII52-
Dtex23 snoRNAs could be obtained in cells transduced with high doses of AAV 
vectors. Conversely, high quantities of high molecular weight species accumulated 
instead in a dose-dependent manner (Figure 66), probably corresponding to non-
processed MBII52-Dtex23 transcripts still surrounded by their host pre-mRNA 
sequences and suggesting a problem in the processing of the pre-snoRNA from the 
debranched intron. As intronic snoRNA processing is physically and functionally linked 
to the splicing of the host pre-mRNA intron [194-195], it is possible that these hMW 
species correspond to full primary transcripts containing the host exons G2-G1 and the 
snoRNA embedded in the intronic sequence and could suggest that the splicing of 
exons G2-G1 is inefficient in the artificial construct.  
It would therefore be important to test whether this transcript is actually being spliced 
and if the snoRNA-containing intron is properly debranched and released in the cells. 
We could for example realise a simple reverse transcription and PCR on RNA extracted 
from AAV-MBII52-Dtex23 transduced cells using primers placed on the surrounding 
exons. This would indicate whether exons G2 and G1 are properly joined in most of the 
transcripts or if an intronic sequence is still maintained in a proportion of them, thereby 
reflecting a default in the splicing of the artificial construct. In the latter case, 
optimisations of the chimeric construct could be proposed to force the splicing of the 
host pre-mRNA: it has been demonstrated that the position of the snoRNA in the host 
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intron relative to consensus splice sites is critical for both pre-mRNA splicing and 
snoRNA synthesis as the modification of the distance between the 3′ end of the 
snoRNA and the branch point disrupts both processes and leads to a strong decrease in 
mature snoRNA accumulation. A distance of about 50 nucleotides between the 
snoRNA coding region and the branch point was then determined optimal for efficient 
snoRNA production [196-199]. In our construct the MBII52-Dtex23 snoRNA is 
located 60 nucleotides away from the intronic branch point sequence between exons G2 
and G1, and it is possible that the splicing process is less effective in this construct as a 
result of non-optimal localisation of the snoRNA in the host intron. We could therefore 
try to optimise the position of the snoRNA in the intron by shortening the distance 
between its 3’ end and the branch point sequence. Alternatively, we might consider 
expressing the snoRNA in another intronic context surrounded by exons that are 
known to be spliced with very high efficiency, such as in the βglobin pre-mRNA [393]. 
It has indeed been demonstrated that all the necessary signals for correct processing of a 
snoRNA reside within the snoRNA sequence itself and that snoRNAs artificially placed 
into introns of mRNAs that do not normally encode snoRNAs are accurately processed 
[191]. We could therefore insert the MBII52-Dtex23 in an optimal intronic context 
between strong splice signals in a constitutively spliced sequence and distant to the 
branch point by approximately 50 nucleotides. By doing this, we might be able to 
eliminate the issue of incomplete processing and hMW species generation and obtain a 
larger amount of antisense sequences expressed in the transduced myotubes. 
Another processing-related issue is that the MBII52 snoRNA may be processed into 
several shorter fragments lacking the 5' and 3' ends by exonuclease trimming that 
finishes at the C and C' boxes [106]. In this case, it is possible that a good proportion of 
MBII52-Dtex23 transcripts would also be shortened into small RNA fragments, called 
psnoRNAs, and that the 105-nucleotide full-length form would be only a minor product 
of the MBII52-Dtex23 expression unit, explaining why only few 105-nt transcripts 
could be detected on the Northern blot assay. Furthermore, as the described shortened 
species often lack 5' and 3' sequences up to the C and C' boxes, such RNAs would not 
contain the Dtex23 sequence anymore and would not hybridize with the MBII52-
Dtex23 radioactive probe, which could explain the absence of short fragments detected 
on the Northern blot. Although the existence of these MBII52-derived psnoRNAs is 
controversial and has since been questioned [388], studies have demonstrated the 
presence of snoRNA-derived short RNA species, usually shorter than 35 nucleotides, 
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stably accumulating and conserved in various cell types [389]. These small RNAs are 
processed from a proportion of C/D box or H/ACA box snoRNAs that are 
transported to the cytoplasm and many of them have been shown to act as regulatory 
RNAs and affect gene expression. Indeed, some of these short RNAs are able to 
associate with the RNA silencing machinery and to function like miRNAs in 
posttranscriptional gene silencing [409-412]. These findings support the fact that various 
snoRNAs can be processed into short RNA species and it is therefore possible to 
suggest that the same phenomenon could affect the modified MBII52 snoRNA, 
processing it into short RNA fragments undetected in our experiments and limiting the 
amount of full-length transcripts expressed in the transduced cells. 
Interestingly, it has been demonstrated that MBII52 snoRNA could assemble into non-
canonical RNPs by recruiting novel proteins distinct from known snoRNP-associated 
proteins [204]. In particular, the study from Kishore et al. suggests that shortened forms 
of the MBII52 RNA lacking the 5'-3' stem sequences are not able to associate with 
snoRNA-specific proteins such as fibrillarin but instead can assemble with hnRNP 
proteins known to be involved in pre-mRNA splicing [106]. The authors describe a 
model where the MBII52 snoRNP associates with its target RNA and is able to 
influence splice site selection through the action of the associated hnRNP proteins.  
Based on this notion, we could imagine a strategy to force the association of the 
chimeric snoRNA with hnRNPs, thereby favouring its action on the splicing of the 
target pre-mRNA. This could be realised by eliminating the stem sequences at each end 
of the snoRNA coding region in our construct in order to artificially influence the 
generation of psnoRNAs that associate with hnRNPs. Although the presence of the 
terminal stem is thought to be necessary for correct processing of the snoRNA, many 
snoRNAs naturally lack a terminal helix and are yet still processed into mature and 
stable snoRNAs. It has been demonstrated that such snoRNAs are processed from the 
intron of host pre-mRNAs owing to the transient formation of external stems in the 
surrounding intronic sequences that enable to bring the C and D boxes close together 
and to allow the binding of snoRNA-associated proteins necessary for correct snoRNA 
processing [413]. Further studies of these flanking sequences and of the signals 
necessary to form an external stem structure could allow us to introduce a stem-less 
MBII52-Dtex23 snoRNA, truncated at the 5' and 3' ends, into intronic sequences able 
to form the necessary external stems. As these intronic structures would then be 
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degraded during snoRNA processing, this strategy could therefore allow the release of 
modified psnoRNAs able to associate with hnRNP proteins and to alter the splicing 
pattern of target pre-mRNAs with high efficiency.  
 
II. 2. Targeted methylation of the branch point adenosine for exon skipping 
II. 2. 1. Rationale for the study and choice of the U24 snoRNA 
Our third line of investigation relates to the improvement of an alternative strategy to 
induce exon skipping in pre-mRNAs through the targeted methylation of the branch 
site by modified snoRNAs. Although this strategy had been previously validated for pre-
mRNA splicing modulation in human cells, the low efficiency reported indicated the 
need for improvements [414]. In a recent study, artificial U24 C/D box snoRNAs 
targeting methylation at different consensus splice sites of a pre-mRNA altered the 
alternative splicing pattern by increasing the proportion of exon-depleted mRNA 
isoforms from 7% in non treated cells to up to 30% in snoRNA-transfected cells [415]. 
We decided to reproduce this approach by re-directing the human U24 snoRNA 
towards the branch point of an exon-skipping reporter construct, aiming to first validate 
this approach before ultimately trying to optimise it for dystrophin exon skipping 
application. The choice of the U24 snoRNA for our study stemmed from the 
demonstration in these earlier studies that this transcript can be derived to target pre-
mRNAs and induce their site-specific methylation. Furthermore, this snoRNA presents 
the advantage of naturally containing two target recognition sequences that can 
hybridize on two adjacent sequences in the target RNA, thereby strengthening the 
association between the molecules. 
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II. 2. 2. low efficiency of the strategy and potential optimisations 
Owing to the published results we were expecting to obtain low levels of exon skipping 
in our reporter system. However, even though the modified U24 snoRNA and the 
luciferase reporter construct were transfected at a 5:1 molecular ratio, providing an 
excess of U24 molecules to target the βglobin sequence in the reporter pre-mRNA, no 
significant increase of luciferase signal was recorded suggesting that no exon skipping 
could be obtained in the target pre-mRNA (Figure 75). Our data therefore implied that 
this exon skipping strategy was greatly inefficient in our system, which could be due to 
various factors. 
 
- Problem associated with the modified snoRNA and its ability to 
direct the methylation of target nucleotides 
 We could consider that the inefficiency of the strategy stemmed from the same 
problems stated before associated with the design of the snoRNA. For example a non-
effective splicing of the host gene or a problem of processing of the snoRNA from the 
debranched host intron could also occur in this system as described for the modified 
MBII52 snoRNA. However, such a processing issue is not likely as good amounts of 
modified U24 transcripts could be observed at the right size on the Northern blot from 
RNAs of cells transfected with both the reporter construct and the chimeric U24 
plasmid. This indicated that U24 synthesis and processing was correctly achieved from 
the synthetic construct and was present in virtually sufficient amounts to direct the 
modification of target pre-mRNAs. A problem of sub-nuclear localisation is not very 
likely either as it has been shown that upon transfection of human cells a similarly 
modified U24 snoRNA was able to interact with the pre-mRNA target inside the 
nucleus to influence its splicing and that artificial snoRNAs could be detected both in 
the cytoplasm and nuclear fraction of transfected cells [415]. This suggested that no 
constraint forced the modified U24 to an exclusive nucleolar localisation but that it 
could instead transit in various sub-cellular compartments. It is therefore likely that the 
U24 transcript in our study was also able to reach different cellular compartments and 
that the absence of activity was not due to a failure to find its target in the nucleoplasm. 
It would however be important to experimentally verify the localisation and processing 
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of the modified U24 snoRNA in the transfected cells using the approach described 
above. 
Another possibility is that the snoRNA was not able to efficiently direct the methylation 
of the pre-mRNA branch point and could not trigger the skipping of the downstream 
exon. Indeed, in the study realised by Stepanov et al., although a splicing impairment 
was obtained in the presence of the artificial U24 snoRNA it could not be clearly 
demonstrated that this increase in exon skipping was the result of site-specific 2’-O-
methylation of the target pre-mRNA as the potential modification of the targeted 
nucleotide could not be verified [415]. It is therefore possible that the inhibition of 
splicing observed was instead the result of an antisense effect obtained by blocking the 
access of the splicing machinery to consensus splice sites via complementary 
hybridization of the artificial snoRNA. In this case, if the beneficial effect observed in 
their study is due to an antisense effect rather than the directed methylation of the splice 
sites, this could explain the absence of efficiency in our system: it is possible that the 
steric blocking of the branch sequence of βglobin pre-mRNA was not enough to inhibit 
the splicing of the downstream exon and that the antisense effect did not apply in this 
situation.  
It would therefore be of key importance to test whether the 2' -O-methylation of the 
target branch point in βglobin pre-mRNA actually occurred in our assay, for example by 
realising a primer extension-based 2′-O-methylation assay at high or low dNTP 
concentrations as previously described [186]. In the case where no nucleotide 
modification could be detected, a likely explanation could be that the modification of 
U24 snoRNA antisense sequences prevented its correct assembly with methyltransferase 
proteins into a functional snoRNP, thereby precluding the 2’-O-methylation of the 
target RNA branch point and the skipping of the downstream exon. However, if the 
targeted branch point was accurately 2'-O-methylated whilst no exon skipping could be 
obtained, this could mean that the methylation of the branch point was not efficient 
enough to compete with the multiple known ESEs contained in βglobin exon 2 and to 
induce splicing inhibition of the downstream exon [60]. Finally, it is possible that the 2'-
O-methylation occurred only on a small proportion of pre-mRNAs and left a majority 
of unmodified transcripts that present a normal splicing pattern, thereby precluding the 
detection of significant luciferase increase associated with exon skipped-transcripts.  
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As an alternative strategy to inhibit splicing we could try to target the 2'-O-methylation 
of nucleotides at different splice sites, such as the splice donor and splice acceptor sites 
at each extremity of the intron, as it has been shown that the targeted modification of 
these consensus splice sequences by C/D box snoRNAs induced the skipping of the 
downstream exon with a comparable efficiency than targeting the branch point [415]. As 
altering or masking different splice sequences in a transcript can trigger exon skipping 
with variable efficiencies depending on the pre-mRNA studied, it is possible that 
methylating the 5' or 3' splice site instead of the branch point in our βglobin-luciferase 
transcript could alter the pre-mRNA splicing with a better efficiency. It could also be 
envisaged to use the ability of U24 snoRNA to simultaneously target and methylate two 
different sequences on the same pre-mRNA: we could for example combine two 
antisense sequences that would concurrently hybridize the branch point and the 3' splice 
site of the pre-mRNA and induce the 2' -O-methylation at both sites, thereby increasing 
the chances of altering the splicing of the 3' exon.  
It has also been recently demonstrated that H/ACA box snoRNAs that naturally 
catalyze the post-transcriptional isomerization of uridine to pseudouridine at specific 
site within target RNAs [416] could be redirected towards various RNAs, including 
mRNAs, by modifying their guide sequence [417-418]. In these studies, artificial 
H/ACA snoRNAs were able to successfully induce the pseudouridylation of a 
premature termination codon within the target pre-mRNA, thus allowing translational 
readthrough and the recovery of a full-length protein, albeit with a limited efficiency (5 - 
10%). Yet, this strategy is not confined to nonsense suppression applications but could 
potentially be derived for splicing modulation purposes. As pseudouridylation of 
uridines induces structural and biochemical changes in the transcript, we hypothesize 
that the isomerisation of a uridine residue situated in a splice site could affect its 
function in the splicing process. Considering that pseudouridylation occurs only on 
uridine residues it is impossible in this case to target the modification of an adenosine 
branch point with this process. We could engineer an H/ACA snoRNA to direct the 
pseudouridylation of the uridine present in the critical GU dinucleotide at the donor 
splice site of our βglobin-reporter transcript in order to inhibit the splicing process.  
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- Problem associated with the luciferase exon skipping reporter 
construct 
It is also plausible that the apparent absence of exon skipping obtained by the snoRNA-
induced BP methylation strategy was linked to a wrong design of the reporter construct. 
The inactivation of the major branch point of intron 1 in the βglobin-luciferase 
transcript through targeted methylation could very possibly have triggered the activation 
of one or several cryptic branch points to restore the normal splicing pattern. Consistent 
with this hypothesis, it has previously been demonstrated that the inactivation by 2'-O-
methylation of an authentic branch point in an intron of the adenovirus pre-mRNA led 
to a correct splicing pattern through the use of cryptic branch points [206]. Moreover, it 
has been shown that the intron 1 of human βglobin pre-mRNA contains several cryptic 
branch points, always adenosine residues situated 22 to 37 nucleotides upstream of the 
3' splice site of exon 2, which can become activated following mutation of the authentic 
branch site to enable the accurate splicing of the pre-mRNA [395]. Providing the 
methylation and inactivation of βglobin intron 1 branch point did actually occur in the 
reporter construct, it is therefore very likely that the splicing machinery selected one or 
several of the cryptic adenosines identified by Ruskin et al. to recover the correct 
splicing pattern of βglobin pre-mRNA and thereby maintain the fused luciferase 
transcript out-of-frame. Therefore, even if the targeted 2'-O-methylation did occur at 
the authentic branch point and efficiently inactivated it, this potential success could have 
been concealed by the presence of cryptic branch points and would have led us to 
conclude on the inefficiency of the strategy. It would then be important to identify and 
mutate all the putative cryptic branch sites present in βglobin intron 1 of the reporter 
construct in order to decidedly assess if the snoRNA-directed BP methylation strategy 
could present some efficiency for the skipping of a downstream exon. This 
demonstrates a weakness of this approach as each target branch site in a specific pre-
mRNA will have to be optimized relative to the presence of cryptic branch points in the 
surrounding intronic sequences, which could be very fastidious. 
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III. Relevance for treatment of diseases by exon skipping 
In this study several exon skipping strategies have been investigated in the aim to 
identify suitable treatments for genetic diseases that could benefit from the skipping of 
one or several exons in a mutated pre-mRNA. The use of modified C/D box snoRNAs 
to direct the methylation of a branch point adenosine and inhibit the splicing of the 
downstream exon in a target pre-mRNA was investigated. However, although this 
strategy could benefit from further analysis, the overall low exon skipping efficiency 
suggests that it presents little potential for an application to disease treatment by exon 
skipping. The use of antisense sequences for the steric blocking of splice signals to 
inhibit the splicing of an exon is to date a much more promising strategy and is more 
likely to continue being the focus of research for the development of clinically 
applicable exon skipping strategies. We therefore concentrate here on these antisense-
based approaches and analyse their potential for a possible translation towards clinical 
application. 
For the intracellular delivery of antisense sequences we investigated and compared two 
different carrier molecules, snRNA or snoRNA cassettes, to express steady levels of 
antisense sequences able to trigger exon skipping. These exon skipping strategies were 
tested in the context of the dystrophin pre-mRNA for the treatment of Duchenne 
muscular dystrophy. Here we consider the difficulties associated with this choice of 
disease model to assess various exon skipping approaches. Furthermore, we expose the 
arguments in favour of the vectorisation of antisense sequences for long-term treatment. 
Finally, we discuss the likelihood of each antisense delivery approaches, snoRNA-based 
or U7 snRNA-based, to realistically be translated into clinical treatments of DMD. 
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III. 1. The model: dystrophin pre-mRNA exon skipping  
Targeting the dystrophin pre-mRNA can be challenging as various factors can hamper 
the action of antisense sequences. As mentioned before, the availability of the 
dystrophin transcript in muscular cells varies depending on the myogenic stage of the 
culture (present study and [303, 362-363]). By expressing antisense sequences too early 
in myoblasts, where the dystrophin transcript has not yet been synthesised, or too late 
when the splicing of most of the transcripts already occurred, could impair the 
efficiency of exon skipping and could lead us to mistakenly judge a strategy as 
inefficient. It is therefore critical to carefully choose the appropriate time to administer 
antisense sequences to modulate the splicing of the dystrophin transcript in order to 
obtain the best exon skipping efficiency possible. In addition, it has been shown that the 
dystrophin transcript folds into transient secondary structures during its transcription 
[419], and this is the time when antisense sequences must hybridize on the transcript as 
the splicing process occurs co-transcriptionally. This pre-mRNA folding can therefore 
impair the accessibility of antisense sequences to their target sequences and therefore 
prevent exon skipping depending on the sequence targeted [419]. It is therefore 
important to verify the potential engagement of the targeted sequence into a secondary 
structure during dystrophin pre-mRNA transcription to ensure the efficiency of the 
exon skipping strategy. 
Furthermore, there is a high variability in exon-skipping efficiency among muscular cell 
types. In our study, we evaluated the different antisense cassettes for dystrophin exon 
skipping in wild-type mouse muscular cells. However, it has been shown that the 
administration of antisense sequences in dystrophic muscles, such as mdx mouse 
muscles, induces superior exon skipping efficiencies than in healthy muscles [314, 420]. 
Testing an antisense-based strategy in wild-type cell cultures could therefore lead to an 
underestimation of efficiency. This observation however applies mainly for synthetic 
AONs and is primarily the result of an enhanced penetration of the oligonucleotides in 
dystrophic muscle fibres that present increased permeability. It is less likely to be a 
variability factor in our study where antisense oligonucleotides are delivered via viral 
vectors, which should enter healthy or pathologic cells with the same efficiency. 
Another important point to consider when testing exon skipping strategies on wild-type 
cells is the probability of disrupting the reading frame of the normal dystrophin 
transcript when inducing exon skipping. In the case of the skipping of dystrophin exon 
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23, the reading frame of the whole transcript is maintained even when altering wild-type 
pre-mRNAs. However, in the context of human dystrophin pre-mRNA splicing, there 
are some cases where the skipping of an exon would only restore the reading frame of a 
mutated transcript but would alter that of a wild type pre-mRNA. This is the case of 
human dystrophin exon 51 skipping that has been designed to restore the reading frame 
of exon 52-deleted transcripts: the reading frame is actually recovered upon skipping of 
the disease-associated transcript but is disrupted in wild-type transcripts that still contain 
exon 52, triggering the apparition of premature stop codons. In this case, wild-type 
mRNAs with disrupted reading frames would be susceptible to degradation by 
nonsense-mediated decay, which would impair the detection of skipping events and lead 
to an underestimation of exon skipping efficiencies [339]. 
In addition, it is to be considered that the situation observed in vitro might be fairly 
different than the one encountered in vivo.  For example, amongst a pathologic muscle 
some muscle fibres are able to respond better than other to exon skipping treatment, 
which often leads to non-uniformly expressed dystrophin in a whole treated muscle, and 
the overall responsiveness to treatment also fluctuates from muscle to muscle in animal 
models [421]. The amount of dystrophin transcripts synthesised in mouse muscles in vivo 
also varies compared to that produced in cultured myotubes: it has been suggested that 
the level of dystrophin pre-mRNA observed in vitro is approximately 10 fold less than 
the one detected in adult mouse muscle, and a similar observation was made in human 
myotubes [364]. This could suggest that the amount of antisense sequences needed to 
be administered in order to correct a good proportion of dystrophin transcripts need to 
be adapted and increased for in vivo treatment.  
Finally, it is now clear that very high doses of antisense sequences expression are 
necessary to correct enough dystrophin transcripts and restore therapeutical levels of 
dystrophin protein expression [422]. This need for high levels of antisense expression 
could lead us to overlook some strategies that display poor efficiencies in the context of 
DMD but that might prove sufficient for applications in other diseases. 
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Altogether, these peculiar characteristics associated with dystrophin expression patterns 
and variability amongst muscular cells point to the difficulty of trying to adapt an exon 
skipping strategy for the treatment of DMD and suggest that this disease might not 
constitute the best model when trying to test and compare new exon skipping strategies. 
For such purposes, it is therefore more adapted to develop exon skipping reporter 
constructs that can provide an easy read-out of exon skipping efficiency. In this study 
however our major aim was to identify strategies that enable to increase the amount of 
antisense sequences that can be expressed in muscular cells specifically for the treatment 
of DMD by exon skipping. In that prospect, the newly designed snoRNA-based system 
showed strong limitations in its ability to deliver high levels of antisense sequences and 
displayed very limited dystrophin exon skipping efficiency, even when high doses of 
vector were administered. This need for high levels of expression of antisense sequences 
therefore led us to dismiss this snoRNA-based strategy for an application to dystrophin 
pre-mRNA splicing modulation. The already well-studied U7 snRNA cassette still 
constitutes the most likely strategy to reach further stages towards potential clinical trials 
for DMD therapy and we will now focus for the remainder of the discussion on this 
system and the optimisations realised in this study. 
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 III. 2. The pros and cons of the vectorisation of antisense sequences  
In this study we have chosen to deliver antisense sequences to muscular tissues and cells 
through the use of viral vectors. The modified U7 snRNA can be used as a carrier and 
expression cassette for antisense sequences and can be easily introduced in a 
recombinant AAV vector for transduction of muscular cells. The use of viral vectors 
presents several advantages over the delivery of synthetic oligonucleotides but still faces 
several challenging barriers that have precluded clinical trial so far. 
Firstly, it is important to note that some antisense sequences that are active and efficient 
for inducing exon skipping when used as synthetic oligonucleotides can be inactive 
when introduced in expression vectors. One example is the M23D sequence that targets 
the donor splice site of mouse dystrophin exon 23, which is able to induce good levels 
of exon skipping when used as an oligonucleotide [423-424] but is not efficient when 
vectorised into a U7 snRNA cassette delivered by AAV vectors (data not shown). A 
plausible explanation for this observation is that a particular sequence introduced into 
the U7 snRNA might trigger the U7 snRNA to form an abnormal secondary structure 
and prevent its association into a functional snRNP, thereby abolishing its potential 
effect to modulate splicing. In addition, the efficient expression of antisense sequences 
introduced into small RNA cassettes can be dependent on the choice of viral vector 
used for intracellular delivery and in some cases, small RNA-antisense cassettes that are 
active when delivered by AAV vectors can display a complete absence of activity in a 
lentiviral background. Nonetheless, once an antisense sequence has proven active when 
introduced into a small RNA cassette in a chosen viral vector, the use of recombinant 
viruses to deliver antisense sequences has proven to be an advantageous strategy on 
many levels. 
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- Administration and biodistribution 
The first advantage of using viral vectors relates to the mode of administration and the 
biodistribution of antisense sequences. In order to target all the muscular tissues in the 
body, including the heart, systemic administration of the sequences is necessary. 
However, although AONs have proven very efficient when administered locally in 
isolated muscles, their widespread distribution after systemic injection in blood 
circulation is still problematic. Conventional AONs administered intravenously, PMO as 
well as 2’-O-Me AONs, present a poor cellular uptake in some muscles particularly in 
the cardiac muscle, leading to an absence of cardiac dystrophin restoration [425]. 
Conjugating PMO with cell-penetrating peptides to improve delivery of AONs in the 
heart has enabled good levels of exon skipping in cardiac muscle of animal models 
[426], but these peptide-conjugates can induce a strong dose-dependent toxicity. 
Therefore, the determination of a dose that would be efficient for bodywide dystrophin 
restoration whilst remaining safe for the patient still constitute a challenge [427]. 
In contrast, the delivery of antisense-carrying U7 cassettes by AAV vectors offers the 
ability to transduce all muscle fibres efficiently, including the heart, when a specific AAV 
serotype is used. AAV serotypes 6, 8 and 9 display strong tropisms for muscle tissues 
and have demonstrated high gene transfer efficiencies in cardiac muscles following 
systemic administration in animal models [318, 358-359, 422, 428]. It is therefore 
possible to greatly improve muscle and heart delivery of U7 snRNA cassettes carrying 
antisense sequences using such AAV serotypes. The potential for an immune reaction to 
the viral capsid in the host when using AAV vectors is however non negligible and 
would often result to a diminution of transduction efficiencies as well as constitute an 
obstacle to readministration of the vector. Yet, AAV-mediated gene therapy in the 
presence of mild immunosuppressive treatment have shown some success in recent 
clinical trials [429] and new strategies aiming at avoiding the immune system are starting 
to emerge. For example the recent creation of a chimeric AAV capsid variant, termed 
AAV2.5, enabled efficient muscle transduction without eliciting any immune response 
even in the presence of preexisting antibodies [430]. The delivery of antisense sequences 
by viral vectors therefore seems to be the favoured method for systemic administration 
applications. 
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- Stability, long-term expression and safety 
The vectorisation of antisense sequences in U7 snRNA cassettes delivered by viral 
vectors also enables to stabilise and protect the antisense sequence against intracellular 
degradation by incorporating them into stable snRNPs. Furthermore, the use of U7 as a 
carrier of antisense sequences promote their accumulation into the nucleus, where the 
splicing reaction takes place, and the SmOPT modifications present on U7 shuttles 
enable to redirect the modified U7 snRNP to the spliceosome, thereby facilitating its 
action on the splicing of the target pre-mRNA. 
Yet, one of the most interesting point associated with the use of viral vectors for 
antisense delivery is that, compared to AON-based therapies that necessitate repeated 
administrations of high doses of oligonucleotides to obtain a prolonged effect, the use 
of U7 snRNA as an expression vector implies that the antisense sequence is 
continuously expressed from the strong U7 promoter, thereby providing a stable and 
long-term production of antisense sequences in transduced tissues and avoiding, or 
strongly reducing, the need for readministration. Although it is possible that a 
readministration of U7-carrying AAV vectors might become necessary over time in 
treated DMD patients, it has been shown that a single administration of AAV9 
containing U7 snRNA cassettes for dystrophin exon 23 skipping was able to rescue the 
phenotype of a severe mouse model of DMD and strongly increased its lifespan, 
demonstrating the long-lasting effect of the treatment [422].  
The development of gene expression profiling methods to evaluate the efficiency and 
safety of various antisense-based therapies in the mdx mouse model enabled to highlight 
the strong potential of AAV-mediated treatment. Following intramuscular AAV delivery 
of modified U7 cassettes specific for dystrophin pre-mRNA, the DMD signature genes 
that correlate with the severity of the disease displayed a highly significant shift towards 
wild-type profiles and a strong reduction in genes implicated in inflammation and 
fibrosis, characteristic of mdx muscle fibres [431]. Additionally, no disruption of other 
unrelated genes was associated with the overexpression of the modified U7 snRNAs, 
except a slight increase in expression of some immunological markers. Such remarkable 
results were on the other hand not obtained with synthetic AONs complexed with 
various carriers, which displayed only mild exon skipping efficiencies, no significant 
change of expression profiles towards the wild-type situation and in some cases an 
aggravation of the inflammation characteristic of muscular dystrophies.  
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- Potential for multiple exon skipping 
Finally, owing to the small size of U7 snRNA cassettes, the use of viral vectors also 
provides the possibility to express several modified U7 snRNAs containing different 
antisense sequences in the same vector, thereby allowing the simultaneous delivery of 
various cassettes into the same cell [269]. This strategy is very attractive for the prospect 
of multiple exons skipping, such as the skipping of exons 45 to 55 of human dystrophin 
pre-mRNA that could constitute a therapy for over 60 % of DMD patients. On the 
other hand, multiexon skipping is still considered challenging using AONs as it is 
difficult to control the simultaneous introduction of many different oligonucleotides in 
the same nucleus, although very encouraging results are starting to emerge [432]. 
Furthermore, as several antisense sequences would then be contained into a single viral 
vector, the development of this construct as a drug would be greatly simplified 
compared to the need to validate and obtain an authorisation for each antisense 
sequence designed for one mutation for personalised treatment.  
  
Altogether, this points at a strong advantage of the AAV-mediated delivery of antisense 
sequences over the administration of synthetic AONs for the correction of dystrophin 
pre-mRNA by exon skipping. Providing the immune reaction towards viral capsids can 
be controlled and diminished, the vectorisation of antisense sequence via AAV vectors 
encoding modified U7 snRNA cassettes therefore seems a very promising strategy for 
the treatment of DMD by exon skipping, allowing a long-term, more targeted and 
stronger effect than the use of AONs. As the immunological reactions against AAV 
viruses appear to be dependent on the dose administered, the importance of identifying 
strategies that would enable the reduction of the dose of vector needed is evident, and 
this is the goal we tried to achieve in this study by increasing the amount of antisense 
sequence that can be expressed from a viral vector. 
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III. 3. Application to DMD - Low efficiency of the strategies versus the 
requirement for strong therapies 
The clinical application of AAV-mediated dystrophin exon skipping for the treatment of 
DMD patients is proving more and more realistic but would still require the 
administration of high doses of viral vectors in order to obtain satisfying therapeutic 
effects, which is currently challenging in terms of safety and vector production capacity. 
In the severe mouse model of DMD, the dKO mouse, it has been demonstrated that a 
minimal dose of 5 x 1012 vg needed to be injected in order to obtain an improvement of 
phenotype and lifespan, and that doses below this threshold were not sufficient to 
restore therapeutic levels of dystrophin expression when administered systemically 
[422].  
Based on the exon skipping efficiencies obtained, we first concluded that both 
snoRNA-based strategies developed here for dystrophin splicing modulation did not 
show much potential for a prospective application to DMD patients. However, the 
results obtained from the various optimisations of U7 snRNA cassettes were more 
encouraging. We observed that the use of self-complementary AAV vectors to express 
U7 snRNA cassettes specific for dystrophin exon skipping induce a faster and better 
transduction efficiency and enable to increase the proportion of exon 23 skipped 
dystrophin mRNA by more than three folds compared to the same dose of 
conventional AAV vector. Additionally, we showed that using the heart and muscle-
specific MHCK enhancer to promote the transcription of U7Dtex23 snRNA cassettes 
in muscular cells induced an increase in dystrophin exon 23 skipping both in vitro and in 
vivo and resulted in a three-to-five fold increase in Dystrophin expression in transduced 
muscles of mdx mice. Both strategies independently demonstrated a potential for 
decreasing the dose of vector necessary to obtain significant levels of dystrophin exon 
skipping, as exon skipping efficiencies or protein rescue levels obtained by each strategy 
reached equivalent levels than that achieved at a five-to-ten fold higher dose of non-
optimised vector.  
However, our data also pointed at a possible saturation of the U7 snRNA 3’ end 
processing machinery when the primary U7 transcript is expressed in too many copies 
in the cells at high doses of vectors, which suggest that the potential for maximising the 
amounts of mature U7 transcripts that can be produced in muscular cells is limited by 
the cellular machinery capacity. Accordingly, further improvement of U7Dtex23 
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cassettes expression and dystrophin exon 23 skipping was not observed following the 
combination of both scAAV and MHCK strategies, probably owing to saturating levels 
of primary U7 transcripts produced.  
Nonetheless, the improvements on exon skipping efficiency and Dystrophin protein 
rescue observed suggest that these optimisation strategies, by allowing a small reduction 
of the vector dose, could be interesting to pursue towards clinical translation. 
Interestingly, we could not observe the accumulation of primary unprocessed U7 
transcripts in vivo in treated mdx muscles even for the highest dose of AAV vector 
administered, which could suggest that this issue of processing machinery saturation 
might not apply in vivo, at least at the doses used and with these vectors. It is therefore 
possible that the combination of scAAV vectors and MHCK enhancer for the 
expression of U7Dtex23 cassettes would display further enhancement of dystrophin 
exon skipping and protein rescue in the mdx mouse model, which would then be very 
encouraging for the clinical application of AAV-mediated delivery of antisense 
sequences for DMD treatment. 
 
III. 4. Further optimisations of exon skipping-based therapy for DMD and 
remaining challenges  
Further optimisation strategies could yet be envisaged and used alongside the AAV-
based delivery of U7 snRNA cassettes to improve the effect of the treatment for 
Duchenne muscular dystrophy. For example, it could be interesting to inhibit miR-31, a 
microRNA that has been shown to reduce Dystrophin protein synthesis, by designing 
an antagomir that would sequester miR-31 and would then allow the increase of protein 
rescue levels, as has been demonstrated before [433]. Alternatively, myostatin is a factor 
that inhibits muscle growth and the inhibition of its expression can be achieved by 
expressing the myostatin propeptide (MRPO) gene, a natural inhibitor, or by exon-
skipping aimed at disrupting the reading frame of the myostatin transcript, thereby 
promoting an increase in muscle mass [434-435]. Finally, the recent discovery that miR-
29 expression is disrupted in DMD and that restoring its expression in pathologic 
muscles improves the dystrophic phenotype could represent a new strategy for DMD 
treatment [436]. These various approaches could then be coupled with the U7-mediated 
exon skipping of dystrophin pre-mRNA by introducing either a miR-31 inhibitor, the 
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miR-29 microRNA, the 288-bp MRPO gene or a cassette expressing an antisense 
sequence for myostatin exon skipping in a multicistronic vector along with the U7 
cassette for dystrophin splicing modulation. Recent studies focus on combining 
strategies to improve muscle mass and function together with the selective skipping of 
dystrophin pre-mRNA and the reported results have so far been very encouraging [433, 
437-438]. 
 
The path towards clinical application of gene therapy for DMD seems now clearer and 
many hopes lie on antisense-based strategies for dystrophin pre-mRNA splicing 
modulation. Yet, it is important to remember that exon skipping approaches, even in 
the eventuality of major successes in the future, would not constitute a cure for the 
disease as exon-skipping of the dystrophin transcript only induce a conversion of DMD 
fibres into BMD-like fibres, which is still not equivalent to the normal situation. 
Furthermore, the muscle tissue lost during the progression of the disease would not be 
repaired as it is replaced by fibrotic and adipose cells that do not express dystrophin. 
Finally, exon skipping approaches is only applicable for patients that present 
frameshifting deletions or non-sense mutations and the identification of other strategies 
for the treatment of patients that cannot benefit from exon skipping is therefore critical. 
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IV. Conclusion 
The work described in this thesis focused on the development of improved vector that 
enable to maximise the amount of antisense sequences delivered to a target tissue for 
the therapeutic modulation of pre-mRNA splicing. We describe various optimisations 
strategies designed for the antisense-mediated exon skipping of dystrophin pre-mRNA 
in the context of Duchenne muscular dystrophy and show that some modest 
improvement can be obtained on exon skipping efficiency and restoration of protein 
expression. This work highlights the fact that exon skipping approaches for pre-mRNA 
splicing modulation can still benefit from further improvements [166].  
It is therefore clear that the use of RNA as a therapeutic molecule for intervention at 
the transcript level is an appealing and very promising strategy for the treatment of 
many RNA-based disorders that are otherwise virtually impossible to correct. The highly 
intricate network of regulatory non-coding RNAs expressed intracellularly is only just 
beginning to be discovered and understood and, although this adds a high level of 
complexity for the fine control of RNA molecules to modulate transcripts, it also 
provides a virtually endless array of possible tools that could be derived to develop 
RNA-based therapeutics. 
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MATERIALS AND METHODS 
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I. Polymerase Chain Reaction (PCR) and fusion PCR 
I. 1. PCR 
For all the PCR reactions the PCR Master Mix from Promega was used following the 
manufacturer’s instructions. One reaction mix of 50 μl is composed of 25 μl of Master 
Mix 2X (containing dNTPs, PCR buffer and Taq polymerase), 1 μl each of 20 μM 
Forward and Reverse primers, and 50 ng of template DNA. The PCR reactions were 
realised under the cycle conditions: a) 94°C for 5 minutes, b) 94°C for 30 seconds, c) 
TM (melting temperature, adapted for each PCR reaction)  for 1 minute, d) 72°C for 1 
minute/kb, repeating from step b) for 29 additional cycles.  
I. 2. Fusion PCR 
To realise a fusion PCR, which enables to introduce or replace an entire stretch of 
nucleotides inside a specific DNA sequence, two pairs of primers are used (Figure 
76a): 
 - an internal pair (Fint and Rint) that enables to insert the chosen modification 
via modified 5'-ends. Each internal primer is composed of a 3' part complementary to 
the template sequence adjacent to the modification, and of a 5' unpaired tail containing a 
fragment of the sequence to be inserted. The 5' ends of both internal primers are 
designed to contain overlapping sequences. 
 - an external pair of primers (Fext and Rext) to amplify the template DNA 
sequence surrounding the region to be modified.  
Two PCR reactions are realised in parallel from the template DNA (Figure 76b): the 
first one (PCRI) with the primers Fext and Rint, and the second one (PCRII) using Fint 
and Rext. As the modified 5' tails of the internal primers contain complementary 
sequences, the products of PCRI and II therefore present overlapping extremities. A 
final amplification with the external primers using PCRI and II products as templates 
therefore enables to fuse both products into the final construct containing the 
modification (PCRIII) (Figure 76c).  
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Figure 55: mechanism of fusion PCR 
 
The final products of amplification are purified on a 1% agarose gel and extracted using 
the QIAGEN gel extraction kit. Restriction sites that produce compatible cohesive ends 
are added at each extremity of the products to allow their cloning into plasmid vectors. 
The sets of primers used for the amplification of each gene are listed in Table 2. 
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PCR PRODUCTS PRIMERS FORWARD PRIMERS REVERSE SOURCE 
U7Dtex23 snRNA  
for mouse dystrophin 
exon 23 skipping 
5’TTTTGCTAGCTAACAACATA
GGAGCTGTG 3’ 
5’TTTTACTAGTCACATACGCGTT
TCCTAGG 3’ 
AAV-pSMD2-
U7Dtex23 [266] 
MHCK synthetic 
enhancer 
Fusion of α-MHC and 
MCK enhancers 
Fext 
5'TTTACTAGTCCCTTCAGATTA
AAAATAACTGA 3' 
Rext 
5'CCCTCTAGAGATCCACCAGGG
ACAGGGTTAT 3' Mouse genomic 
DNA from 
C2C12 cells Fint 
5'CCCTGCTGTCCCACTACGGG
TCTAGGCTGC 3' 
Rint 
5'CCCGTAGTGGGACAGCAGGGC
CCCAAGGTT 3' 
U7M23D snRNA 
(fusion PCR) 
Fext 
5'TTTTGCTAGCTAACAACATA
GGAGCTGTGATTGGC 3' 
Rext 
5'ACCUCGGCUUACCUGAAAAAT
TTTTGGAGCAGGTT 3' AAV-pSMD2-
U7Dtex23 [266] Fint 
5'ACCUCGGCUUACCUGAAAA
ATTTTTGGAGCAGGTT 3' 
Rint 
5'CGAGGTTTGGCCGCGGAAGTG
CG 3' 
MBIIDtex23  
(fusion PCR) 
Fext 
5’TTTTCTCGAGCTGCTTAGGT
AAGACATTCTTCC 3’ 
Rext 
5’TCTATTTAGGTAAGCCGAGGT
TTGGCCGAATTTTATGTCATCAC 
3’ 
 
 
pCMV-MBII-
52 [203] 
Fint 
5’CCTAAATAGAAGTTCATTTA
CACTAACCTGAGGCCCAACCA
GGA 3’ 
Rint 
5’TTTTTCTAGATGACCACTTACC
TGATTATCTGTGTTTCT 3’ 
U24 snoRNA 
(RPL7A gene) 
5’TTAGCTCTCGAGTTCTGCCC
AGCCGAAAGGAAAGAAG 3’ 
5’TGAACTTCTAGAAGAACCTCA
CCTGTTTGGCGGTCCA 3’ 
Human 
genomic DNA 
from 293T cells 
human β-globin 5’TTTTGCTAGCACATTTGCTTCTGACACAAC 3’ 
5’TTTTGCTAGCGTGATACTTGTG
GGCCA 3’ 
Human 
genomic DNA 
from 293T  
X12-Luciferase 5’TTTGCTAGCGAAGACGCCAAAAACATAA 3’ 
5’TTTTACTAGTTTACAATTTGGA
CTTTCCGCCC3’ 
pET16b-lucX12 
[399] 
Gift from 
M.Pule  
Table 2: list of primers used for the PCR reactions 
  
186 
 
II. Mutagenesis 
The various site-specific mutagenesis reactions, used to modify few nucleotides inside a 
particular sequence, were realized using the QuikChange II Site-Directed Mutagenesis 
Kit from Stratagene following the manufacturer’s instructions. 
The sets of primers used for each site-specific modification are listed in Table 3. 
 
MHCK synthetic enhancer: 
Deletion 63 bp in the MCK part of 
MHCK [21] 
Fwd: 
5'CCCCAACACCTGCTGCCTGCTAAAAATAACCCTGTCCCTGGTG
G 3' 
Rev: 
5'CCACCAGGGACAGGGTTATTTTTAGCAGGCAGCAGGTGTTGGG
G 3' 
U7Dtex23-Sm: 
Modification SmOPT site of the 
U7Dtex23 into canonical Sm site 
Fwd: 
5'GCTTACCTAAATAGAAGTTCATTTACACTAACAATTTGTCTAGC
AGGTTTTCTGACTTCG 3' 
Rev: 
5'CGAAGTCAGAAAACCTGCTAGACAAATTGTTAGTGTAAATGAA
CTTCTATTTAGGTAAGC 3' 
U7wt-SmOPT: 
Modification Dtex23 antisense of the 
U7Dtex23 into original U7snRNA 
antisense 
Fwd: 
5'CAGACGCACTTCCGCAAGTGTTACAGCTCTTTTAGAATTTTTGG
AGCAGGTTT 3' 
Rev: 
5'AAACCTGCTCCAAAAATTCTAAAAGAGCTGTAACACTTGCGGA
AGTGCGTCTG 3' 
U7wt-Sm: 
Modification SmOPT site of the 
U7wt-SmOPT into canonical Sm site 
Fwd: 
5'ACTTCCGCAAGTGTTACAGCTCTTTTAGAATTTGTCTAGCAGGT
TTTCTGACTT 3' 
Rev: 
5'AAGTCAGAAAACCTGCTAGACAAATTCTAAAAGAGCTGTAACA
CTTGCGGAAG 3' 
pCMV-βglobin-X12Luc: 
Deletion 2bp in β-globin exon3 
Fwd: 5' GCTCCTGGGCAACGCTGGTCTGTGTG3' 
Rev: 5' CACACAGACCAGCGTTGCCCAGGAGC3' 
pCMV-U24metβglob: 
Modification antisense 1 in pCMV-
U24snoRNA 
Fwd: 
5’TGCAGATGATGTAAAAATAGACCAATAGTCTGAGAGATGGTGA
TG 3’ 
Rev: 
5’CATCACCATCTCTCAGACTATTGGTCTATTTTTACATCATCTGC
A 3’ 
pCMV-U24metβglob: 
Modification antisense 2 in pCMV-
U24snoRNA 
Fwd: 
5’TGGTGATGACATTTTAAAGAGAGAGTCAGGCTGATGCACCAAC
AC 3’ 
Rev:  
5’GTGTTGGTGCATCAGCCTGACTCTCTCTTTAAAATGTCATCACC
A 3’ 
Table 3: list of primers used for the PCR-directed mutagenesis reactions 
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III. Molecular cloning and plasmid preparation 
The various PCR fragments produced were digested by New England Biolabs (NEB) 
restriction enzymes in order to create cohesive ends. The backbone vectors were 
digested with matching restriction enzymes. The ligation reactions were done using the 
Quick ligation kit from NEB following the manufacturer’s instructions and were 
transformed in NEB 5α competent cells. The bacteria were plated on agar plates 
containing ampicillin and incubated at 37°C overnight. The colonies obtained were 
cultured in LB medium supplemented with ampicillin and incubated in a shaker at 37°C 
for 8h. The plasmid DNA obtained was purified using the Qiagen Miniprep kit. The 
constructs were verified by specific enzyme digestion and sequencing and, when correct, 
were amplified and purified using the Qiagen MegaPrep and PureLink HiPure Plasmid 
DNA GigaPrep (Invitrogen) kits. 
The different vectors constructed are listed thereafter. 
 
- AAV-sc-U7Dtex23 
The self-complementary AAV-U7Dtex23 vector was constructed by subcloning the 
U7Dtex23 PCR product amplified from the AAV-U7DTex23 vector (previously 
described as AAV-U7-SD23/BP22 [266]) into the self-complementary AAV backbone 
scAAV-LP1-hFIX [378], from which the LP1-hFIX sequence was removed (Figure 
77). The polyA fragment was conserved in the plasmid to facilitate the quantification by 
RQ-PCR of the copy number of viral genome present in the self-complementary AAV 
vectors produced. 
The self-complementary AAV backbone contains a mutation in one of the AAV 
inverted terminal repeats (ITRs): one of the ITRs is deleted of the D-sequence (the 
packaging signal) and the adjacent terminal resolution site (trs), allowing the AAV vector 
to package an inverted repeat genome that can fold directly into double stranded DNA.  
 
Figure 56: plasmid AAV-sc-U7Dtex23 
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- AAV-sc-U7M23D 
The plasmid AAV-sc-U7M23D  was constructed by subcloning the U7M23D cassette 
into the self-complementary AAV backbone scAAV-LP1-hFIX [378] (Figure 78). The 
U7M23D was produced by fusion PCR to replace the Dtex23 double target antisense 
sequence in  the U7Dtex23 snRNA by the M23D(+07-18) antisense targeting the donor 
splice site of dystrophin exon 23 [379].  
 
Figure 57: plasmid AAV-sc-U7M23D 
 
- AAVsc-U7DTex23-Sm, AAVsc-U7wt-SmOPT and AAVsc-U7wt-Sm 
The SmOPT site of the U7DTex23 sequence (AAUUUUUGGAG) was changed into 
the native U7 Sm sequence (AAUUUGUCUAG) in the AAV-sc-U7DTex23 vector by 
site-specific mutagenesis to obtain the AAV-sc-U7Dtex23-Sm vector. 
The AAV-sc-U7wt-SmOPT was obtained by modifying the Dtex23 antisense sequence 
of the AAV-sc-U7Dtex23 plasmid into the original U7snRNA antisense sequence 
(AAGTGTTACAGCTCTTTTAG). 
Finally the AAV-sc-U7wt-Sm vector was obtained by changing the SmOPT sequence of 
the AAV-sc-U7wt-SmOPT into the canonical Sm sequence by site-specific mutagenesis 
(Figure 79). 
 
Figure 58: representation of AAV-sc-U7DTex23-Sm, AAV-sc-U7wt-SmOPT 
and AAV-sc-U7wt-Sm constructs 
 
189 
 
- AAV-MHCK-U7Dtex23 and AAV-sc-MHCK-U7Dtex23 
The AAV-MHCK-U7Dtex23 vector was obtained by introducing the MHCK PCR 
product upstream of the U7snRNA cassette in the AAV-U7DTex23 vector [266]. The 
MHCK enhancer was obtained by fusing the 188 base pairs (bp) long murine α- MHC 
enhancer, and the 207 bp murine MCK enhancer. To faithfully reproduce the MHCK 
cassette as was described by Salva et al. [383], a 63 base pairs deletion in the MCK part 
of the synthetic enhancer was realized by mutagenesis (Figure 80). 
 
 
Figure 59: AAV-MHCK-U7Dtex23 and AAV-sc-MHCK-U7Dtex23 
 
When verified by sequencing, the final AAV-MHCK-U7DTex23 construct showed a 
deletion of three cytosines between the left and right E-boxes of the MCK enhancer 
compared to the published NCBI sequence (GenBank: AF188002.1). However, this 
deletion was also observed in C2C12 genomic DNA and was considered a 
polymorphism. 
The vector AAV-sc-MHCK-U7 was constructed by subcloning the MHCK-U7Dtex23 
fragment from the aforementioned vector into the self-complementary AAV vector 
scAAV-LP1-hFIX. 
 
- AAV-sc-PGK-GFP and AAV-sc-MHCK-PGK-GFP vectors. 
The AAV-sc-PGK-GFP plasmid was constructed by subcloning the PGK-GFP 
digested fragment from the pRRLSIN-cPPT-PGK-GFP-WPRE lentiviral vector [439] 
into the scAAV backbone vector. The MHCK enhancer isolated by restriction digest 
from the AAV-MHCK-U7Dtex23 plasmid was then inserted upstream of the PGK 
promoter to obtain the AAV-sc-MHCK-PGK-GFP vector (Figure 81). 
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 Figure 60: plasmids AAV-sc-PGK-GFP and AAV-sc-MHCK-PGK-GFP 
 
- AAVsc-CMV-MBIIDtex23 and pRRL-CMV-MBIIDtex23-PGK-GFP 
The MBII52-Dtex23 cassette was produced by fusion PCR to replace the natural 
antisense sequence present in the snoRNA MBII-52 by the Dtex23 antisense for 
dystrophin exon 23 skipping, using the plasmid pCMV-MBII-52 as a template [203]. 
The plasmid pCMV-MBII52-Dtex23 was then constructed by subcloning the MBII52-
Dtex23 PCR product into the pcDNA3.1(+) (Invitrogen) backbone under the control 
of the CMV promoter. Finally, the AAV-sc-CMV-MBII52-Dtex23 vector was obtained 
by subcloning the CMV-MBII52-Dtex23 digested fragment into the self-complementary 
AAV backbone [378] (Figure 82). 
 
Figure 61: plasmid AAV-sc-CMV- MBII52-Dtex23  
 
The lentiviral vector pRRL-CMV-MBII52-Dtex23-PGK-GFP was obtained by inserting 
the CMV-MBIIDtex23-polyA restriction fragment from the pCMV-MBII52-Dtex23 
vector into the pRRLSIN-cPPT-PGK-GFP-WPRE vector [439] (Figure 83). 
 
Figure 62: plasmid pRRL-CMV-MBIIDtex23-PGK-GFP 
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- pCMV-βglobin-Luciferase 
The plasmid pCMV-βglobin was constructed by subcloning the β-globin PCR fragment 
into the pcDNA3.1 (+) vector (Invitrogen) under the control of the CMV promoter. 
The pCMV-βglobin-Luciferase was obtained by inserting the X12-Luciferase PCR 
fragment downstream of the βglobin gene in the pCMV-βglobin plasmid. The X12-
Luciferase is a highly thermostable and pH-tolerant mutant of the wild-type firefly 
luciferase [399]. The X12-luciferase product, without its ATG initiation codon, was 
inserted in the same open reading frame as the βglobin. 
The pCMV-βglobin-Luciferase construct was further modified by deleting 2 base pairs 
in exon 3 of the βglobin sequence to generate an out of frame construct. The 2 base pair 
deletion (GT) was realised by site-specific mutagenesis (Figure 84). 
 
Figure 63: pCMV-βglobin-Luciferase plasmid 
 
- pCMV-U24metβglob 
The plasmid pCMV-U24 was constructed by subcloning the U24 snoRNA PCR 
fragment, surrounded by the host exons 2 and 3 of the RPL7A gene, into the 
pcDNA3.1(+) backbone under the control of the CMV promoter. The pCMV-
U24metβglob was obtained by replacing the U24 snoRNA natural antisense sequences 
with sequences complementary to the branch point of βglobin intron 1 in the pCMV-
U24 vector (Figure 85). Two successive site-specific mutagenesis reactions were 
necessary to modify both antisense sequences. 
 
Figure 64: pCMV-U24metβglob plasmid 
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IV. AAV virus preparations 
To produce recombinant AAV (rAAV) vectors, cells are transiently co-transfected with 
three plasmids: the plasmid containing the trangene flanked by the ITRs of AAV2, a 
plasmid helper that provides the excised AAV-specific genes rep and cap in trans, and a 
plasmid containing the adenovirus helper functions necessary for virion formation 
(Figure 86). 
 
Figure 65: production of recombinant AAV vectors 
 
AAV vectors were produced by calcium phosphate triple transfection of HEK293T 
cells. For each AAV production, 40 plates of 70-90% confluent 293T cells were 
transfected with 400 µg of transgene plasmid, 400 µg of capsid plasmid AAV2/8 
(LTAAVhelp2-8 [440]) or AAV2/5 (Napoli 2/5 [441]), and 1200 µg of the plasmid for 
adenovirus helper function (pHGTI-Adeno1 [442]). The plasmids were added to 5 mL 
of 2.5M CaCl2 in a total volume of 50mL. Then, 50 mL of 2x HEPES buffered solution 
(HBS: 273.9mM NaCl, 9.9mM  KCl, 1.5mM NaH2PO4H2O, 11.1mM Dextrose, 
41.9mM HEPES –  pH 7.05) were added drop by drop in the plasmid mix whilst 
vortexing, and 100 mL of D10 medium was finally added to stop the reaction. The total 
volume was divided between 40 plates, which were then incubated for 72 hours at 37°C.  
Cells were harvested by scraping and centrifugating the media and cells at 1800rpm for 
10 minutes at 4°C. The supernatant was removed and the pellets resuspended in 40 ml 
of TD buffer (140.4mM NaCl, 4.9mM KCl, 0.7mM K2HPO4, 3.4mM MgCl2, 24.7mM 
Tris - pH 7.5).  A second centrifugation, aspiration of the supernatant, and resuspension 
in 40ml of TD buffer was performed.  The harvested cells underwent five freeze/thaw 
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cycles to lyse the cells, where each cycle consists of 30 minutes at -70°C followed by 30 
minutes at 37°C.  After the last thaw 2000U of benzonase were added, the suspension 
was incubated for 30 minutes at 37°C and centrifuged for 20 minutes at 3,000g. The 
resulting supernatant was filtered using a 0.45 µm cellulose acetate filter and the 
AAV2/5 or AAV2/8 virus preparations were purified on an AVB-sepharose column.  
 
V. rAAV virus purification with AVB Sepharose Column 
The prepared virus sample was purified by affinity chromatography using the 
ÄKTAexplorer™ chromatography system (GE Healthcare) and a prepacked AVB 
sepharose affinity column (HiTrap™ AVB Sepharose High Performance, GE 
Healthcare – 5ml). After equilibration of the column with 1 column volume (CV - 1 CV 
= 5.228ml) with filtered PBS at pH 7, the virus sample is loaded into the system at a rate 
of 2ml/min. The unbound sample is then washed with 4 CV of filtered PBS. The 
sample is eluted with 7 CV of 50mM Glycine at pH2.7 and collected into fractionating 
tubes containing 30μl each of Tris 0.5M pH 8.8 to neutralise the glycine elution buffer. 
The chromatogram shows the graphs of the absorbance at 260nm and at 280nm, and a 
peak on these graphs represents the fraction containing the eluted viral sample. The 
corresponding fractions are pooled and injected into a dialysis cassette (Slide-A-Lyser 
Dialysis cassette 10000MWCO – Thermo scientific) and the sample is allowed to dialyse 
in 2L of filtered PBS at 4°C, stirring for 12-16 hours. Finally the dialysed virus 
preparation is sterilised by filtration through a 0.2μm cellulose acetate filter.  
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VI. Lentiviral vectors preparation 
The production of SIN lentiviral vectors involves transient transfection of a cell line 
with four different plasmids: a plasmid containing the gag and pol genes, one with the 
envelope gene - most commonly the VSV-G gene, a third one containing the rev gene, 
and last the SIN vector containing the transgene of interest (Figure 87).  
 
Figure 66: lentiviral vectors production 
 
Lentiviral virions were produced by calcium phosphate transfection of HEK293T cells. 
The day before transfection, 6.106 293T cells were seeded per 150 mm culture dishes. 
The following day, 7.9 μg of the envelope plasmid pMD.G (VSV-G, [443]), 1 μg each of 
the packaging plasmids pHDM15 gpm2 (codon-optimized HIV-1 Gag-Pol) and 
pRC/CMV-REV1B (REV) (both gifts from Dr Jeng-Shin Lee, Harvard Medical 
School), and 22.5 μg of the plasmid pRRLSIN-transgene were cotransfected by the 
calcium phosphate method.. Viral supernatants were harvested 20 hours, 28 hours, 36 
hours and 44 hours post-transfection, pooled and centrifuged 5 minutes at 1500 rpm, 
filtered through a 0.45 μm filter, and ultracentrifuged 2 hours at 19500 rpm at 12°C. 
Pellets were resuspended in PBS 1%BSA and stored at −80 °C. 
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VII. Cell culture and transduction 
All cells were cultivated at 37°C and 5% CO2. HEK 293T cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% 
fetal calf serum (Invitrogen). C2C12 mouse myoblast cells were grown in proliferation 
medium containing DMEM supplemented with 20% fetal calf serum. Differentiation of 
C2C12 was induced in DMEM supplemented with 2% Horse serum (Sigma).  
For AAV vector transduction, 100 000 C2C12 cells were seeded in each well of a 12- 
wells plate. The following day proliferation medium was changed into differentiation 
medium and the cells were left to differentiate into myotubes for a week. The cells were 
then transduced with the AAV preparation at the chosen multiplicity of infection (MOI) 
in a total volume of 300 μl of medium without serum. Each condition is realized in 
triplicate. After 6 hours of incubation, 1 ml of differentiation medium was added per 
well. Cells were incubated for seven additional days in differentiation medium before 
harvesting for analysis. 
For lentiviral vector transduction, 30000 C2C12 cells were seeded in each well of a 12-
wells plate. 24 hours later, the lentiviral vector preparation was administered to the cells 
in a total volume of 250 μL of proliferation medium at the chosen multiplicity of 
infection (MOI). After 6 hours incubation, 1 ml of D20 medium was added per well. 72 
hours post-transduction, the medium was replaced with differentiation medium and 
cells were incubated for 72 additional hours. Cells were then harvested for analysis. 
VIII. Cell transfections 
293T cells at an average of 80% of confluence are transfected with X µg of transgene 
plasmid (scAAV-U7Dtex23, scAAV-U7Dtex23-Sm, scAAV-U7wt-Sm, scAAV-U7wt-
SmOPT or scAAV-MBII52 Dtex23) in 100mm plates using Lipofectamine 2000 from 
Invitrogen following the manufacturer’s protocol. The transfected cells are incubated 
for 48h at 37°C before RNA extraction and Northern blot analysis. The reporter 
plasmid pcDNA-βglobin-X12Luc and the pCMV-U24metβglob constructs were co-
transfected into 80% confluent 293T cells in a 6-well plate using Lipofectamine 2000, in 
order to obtain a 1:5 molar ratio. Each transfection condition was realized in triplicate. 
The cells were left to incubate at 37ºC for 48h before harvesting. 
196 
 
IX. Western blot 
IX. 1. GFP detection 
C2C12 protein extracts were obtained by incubation 30 minutes at 4°C of cells in lysis 
buffer (1× complete protease inhibitor cocktail (Roche, Diagnostics), 0.5% NP-40, 20 
mM Tris pH 7.5, 10% glycerol, 100 mM (NH4)2SO4). Equal amounts of protein 
(determined by the Bradford kit (Bio-Rad)) were mixed with 3X loading buffer (30% 
glycerol, 150 mM Tris pH 6.8 , 6% SDS, 0.03% bromophenol blue, 15% β-
mercaptoethanol) denaturated 5 minutes at 95°C, separated on a 12% polyacrylamide 
gel 1 hour at 110 V and transferred to a PVDF membrane (Amersham) 90 minutes at 
100 V. The membrane was blocked with PBS 5% milk 0,1% Tween 20 and probed with 
the rabbit polyclonal anti-GFP antibody (sc-8334; Santa Cruz Biotechnology) used at a 
1:500 dilution and the mouse anti-actin (A-5441; Sigma)  used at a 1:15000 dilution, and 
then with secondary goat anti-mouse antibody and goat anti-rabbit antibody, both 
conjugated with peroxidase (Sigma) used at a 1:2000 dilution. Signals were detected with 
the ECL kit (Amersham). 
IX. 2. Dystrophin detection 
Total protein was extracted from muscle samples with Newcastle buffer (3.8% SDS, 75 
mM Tris-HCl pH 6.7, 4 M urea, 10% β-mercaptoethanol, 10% glycerol, 0.001% 
bromophenol blue) and quantified using the bicinchoninic acid (BCA) protein assay kit, 
according to the manufacturer’s instructions (Perbio Science, UK). Samples were 
denatured at 95°C for 5 minutes before 100 µg of protein was loaded in a 5% 
polyacrylamide gel with a 4% stacking gel. Gels were electrophoresed for 4-5 hours at 
100 V and blotted to a PVDF membrane overnight at 50 V. Blots were blocked for 1 
hour with 10% non-fat milk in PBS–Tween (PBST) buffer. Dystrophin and α-Actinin 
proteins were detected by probing the membrane with 1:100 dilution of NCL-DYS1 
primary antibody (monoclonal antibody to dystrophin R8 repeat; NovoCastra) and 
1:200 dilution of α-actinin primary antibody (Santa Cruz Biotechnology) respectively. 
Incubation with mouse horseradish peroxidase-conjugated secondary antibody (1:2000) 
or goat horseradish peroxidase-conjugated secondary antibody (1:160,000) allowed 
visualisation using ECL Analysis System (GE Healthcare). Membranes were converted 
to numerical pictures and band intensities were analysed using ImageJ 1.33a software. 
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X. RNA isolation and Nested RT-PCR analysis 
Total RNAs from C2C12 cells were extracted using the miRvana miRNA Isolation Kit 
from Ambion according to the manufacturer's instructions. RNAs from mice muscles 
were isolated using TriZol Reagent according to the manufacturer's instructions 
(Invitrogen).  
The reverse transcription-polymerase chain reaction (RT-PCR) reaction was carried out 
on 300 ng of total RNA as the starting material using the Access RT-PCR System 
(Promega), which enables to realise the reverse transcription and the PCR in one single 
step. The cDNA synthesis was carried out at 45°C for 45 min, directly followed by the 
primary PCR of 30 cycles of 94°C (30 s), 55°C (1min) and 72°C (2 min). The forward 
and reverse primers used, amplifying from exons 20 and 26 respectively, were as follow: 
Ex20Fext: 5’-CAGAATTCTGCCAATTGCTGAG-3’; 
Ex26Rext: 5’-TTCTTCAGCTTGTGTCATCC-3’.  
Two microlitres of the RT-PCR product was used as template in a 50 µl secondary 
nested PCR that was carried out for 22 cycles under cycling conditions identical to the 
primary amplification and using the PCR master mix kit (Promega). The internal 
primers used were: 
Ex20Fint: 5’-CCCAGTCTACCACCCTATCAGAGC-3’; 
Ex26Rint: 5’-CCTGCCTTTAAGGCTTCCTT-3’. 
The products were analysed on 2% agarose gel. 
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XI. Real-time quantitative (RQ) PCR 
XI. 1. Titration of AAV vectors by RQ-PCR 
The titers of the AAV virus preparations were assessed by real-time PCR quantifying of 
vector genome copies using the SYBR Green master mix (Applied Biosystems). A mix 
for one reaction contained 1 µL each of 2.5 µM Forward  and  2.5 µM Reverse primers, 
12.5 µL SYBR Green master mix and 0.5 µL H2O. Each AAV sample was diluted 1 in 
100, 1 in 1000, or 1 in 10000, and 10 µL of either dilution was added in each well. Each 
condition was realised in triplicate and the qPCR reaction was realised under the cycle 
conditions: a) 95°C for 2 minutes, b) 95°C for 15 seconds, c) 60°C for 15 seconds, 
repeating from step b) for 40 cycles. The primers used for each AAV vector titration are 
listed in Table 4. 
 
AAV VECTORS PRIMERS FORWARD PRIMERS REVERSE 
All AAV vectors 
containing the Dtex23 
sequence 
F-Dtex23 
5'GGCCAAACCTCGGCTTA 3' 
R-Dtex23 
5'GTTAGTGTAAATGAACTTC 3' 
scAAV-U7M23D 
scAAV-U7wt-SmOPT 
scAAV-U7wt-Sm 
F-polyA 
5'ATTTTATGTTTCAGGTTCAGGGGGA
GGTG 3' 
R-polyA 
5'GCGCAGAGAGGGAGTGGACT
AGT 3' 
scAAV-PGK-GFP 
scAAV-MHCK-PGK-GFP 
F-GFP 
5'GACGGCAACATCCTGGGGCACAAG 
3' 
R-GFP 
5'CGGCGGCGGTCACGAACTC 3' 
Table 4: list of primers used for AAV vectors qPCR titrations 
 
XI. 2. Titration of lentiviral vectors by RQ-PCR 
After transduction of 293T cells with different dilutions of the lentiviral preparation, 
total DNA was extracted from the cells with the Qiagen DNeasy Blood and Tissue Kit. 
The infectious titers were determined by quantitative PCR using the SYBR Green PCR 
Master Mix (Applied Biosystems). A mix for one reaction contained 0.5 µL each of 10 
µM Forward and 10 µM Reverse primers, 12.5 µL SYBR Green master mix, 1 µL H2O 
and 10 µL of each DNA sample at 10 ng/µl. Each condition was realised in triplicate 
and the qPCR reaction was realised under the cycle conditions: a) 95°C for 2 minutes, b) 
95°C for 15 seconds, c) 60°C for 1minute, repeating from step b) for 40 cycles. Primers 
specific for the lentiviral genome (HIV-LTR) allowed the quantification of viral genome 
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copies integrated in the DNA, and primers for the albumin endogenous gene were used 
in parallel for normalization. The primers used for lentiviral vector titrations are listed in 
Table 5. 
 PRIMERS FORWARD PRIMERS REVERSE 
HIV-LTR 
primers 5'AGCTTGCCTTGAGTGCTTCAA 3' 
5'AGGGTCTGAGGGATCTCTAGTTA
CC 3' 
Albumin 
primers 5'GCTGTCATCTCTTGTGGGCTGT 3' 5'ACTCATGGGAGCTGCTGGTTC 3' 
Table 5: primers used for lentiviral vectors titrations 
 
XI. 3. Taqman assay for Dystrophin levels quantification 
The Taqman RQ-PCR assay relies on the 5´–3´ exonuclease activity of Taq polymerase 
to cleave a dual-labeled probe designed to hybridize within the complementary target 
sequence [444-445]. After the reverse transcription step successful quantification 
requires the annealing of three oligonucleotides to the DNA. The probe is covalently 
linked to a fluorophore at the 5' end and to a quencher at the 3’-end, which inhibits the 
fluorescence emitted by the fluorophore via Fluorescence Resonance Energy Transfer 
(FRET) as long as the molecules are in close proximity [446]. During the amplification 
of the target sequence through the use of a specific set of primers surrounding the 
Taqman probe, the 5'-nuclease activity of the Taq polymerase displaces and hydrolyses 
the labelled probe, which releases the fluorescent dye from its proximity to the quencher 
and allows the emission of a fluorescent signal that is directly proportional to the 
amount of product formed at each PCR cycle [445] (Figure 88). The Ct (cycle 
threshold) value is defined as the number of PCR cycles required for the fluorescent 
signal to cross the threshold level and is therefore a relative measure of the 
concentration of target DNA in the PCR reaction. In relative quantification we can then 
compare the proportion of two target DNAs by subtracting the Ct value of one target 
gene to another, which is called the delta Ct value (ΔCT). As the PCR reactions are 
exponential functions, the fold difference in the amounts of two target DNAs is 
therefore calculated by the formula 2ΔCT. 
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 Figure 67: Taqman assay 
a) Probe and primers annealing on denaturated DNA. The fluorophore on 5’ of 
the probe is inhibited by the proximity of the quencher on 3’. 
b) Polymerisation starts and the Taq polymerase displaces the probe. 
c) The polymerase hydrolyses the probe, the fluorescent dye is released from its 
proximity to the quencher and fluorescence is emitted.  
d) The fluorescent signal is proportional to the number of molecules at the end 
of the cycle 
 
Total RNAs from C2C12 cells were extracted using the miRvana miRNA Isolation Kit 
from Ambion according to the manufacturer's instructions. For each sample 1 µg of 
total RNA was used for reverse transcription using the SuperScript II RT system by 
Invitrogen. Reverse transcription was carried out according to the manufacturer’s 
instructions, using random hexamers as the priming nucleotides. For qPCR analysis, 
comparative CT quantitative analysis of dystrophin exon 22-23 junction (Taqman Assay 
Mm01216934_m1, Applied Biosystems) and 18S rRNA (Eukaryotic 18s rRNA Control, 
Applied Biosystems) was performed on each RNA sample. A mix for one reaction 
contained 1 µL of 20X TaqMan Gene Expression Assay containing the primers and the 
Taqman probe, 10 µL of 2X TaqMan Gene Expression Master Mix, 10 ng of the cDNA 
sample and water up to 20 µL. Reactions were performed in triplicate using the cycle 
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conditions: 95°C for 10 minutes, and 40 cycles at 95°C for 15 seconds and 60°C for 1 
minute. 
Data Analysis: For each sample the CTs for the 22-23 assay (dystrophin) are normalised 
18S Ct to generate a delta-CT value.  This involves the subtraction of the 18S Ct from 
the experimental Ct.  The delta Ct can be used to calculate the relative amounts of 
dystrophin expressed relative to 18S.  All results are expressed as mean values ± SEM. 
 
XI. 4. Taqman assay for Dystrophin exon skipping 
Total RNAs from transduced C2C12 cells were extracted using the miRvana miRNA 
Isolation Kit from Ambion according to the manufacturer's instructions. For each 
sample 1 µg of total RNA was used for reverse transcription using the SuperScript II 
RT system according to the manufacturer’s instructions and using random hexamers as 
the priming nucleotides. For qPCR analysis, 10 ng of the resulting cDNA was used per 
well.  Comparative CT quantitative analysis of the exon 22-23 junction (Taqman Assay 
Mm01216934_m1, Applied Biosystems) and the exon 22-24 junction (Fw: 5'-
CTGAATATGAAATAATGGAGGAGAGACTCG-3', Rev: 5'-
CTTCAGCCATCCATTTCTGTAAGGT-3', probe: FAM-
ATGTGATTCTGTAATTTCC-NFQ) was performed on each RNA sample. Reactions 
were performed in triplicate with the appropriate non-template controls (NTCs) using 
the cycle conditions: 95°C for 10 minutes,  and 40 cycles at 95°C for 15 seconds and 
60°C for 1 minute. 
Data Analysis: For each sample the CTs for the 22-24 assay (skipped dystrophin) are 
normalised to the CT for the 22-23 assay (non-skipped dystrophin) to generate a delta-
CT value.  This involves the subtraction of the 22-23 CT from the 22-24 Ct.  The delta 
CT can be used to calculate the relative abundance in skipped dystrophin RNA species 
relative to full length species. 
An unpaired Student’s t-test was used to assess statistical significance of differences 
between the samples treated with AAV-U7Dtex23 and the samples treated with AAV2-
MHCK7-U7Dtex23. A P-value below 0.05 was considered statistically significant. All 
results are expressed as mean values ± SEM. 
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XII. Northern blot assay 
Northern blots were realized on 7 µg of total RNA. Samples of total RNA were mixed 
with an equal volume of loading buffer (8M Urea, 2xTBE, Bromephenol Blue and 
Xylene Cyanol) and heated at 70°C for 15 minutes. RNAs were loaded on a 15% Novex 
TBE-Urea precast gel (Invitrogen) along with 1 µl of γ-32P-labeled RNA Decade 
Markers (Ambion). Gels were electrophoresed for 1 hour at 180 V in 2,5X TBE buffer, 
and transfered to a Hybond-N+ membrane (Amersham) for 1 hour at constant current 
(390 mA) in 2X TBE buffer. The membrane was then UV-crosslinked with 100 mJ of 
energy and prehybridized in 10 ml of Rapid Hyb buffer (Amersham) containing salmon 
sperm DNA (50 µg/ml) at 42°C. For radiolabeling of the complementary DNA probe, 
50 pmol of oligonucleotide was end-labeled using γ-32P-ATP (Amersham, 6000 
Ci/mmol) and T4 PolyNucleotide Kinase (BioLabs) for 1 hour at 37°C. The reaction is 
stopped by adding 1 µl of 0,2M EDTA. The probe was purified from unincorporated 
label using G-25 MicroSpin Columns (Amersham), and heated for 1 minute at 95°C 
before addition to the membrane in the hybridization solution and incubation overnight 
at 42°C. The following day 3 successive washes of the membrane are realized for 15 min 
at 42°C: a first wash with 50ml of wash solution A (2xSSC, 0,2% SDS), the second with 
50 ml of wash solution B (1xSSC, 0,2% SDS), and the third with 50 ml of Stringent 
Wash solution (0,1xSSC, 0.2%SDS). The blots are enveloped in Saran wrap, placed in a 
cassette with an autoradiogram. The films were exposed for 72 hours.  
The probes used for detection of the different transcripts are listed in Table 6. 
TRANSCRIPTS PROBES 
U7Dtex23 
MBII-52-Dtex23 
Dtex23: 
5’ 32P- GTTAGTGTAAATGAACTTC 3’ 
Mouse U2 snRNA 
U2snRNA: 
5’-32P-CTGATAAGAACAGATAC-3’ 
Mouse and human U7 snRNA U7wt: 5’-32P-CTAAAAGAGCTGTAACACTT-3’ 
Unprocessed U7 snRNA U7unprocess: 5’-32P-CATTGTAGACCAGTGAAATT-3’ 
U7M23D probeM23D: 5’-32P-TTTCAGGTAAGCCGAGGTT-3’ 
Unprocessed MHCK-U7 ProbeMHCK: 5’-32P-GATCCACCAGGGACAGGGTTA-3’ 
Human U24 snoRNA 
U24human: 
5’-32P-GCAAATATTCTTTTACATCATCTGCA-3’ 
Chimeric U24MetBP-βglob ProbeU24mod: 5’-32P-ATTGGTCTATTTTTACATCATCTGCA-3’ 
Table 6: list of probes used for Northern blot detection 
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XIII. Luciferase assay 
The Luciferase Assay System from Promega was used to assess the expression of 
luciferase obtained after transfection of the βglobin-Luciferase reporter construct in 
293T cells. The cells were harvested two days after transfection by adding 150 μL of 
room temperature CCLR in each well and incubating for 2min. The collected samples 
were centrifuged to pellet the debris and 20μL of supernatant was mixed with 20μL of 
room temperature Luciferase Assay Reagent containing the substrate luciferin. We 
immediately measure the light produced by the cell lysates with a luminometer at 
600nm. 
The bioluminescence data were normalised to the total amount of proteins expressed 
for each sample. The Pierce BCA Protein Assay Kit (Thermo Scientific) was used 
according to the manufacturer’s instructions for the colorimetric detection and 
quantitation of total protein per sample, using a standard curve reference of bovine 
serum albumin (BSA) protein.  
 
XIV. MDX mice injection 
All animal experiments were performed according to the guidelines and protocols 
approved by the Home Office. Five month-old mdx mice were anesthetized under 
isoflurane and injected in the tibialis anterior with 5.109, 2.1010 or 1011 viral genome 
copies (vg) of AAV2/8-U7DTex23 or AAV2/8-MHCK-U7DTex23 (n=3 for each 
condition). For each mouse, contra-lateral muscle was injected with PBS as a negative 
control of injection. Mice were sacrificed 4 weeks after injection and tibialis anterior 
muscles were isolated and snap frozen in liquid nitrogen-cooled isopentane. 
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INTRODUCTION
A variety of mRNAs with different exon composition, stability 
or subcellular localization, as well as small RNAs with regu-
latory roles can be produced from a single transcription unit, 
thus increasing the complexity of genome information.1 A 
large proportion of disease-associated mutations in humans 
affect the processing of pre-mRNAs2 often by disturbing the 
delicate balance of alternative splicing, which is observed in 
over 90% of transcription units.3 The modulation of pre-mRNA 
splicing has been proposed as an approach to compensate 
the deleterious effect of mutations.4 It can be achieved with a 
high-specificity, using antisense oligoribonucleotides (AON) 
that mask key splicing signals through Watson-Crick pairing 
with the pre-mRNA. The successful AON-mediated restora-
tion of correct splicing has been reported in a number of cel-
lular and animal models of genetic diseases.5 In particular 
cases, AONs can be exploited to induce exon skipping in such 
a way that it removes deleterious mutations or re-establish 
a reading frame disrupted by a deletion. This approach is 
actively pursued in clinical trials involving patients with Duch-
enne muscular dystrophy (DMD).6–9
A limitation of AON-based therapies for treating chronic 
genetic diseases such as DMD is the need for repeated 
administration of high doses of oligonucleotides (up to sev-
eral mg/kg). A sustained intracellular production of antisense 
sequences can be obtained using modified small nuclear (sn) 
RNAs such as U1, U2, or U7 delivered by viral vectors.10–12 
We and others have demonstrated the efficacy of chimeric 
snRNAs for sustained therapeutic exon skipping in animal 
models of DMD, following local or systemic gene delivery with 
AAV vectors targeting skeletal muscles, heart, and brain.13–16 
Yet, clinical applications to DMD patients by systemic adminis-
tration of AAV vectors carrying a modified snRNA will require 
very high doses that are potentially toxic and represent a 
challenge for the current capacity of vector manufacturing. 
Reducing the injected dose is paramount to the success of 
current translational studies that aim at implementing vector 
mediated exon skipping into the clinic. It may be achieved in 
part by using the appropriate AAV serotype for muscle and 
heart delivery,14 but also by optimizing the amount of chimeric 
snRNAs transcribed and assembled into active snRNPs.
The Sm-class snRNA genes are transcribed by RNA poly-
merase II in association with a specialized complex called Inte-
grator. The polymerase initiate transcription on short bipartite 
promoters composed of proximal and distal sequence ele-
ments (PSE and DSE, respectively), while the Integrator com-
plex recognizes signals in the internal stem-loop structures of 
the coding sequence, as well as in a conserved 3′ box and 
mediates co-transcriptional 3′ processing.17 The snRNAs are 
then exported to the cytoplasm where they undergo further 
modifications and assemble with Sm proteins before re-entry 
into the nucleus. Proper assembly requires a consensus Sm 
binding site.18 U7 is a non-spliceosomal snRNA that functions 
as a processing factor of the non-polyadenylated replication 
dependent histone mRNA. It is the shortest and simplest of 
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snRNAs and it includes a 5′ antisense sequence recogniz-
ing the histone pre-mRNA, a non-consensus Sm-binding site 
and a stem-loop structure containing determinants for the 
co-transcriptional 3′ endonucleolytic cleavage. The low abun-
dance of the U7 small nuclear ribonucleoproteins (snRNP) 
is reversed when a consensus spliceosomal Sm sequence 
is introduced (SmOPT) and substitutions of the original 5′ 
sequences result in abundant and stable shuttles for ectopic 
antisense delivery.10,19
Here, we have added a strong muscle- and heart-specific 
transcriptional enhancer upstream of the DSE in chime-
ric U7 genes carrying antisense sequences for exon skip-
ping on the human or murine DMD pre-mRNAs. We have 
observed that although the amount of transcripts produced 
by the U7 promoter is readily enhanced, many of them are 
not processed and may not be assembled in snRNPs with 
exon-skipping activity on the DMD gene pre-mRNA. In addi-
tion, the SmOPT sequence required for stabilizing the U7 
transcript induces the generation of 3′-processed species 
missing 20 nucleotides (nt), whose stability or activity may 
be affected. We conclude that the potential for enhancing 
exon-skipping activity of chimeric U7 cassettes is limited by 
the snRNA processing capacity of the host cell.
RESULTS
Design and validation of an enhanced U7 cassette
Brun et al. have shown that transcription from the U7 pro-
moter can be increased by placing an enhancer upstream of 
the Distal Sequence Element.20 Based on this observation, 
we have constructed a U7 cassette in which a strong mus-
cle-specific transcriptional enhancer was inserted (Figure 
1a). Salva et al. have designed such an enhancer by fusing 
elements from the α-myosin heavy chain (α-MHC) and the 
muscle creatin kinase (MCK) enhancers, and shown that, in 
combination with the CK promoter it results in a very strong 
and mostly tissue-specific enhancement of gene expression 
when used in AAV vectors.21 We have assembled a similar 
enhancer [muscle- and heart-specific enhancer (MHCK), see 
Materials and Methods] and its activity was first validated in 
murine C2C12 myoblasts using an AAV vector carrying green 
fluorescent protein (GFP) under the control of the human 
PGK promoter (Supplementary Figure S1). The MHCK 
enhancer was then introduced upstream of a U7snRNA cas-
sette containing an antisense sequence able to induce skip-
ping of exon 51 on the human DMD pre-mRNA by masking 
an exonic splicing enhancer (U7ex51)22 (Figure 1a). Lenti-
viral vectors carrying U7ex51 with or without the enhancer 
were constructed and human CHQ myoblasts were trans-
duced with increasing multiplicities of infection (MOI, see 
Materials and Methods). Three days post-transduction, cells 
were differentiated into myotubes for 3 days and exon-skip-
ping efficiency was analyzed by reverse transcription (RT)-
PCR. The efficiency of skipping was evaluated by estimating 
the relative intensities of the skipped versus nonskipped 
diagnostic bands appearing after electrophoresis of RT-PCR 
products on agarose gels (Figure 1b). The results indicate a 
dose-dependent exon skipping for both vectors, with a higher 
activity for the one containing the MHCK enhancer, detect-
able at lower doses.
In order to test the efficiency of the MHCK enhancer in 
the skeletal muscle of mdx mice, we introduced it into an 
AAV vector containing the U7DTex23 cassette that carries 
antisense sequences able to induce skipping of exon 23 in 
the murine Dmd pre-mRNA13 (Figure 2a). AAV 2/5 vectors 
were produced with or without enhancer and used to trans-
duce murine C2C12 myoblasts (see Materials and Methods). 
The U7DTex23 transcripts were analyzed by northern blot 
on total RNA isolated from transduced cells and normalized 
to the quantity of U2 snRNA (Figure 2b). Unexpectedly, two 
small RNA species reacted with a probe in the Dmd anti-
sense region (Figure 2a and Materials and Methods). The 
predicted 86 nt U7DTex23 transcript was present along with 
equivalent quantities of a shorter species of ~66 nt. Alto-
gether, the amounts of chimeric U7 RNA were enhanced in 
the presence of the MHCK sequences. This effect was clearly 
visible at the lower vector dose, presumably because non-
saturating levels of transcripts are made under these con-
ditions. Of note, high-molecular weight RNA recognized by 
Figure 1 Muscle- and heart-specific enhancer (MHCK) en-
hances U7ex51-mediated exon skipping on the Duchenne 
muscular dystrophy (DMD) pre-mRNA in cultured human 
myotubes. (a) U7ex51 expression is driven by the U7 pro-
moter containing distal and proximal sequence elements (DSE 
and PSE, respectively, shaded boxes). The MHCK enhancer21 
has been placed upstream. The rightward arrowhead indicates 
the site of transcription initiation and the downward arrowhead 
is the site of 3′ processing, activated by recognition of the 3′box 
(shaded). The sequence of the U7ex51 transcript is shown, in-
cluding an antisense sequence (underlined) that corresponds to 
an exonic splicing enhancer (ESE) in exon 51 of the human DMD 
pre-mRNA (h51AON1: 5′-UCAAGGAAGAUGGCAUUUCU-3′).22 
The optimized Sm binding sequence (SmOPT) is shown in bold. 
(b) Reverse transcription and nested PCR detection of DMD exon 
51 skipping after transduction of human CHQ cells with lentivi-
ral vectors containing the U7ex51 (upper panel) or the MHCK-
U7ex51 (lower panel) cassettes, at increasing multiplicities of 
infection (MOI) Controls include nontransduced cells (0) and no 
reverse transcriptase (RT–). The native human DMD mRNA con-
taining exon 51 is detected as a 886-bp fragment and the skipped 
mRNA yields a 653-bp product.
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the probe accumulated at the high dose and in the presence 
of the enhancer. Further analysis indicated that it contained 
sequences 3′ of the U7-coding sequence and therefore rep-
resented unprocessed primary U7 RNA, possibly transcribed 
from tandem or circle copies of the AAV vector genome23 
(Supplementary Figure S2). It suggests that the integrator-
mediated formation of the U7 snRNA 3′end may be limiting 
when the transcript is too abundant.
RNAs from transduced myoblasts were also analyzed by 
RT-PCR and quantitative RT-PCR (Figure 3). Consistently, 
the results indicate that the MHCK sequences increase exon 
23 skipping, particularly at the lower dose of AAV.
The SmOPT sequences induce an additional processing 
of the U7snRNA cassette
To investigate the origin of the short RNA species detected 
with the antisense probe, variants of the U7snRNA cassette 
were analyzed. Human 293T cells were transfected with 
plasmids expressing an unmodified U7 which retains its nat-
ural 5′ sequences targeting Histone H1 mRNA or U7SmOPT, 
the parent construct for all U7 antisense shuttles.19 An addi-
tional shorten transcript was generated only in the presence 
of the SmOPT mutations, suggesting that they were respon-
sible for the extra processing (Supplementary Figure S3). 
Since probes at the 5′ extremity of the U7snRNA were used, 
the experiment also indicated that the processing removes 
the 3′ extremity. U7DTex23 cassettes with or without the 
SmOPT mutations were compared in AAV2/5 transductions 
of C2C12 myoblasts (Figure 4). The inclusion of the SmOPT 
mutations resulted in higher levels of chimeric U719 and the 3′ 
deleted U7 transcripts were enhanced accordingly. The higher 
molecular weight species were also proportionally increased 
in the presence of the SmOPT mutations. The cassette con-
taining the original Sm sequences yielded lower levels of 
transcripts, which were not further processed in 3′, confirm-
ing that the SmOPT mutations determine this modification.
The amounts of the different U7-derived species (86 nt, 
66 nt, and over 200 nt) were evaluated by densitometry of 
the northern blot showed in Figure 4. The 86 nt species rep-
resented 30% and 40% of all transcripts in lanes 1 and 2, 
respectively. The difference was due to the lower amounts 
of high-molecular weight unprocessed species at the lower 
MOI. In contrast, when the original Sm sequence was pres-
ent, the 86-nt band accounted for >85% of total signal.
RT-PCR analysis of the Dmd pre-mRNA skipping was con-
sistent with the U7snRNA expression analysis. The SmOPT 
construct induced a strong exon 23 skipping whereas the 
Sm construct was almost inactive (Figure 4, lower panel).
Figure 2 Enhancement of U7DTex23 small nuclear RNAs 
(snRNAs) expression in murine C2C12 cells. (a) The sequence 
of the U7DTex23 transcript is shown, including two antisense se-
quences (underlined) that encompass the donor splice site of exon 
23 (SD23, shown in italics) and the branch point region of intron 
22 (BP22) on the murine Duchenne muscular dystrophy (Dmd) 
pre-mRNA.13 The optimized Sm-binding sequence (SmOPT) is 
shown in bold. The probe used for the northern blot analysis in 
(b) is underlined in bold. (b) Northern blot analysis of U7DTex23 
transcripts expressed in C2C12 cells transduced with AAV2/5-
U7DTex23 (–MHCK) or AAV2/5-MHCK-U7DTex23 (+MHCK) at 
different multiplicities of infection (MOI) (105 or 106 viral genome 
per cell). NT, nontransduced cells. The blot was hybridized with 
two 32P end-labeled probes recognizing the U2 snRNA and the 
U7DTex23 chimera (underlined in bold in (a)), respectively. U2 
snRNA shows up as a 187-nt band. Two bands of 86 nt and ~66-nt 
react with the U7DTex23 probe.
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Figure 3 U7-mediated exon 23 skipping on the Duchenne 
muscular dystrophy (Dmd) pre-mRNA. (a) Reverse transcrip-
tion and nested PCR detection of Dmd exon 23 skipping after 
transduction of C2C12 cells with AAV2/5-U7DTex23 (–MHCK) or 
AAV2/5-MHCK-U7DTex23 (+MHCK) with different multiplicities of 
infection (MOI) (105 or 106 viral genome per cell). Controls include 
nontransduced cells (NT) and no reverse transcriptase (RT–). The 
native Dmd mRNA containing exon 23 is detected as a 901-bp 
fragment and the skipped mRNA yields a 688-bp product. Re-
sults are representative of at least three independent transduc-
tions. (b) Analysis of mouse exon 23 skipping by quantitative PCR. 
The graph represents the ratio between the exon 22–24 junction 
(skipped mRNA species) and the exon 22–23 junction (full-length 
mRNA species). Quantification was performed on mRNA extract 
from C2C12 cells transduced with AAV2/5-U7DTex23 or AAV2/5-
MHCK-U7DTex23 at the indicated MOI. A significant difference is 
observed at MOI 105 as shown by the P value (P = 0.023), accord-
ing to Student’s t-test. Error bars are shown as mean ± SEM (n = 
6). MHCK, muscle- and heart-specific enhancer.
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MHCK enhances dystrophin rescue in the skeletal 
muscle of mdx mice
In order to determine the efficiency of the MHCK containing 
construct in vivo, AAV2/8 vectors with or without the MHCK 
enhancer were produced. Mdx mice received doses of 1011, 
2 × 1010, or 5 × 109 viral genomes into the tibialis anterior. 
One month after injection, mice were sacrificed and protein 
and RNA were isolated from the injected muscles. U7DTex23 
and U2snRNA were analyzed by northern blot, and exon 23 
skipping efficiency was evaluated by RT-PCR and quantita-
tive RT-PCR (Figure 5a,b). The northern blot analysis indi-
cated that the processed U7 species was present and that 
the MHCK resulted in a modest increase of U7 levels in the 
muscle. This increase resulted in slightly higher efficiencies 
of skipping, although the differences analyzed by quantita-
tive PCR were not significant. A stronger evidence of the 
MHCK enhancement was obtained by analyzing Dystrophin 
rescue in the injected tissues by western blot. At each dose 
analyzed, animals receiving the MHCK vector had three- to 
fivefold increased levels of rescued Dystrophin (Figure 6).
DISCUSSION
The successful clinical translation of AAV-based approaches 
for exon skipping in diseases such as DMD will depend on 
our ability to improve the therapeutic index of the vectors. The 
effective dose should be sufficient to reach extended skeletal 
muscle territories and to introduce enough transcriptionally 
active copies of the vector genome in each cell nucleus, with-
out compromising safety. Minimizing the dose will therefore 
be a combination of using an AAV vector with the appropriate 
tropism14 and optimizing the snRNA transcription unit.
The promoters of snRNA genes are compact—around 250 
base pairs (bp) in length—and very active. For example, the 
U1 promoter was shown to be equivalent to the immediate 
Figure 4 The SmOPT sequence induces an additional 3′ pro-
cessing of the U7 small nuclear RNA (snRNA). Northern blot 
analysis of U7DTex23 transcripts expressed in C2C12 cells trans-
duced with AAV2/5-U7DTex23 containing the SmOPT sequence 
(AAUUUUUGGAG, Figure 1a), or the native U7 Sm sequence 
(AAUUUGUCUAG). NT, nontransduced cells. The blot was hybrid-
ized with two 32P end-labeled probes recognizing the U2 snRNA 
and the U7DTex23 chimera, respectively. U2 snRNA shows up as 
a 187-nt band. Two bands of 86 nt and ~66-nt react with the U7D-
Tex23 probe. The lower panel presents the analysis of exon 23 
skipping performed in the same RNA samples. The native Dmd 
mRNA containing exon 23 is detected as a 901-bp fragment and 
the skipped mRNA yields a 688-bp product.
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Figure 5 Muscle- and heart-specific enhancer (MHCK) en-
hances U7DTex23-mediated exon skipping on the Duchenne 
muscular dystrophy (Dmd) pre-mRNA in the muscle of mdx 
mice. (a) Northern blot analysis of U7DTex23 transcripts ex-
pressed in mdx mice muscles treated with AAV2/8-U7DTex23 
(–MHCK) or AAV2/8-MHCK-U7DTex23 (+MHCK). Total injected 
vector doses in vector genomes are indicated on top. The blot 
was hybridized with two 32P end-labeled probes recognizing 
the U2 small nuclear RNA (snRNA) and the U7DTex23 chimera, 
respectively. U2 snRNA shows up as a 187-nt band. Two bands 
of 86 nt and ~66-nt react with the U7DTex23 probe. The lower 
panel presents the analysis of exon 23 skipping performed in the 
same RNA samples. The native Dmd mRNA containing exon 23 
is detected as a 901-bp fragment and the skipped mRNA yields a 
688-bp product. NT, nontransduced muscle; RT–, no reverse tran-
scriptase. Results are representative of at least three independent 
transductions. (b) Quantitative PCR analysis of exon 23 skipping 
in RNA samples prepared from injected muscles. The graph rep-
resents the ratio between the exon 22–24 junction (skipped mRNA 
species) and the exon 22–23 junction (full-length mRNA species). 
No statistically significant difference could be observed between 
the groups (Student’s t-test, P > 0.05). Error bars are shown as 
mean ± SEM (n = 3 per cohort).
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early CMV enhancer/promoter for expressing a lacZ reporter 
gene.24 Although the related U7 promoter is of comparable 
strength,12,19,25 Brun et al. have shown that it can be boosted 
by a muscle-specific MCK enhancer.20 Here, we have 
introduced a strong dual muscle- and heart-specific tran-
scriptional enhancer (MHCK) upstream of a U7 shuttle for 
antisense sequences in order to evaluate the improvement 
of exon-skipping efficiency associated with a higher number 
of chimeric snRNA molecules in cultured myogenic cells and 
in the mouse skeletal muscle.
The effect of the enhancer on the amounts of snRNA pro-
duced in cultured cells or in vivo is modest relative to the one 
reported in association with the CK promoter and 5′ untrans-
lated region.21 This is likely due to the high constitutive activ-
ity of the U7 promoter. We have observed that transcription 
enhancement by the MHCK sequences also occurs in 293 
cells, indicating that the ubiquitous nature of the U7 promoter 
overrides the tissue specificity of the enhancer (Supplemen-
tary Figure S4). This is consistent with reports showing that 
both MCK and MHC enhancers lose their tissue specificity 
when combined with constitutive promoters.26
Recombinant AAV genomes are found as either linear or 
circular monomers and concatemers. High doses of AAV 
vectors result in the formation of concatemers of the vec-
tor genome.23,27 With increasing doses of vector applied to 
myogenic cells we observe the formation of high-molecular 
weight RNA species containing internal U7 sequences as 
well as sequences in the 3′ box. These are consistent with 
unprocessed read through transcripts generated from AAV 
concatemers. A similar dose-dependent accumulation of 
unprocessed U7 transcripts has been reported following 
injection of U7-based constructs in Xenopus oocytes and it 
was attributed to a saturation of the U7 3′ end processing 
machinery.19,25 The fact that high-molecular weight U7 tran-
scripts were not observed in the injected muscle is probably 
due to the lower MOI reached in vivo, but could also reflect a 
higher U7 processing capacity in muscle fibers compared to 
cultured myotubes.
Our data also indicate the presence in transfected or AAV 
transduced cells of a U7 species lacking 20 nt at the 3′ end. 
Such 3′-deleted forms of U7 chimeras have been observed 
previously12 and we show here that they are a consequence 
of the SmOPT mutations. U7 is normally assembled into non-
spliceosomal snRNP where a specific core of Sm proteins 
interacts with the Sm sequence.28 Changing this sequence to 
SmOPT redirects U7 transcripts into snRNPs containing the 
canonical Sm proteins, which accumulate to a much higher 
levels than unmodified U7 transcripts.19 As shown in Figure 
4, the efficiency of U7 shuttles for antisense delivery critically 
depends on the presence of an SmOPT sequence.10,29 The 
shortened U7 transcripts could be generated by a mispro-
cessing of the 3′ end associated with mutations in the Sm 
sequences, as observed for U1.30 So far however, only muta-
tions in the 3′ box or in the U7 stem loop are known to affect 
processing.31 More likely, the packaging of U7SmOPT into a 
spliceosomal snRNP may expose a cryptic nucleolytic site 
in the stem loop and trigger a partial cleavage or degrada-
tion during particle maturation.18 It is unlikely that the mis-
processed U7SmOPT species remain properly assembled 
into functional snRNPs and therefore functional for antisense 
delivery. Moreover, the shortened U7 RNAs are probably 
destabilized since the 3′ stem loop of snRNAs acts as a pro-
tection against exonucleases. Therefore, the steady-state 
ratio of full-length versus misprocessed U7 RNA observed 
by northern blot may in fact underestimate the proportion of 
transcripts that undergo removal of the terminal 20 nt.
Our study indicates that potentially inactive by-products of 
U7SmOPT shuttles may be produced following gene transfer. 
Further understanding of the formation of these molecules 
may allow improving the potency of U7-based chimera for 
antisense delivery.
MATERIALS AND METHODS
Primer oligonucleotides
F1 5′-TTTACTAGTCCCTTCAGATTAAAAATAACTGA-3′
R1 5′-CCCGTAGTGGGACAGCAGGGCCCCAAGGTT-3′
F2 5′-CCCTGCTGTCCCACTACGGGTCTAGGCTGC-3′
R2 5′-CCCTCTAGAGATCCACCAGGGACAGGGTTAT-3′
FMCKdel63 5′-CCCCAACACCTGCTGCCTGCTAAAAATAACCCTG
TCCCTGGTGG-3′
RMCKdel63 5′-CCACCAGGGACAGGGTTATTTTTAGCAGGCAGCA
GGTGTTGGGG-3′
FDTex23Sm 5′gcttacctaaatagaagttcatttacactaacaatttgtctagcaggttttc
tgacttcg-3′
RDTex23Sm 5′cgaagtcagaaaacctgctagacaaattgttagtgtaaatgaacttctat
ttaggtaagc-3′
HIV_LTR_F 5′-AGCTTGCCTTGAGTGCTTCAA-3′
HIV_LTR_R 5′-AGGGTCTGAGGGATCTCTAGTTACC-3′
DTex23F 5′-GGCCAAACCTCGGCTTA-3′
DTex23R 5′-GTTAGTGTAAATGAACTTC-3′
PolyA-F 5′-ATTTTATGTTTCAGGTTCAGGGGGAGGTG-3′
PolyA-R 5′-GCGCAGAGAGGGAGTGGACTAGT-3′
Ex46Fo 5′-AGGAAGCAGATAACATTGCT-3′
Ex53Ro 5′-TTTCATTCAACTGTTGCCTC-3′
Ex47Fi 5′-TTACTGGTGGAAGAGTTGCC-3′
Ex52Ri 5′-TGATTGTTCTAGCCTCTTGA-3′
Ex20Fo 5′-CAGAATTCTGCCAATTGCTGAG-3′
Ex26Ro 5′-TTCTTCAGCTTGTGTCATCC-3′
Ex20Fi 5′-CCCAGTCTACCACCCTATCAGAGC-3′
Ex26Ri 5′-CCTGCCTTTAAGGCTTCCTT-3′
Figure 6  Muscle- and heart-specific enhancer (MHCK)-medi-
ated enhancement of Duchenne muscular dystrophy (Dmd) 
exon skipping in mdx mice leads to an increased rescue of 
Dystrophin protein in treated muscles. Western blot analysis 
of dystrophin levels in muscles of mdx mice treated with AAV2/8-
U7DTex23 (–MHCK) or AAV2/8-MHCK-U7DTex23 (+MHCK), at 
doses of 2 × 1010 or 1 × 1011 vg/muscle. Samples from two different 
animals are analyzed for each condition. The wild type C57 mouse 
Dystrophin is shown as a positive control and the endogenous 
α-actinin is detected for normalization.
1011 2.1010
+ +−− + +−−
C57
MHCK
Dystrophin
α-Actinin
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Vector constructions. The MHCK enhancer was obtained by 
fusing the 188 bp long-murine α-MHC enhancer, and the 207 
bp murine MCK enhancer, as described by Salva et al.21 The 
sequences were amplified from C2C12 genomic DNA using 
the PCR Master Mix (Promega, Madison, WI) following the 
manufacturer’s instructions, and primers F1 and R1 (α-MHC 
enhancer) or F2 and R2 (MCK enhancer). The two amplicons 
were fused by PCR using primers F1 and R2 and introduced 
upstream of the U7snRNA cassette in the AAV-U7DTex23 
vector, previously described as AAV-U7-SD23/BP22.13 The 
α-MHC-MCK fusion was further modified by deleting a 63 bp 
region as described,21 using the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) and the primers 
FMCKdel63 and RMCKdel63.
A deletion of three cytosines between the left and right 
E-boxes of the MCK enhancer was observed in the final 
AAV-MHCK-U7DTex23 construct, compared to the published 
NCBI sequence (GenBank: AF188002.1). This deletion was 
also observed in C2C12 genomic DNA and was considered 
a polymorphism.
U7ex51 was derived from U7DTex23 with the mouse dys-
trophin antisense sequences replaced by a sequence tar-
geting a splicing enhancer (underlined) in human dystrophin 
exon 51 (5′-GCAGGTACCTCCAACATCAAGGAAGATGGC
ATTTCTAGTTTGGAG-3′).22 U7ex51 was introduced in the 
pRRLSIN-cPPT-PGK-GFP-WPRE lentiviral vector32 to cre-
ate pRRLSIN-U7ex51. The MHCK enhancer was introduced 
upstream of the U7snRNA cassette to generate pRRLSIN-
MHCK-U7ex51.
The SmOPT site of the U7DTex23 sequence was changed 
into the canonical Sm sequence in the AAV-U7DTex23 vector 
by site-specific mutagenesis using the primers FDTex23Sm 
and RDTex23Sm.
The scAAV-PGK-GFP plasmid was constructed by 
introducing the PGK-GFP fragment from pRRLSIN-cPPT-
PGK-GFP-WPRE into the self-complementary vector 
scAAV-LP1-hFIX,33 from which the LP1-hFIX sequence was 
removed. The MHCK enhancer was inserted upstream of the 
PGK promoter to obtain scAAV-MHCK-PGK-GFP.
Lentiviral vectors preparation. Lentiviral virions were pro-
duced by calcium phosphate transfection of HEK293T cells 
with the envelope plasmid pMD.G (VSV-G34), the packaging 
plasmids pHDM-gpm2 (codon-optimized HIV-1 Gag-Pol) and 
pRC/CMV-REV1B (REV) (both gifts from Dr Jeng-Shin Lee, 
Harvard Medical School), and the vector plasmid pRRLSIN-
U7ex51. Viral supernatants were harvested 20, 28, and 36 
hours post-transfection, centrifuged 5 minutes at 1,500 rpm, 
filtered through a 0.45-μm filter, and ultracentrifuged 2 hours 
at 19,500 rpm at 12 °C. Pellets were resuspended in phos-
phate-buffered saline (PBS) 1% bovine serum albumin and 
stored at −80 °C. The infectious titers were determined by 
quantitative PCR using the SYBR Green PCR Master Mix 
(Applied Biosystems, Life Technologies, Carlsbad, CA) and 
primers specific for the lentiviral genome HIV_LTR_F and 
HIV_LTR_R. The albumin endogenous gene was used for 
normalization.
AAV vectors preparations. AAV vectors were produced by 
calcium phosphate transfection of HEK293T cells with the 
transgene plasmid, the capsid plasmid AAV2/8 (LTAAVhelp2-
835) or AAV2/5 (Napoli 2/536), and the plasmid for adenovirus 
helper function (pHGTI-Adeno137). After 72 hours cells and 
media were harvested and centrifuged at 1,800 rpm for 10 
minutes at 4 °C and the pellets resuspended in 40 ml of 
TD buffer (140.4 mmol/l NaCl, 4.9 mmol/l KCl, 0.7 mmol/l 
K2HPO4, 3.4 mmol/l MgCl2, 24.7 mmol/l Tris—pH 7.5). After 
five freeze/thaw cycles of the suspension (30 minutes at –80 
°C followed by 30 minutes at 37 °C) 2,000 U of benzonase 
were added, the suspension was incubated for 30 minutes at 
37 °C and centrifuged for 20 minutes at 3,000g. The super-
natant was filtered through a 0.45-μm filter and the AAV 
preparations were purified by affinity chromatography using 
the AKTA explorer chromatography system (GE Healthcare, 
Waukesha, WI) and a prepacked AVB sepharose affinity col-
umn (HiTrap; GE Healthcare). The collected fractions of AAV 
vectors sample were pooled and dialysed in PBS at 4 °C 
for 16 hours. The viral genome titers were assessed by real-
time PCR using the SYBR Green PCR Master Mix (Applied 
Biosystems). For titration of the AAV-U7DTex23 and AAV-
MHCK-U7DTex23 vectors, primers specific of the DTex23 
antisense sequence were used: DTex23F and DTex23R. 
For the scAAV-PGK-GFP and scAAV-MHCK-PGK-GFP vec-
tors, primers in the polyA sequence were used: PolyA-F and 
PolyA-R.
Cell culture and transduction. All the cells were cultivated 
at 37 °C and 5% CO2. 293T cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal calf serum (Invitrogen). CHQ 
cells were grown in F-10 medium (Invitrogen) supplemented 
with 20% fetal calf serum (Invitrogen). Differentiation of CHQ 
cells was induced in DMEM without pyruvate (Invitrogen) 
supplemented with 100 μg/ml of human apolipotransferrin 
(Sigma, St Louis, MI) and 10 μg/ml of bovin insulin (Sigma). 
C2C12 cells were grown in DMEM supplemented with 20% 
fetal calf serum (Invitrogen). Differentiation of C2C12 was 
induced in DMEM supplemented with 2% horse serum 
(Sigma).
For lentiviral vector transduction, 30,000 CHQ cells were 
seeded in each well of a 12-wells plate. After 24 hours, the 
lentiviral vector preparation was administered in a total vol-
ume of 250 μl of proliferation medium at the chosen MOI. After 
6-hour incubation 1 ml of proliferation medium was added 
per well. Seventy two hours post-transduction the medium 
was replaced with differentiation medium for 72 additional 
hours. Cells were then harvested for analysis.
For AAV vector transduction, 100,000 C2C12 cells were 
seeded in each well of a 12-wells plate. The following day pro-
liferation medium was changed to differentiation medium and 
the cells were left to differentiate into myotubes for a week. 
The cells were then transduced with the AAV preparation at 
the chosen MOI in a total volume of 300 μl of medium with-
out serum. After 6 hours of incubation 1 ml of differentiation 
medium was added per well. Cells were incubated for 7 days 
in differentiation medium before harvesting for analysis.
Western blot. For dystrophin detection total protein was 
extracted from muscle samples with Newcastle buffer 
(3.8% SDS, 75 mmol/l Tris–HCl pH 6.7, 4 mol/l urea, 10% 
β-mercaptoethanol, 10% glycerol, 0.001% bromophenol 
blue) and quantified using the bicinchoninic acid protein 
assay kit, according to the manufacturer’s instructions (Per-
bio Science, Brebieres, France). Samples were denatured at 
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95 °C for 5 minutes before 100 μg of protein was loaded in 
a 5% polyacrylamide gel with a 4% stacking gel. Gels were 
electrophoresed for 4–5 hours at 100 V and blotted to a 
PVDF membrane overnight at 50 V. Blots were blocked for 
1 hour with 10% nonfat milk in PBS–Tween (PBST) buffer. 
Dystrophin and α-actinin proteins were detected by prob-
ing the membrane with 1:100 dilution of NCL-DYS1 primary 
antibody (monoclonal antibody to dystrophin R8 repeat; 
NovoCastra) and 1:200 dilution of α-actinin primary antibody 
(Santa Cruz Biotechnology), respectively. An incubation with 
a mouse horseradish peroxidase-conjugated secondary anti-
body (1:2,000) or goat horseradish peroxidase-conjugated 
secondary antibody (1:160,000) allowed visualization using 
ECL Analysis System (GE Healthcare). Membranes were 
converted to numerical pictures by scanning.
RNA isolation and nested RT-PCR analysis. RNA were 
isolated from cells or muscle sections using TriZol Reagent 
according to the manufacturer’s instructions (Invitrogen). 
RT-PCR was carried out on 300 ng of total RNA using the 
Access RT-PCR System (Promega). For human sequences 
analysis external primers Ex46Fo and Ex53Ro were used. 
The cDNA synthesis was carried out at 45 °C for 45 minutes, 
directly followed by the primary PCR of 30 cycles of 94 °C (30 
s), 55 °C (1 minute) and 72 °C (2 minutes). Two microlitres 
of the RT-PCR product was used for the nested PCR with 
the internal primers Ex47Fi and Ex52Ri for 22 cycles under 
identical cycling conditions. The same nested PCR condi-
tions were used for mouse sequences analysis, with external 
primers Ex20Fo and Ex26Ro, and internal primers Ex20Fi 
and Ex26Ri. Products were analyzed on 2% agarose gel.
Quantitative PCR. For each sample, 1 μg of total RNA was 
used for RT using the SuperScript II RT system (Invitrogen) 
and random hexamers as the priming nucleotides, according 
to the manufacturer’s instructions. For quantitative PCR anal-
ysis, 10 ng of the resulting cDNA was used per well. Com-
parative CT quantitative analysis of the exon 22-23 junction 
(Taqman Assay Mm01216934_m1; Applied Biosystems) and 
the exon 22-24 junction (Fw: CTGAATATGAAATAATGGAG-
GAGAGACTCG, Rev: CTTCAGCCATCCATTTCTGTAAGGT, 
probe: FAM-ATGTGATTCTGTAATTTCC-NFQ) was per-
formed on each RNA sample. Reactions were performed in 
triplicate with the appropriate non-template controls using 
the cycle conditions: 95 °C for 10 minutes, and 40 cycles at 
95 °C for 15 seconds and 60 °C for 1 minute.
Data analysis. For each sample, the CTs for the 22–24 
assay (skipped dystrophin) are normalized to the CT for the 
22–23 assay (nonskipped dystrophin) to generate a delta-CT 
value. This involves the subtraction of the 22–23 CT from the 
22–24 Ct. The delta CT can be used to calculate the rela-
tive abundance in skipped dystrophin RNA species relative 
to full-length species.
An unpaired Student’s t-test was used to assess the statis-
tical significance of differences between the samples treated 
with AAV-U7DTex23 and the samples treated with AAV2-
MHCK-U7DTex23. A P value <0.05 was considered statisti-
cally significant. All results are expressed as mean values ± 
SEM.
Northern blot. Northern blots were realized on 7 μg of total 
RNA. Samples of total RNA were denaturated at 70 °C for 15 
minutes and loaded on a 15% Novex TBE-Urea precast gel 
(Invitrogen) along with 1 μl of γ-32P-labeled RNA Decade 
Markers (Ambion, Austin, TX). Gels were electrophoresed 
for 1 hour at 180 V in 2.5× TBE buffer, and transferred to a 
Hybond-N+ membrane (Amersham, UK) for 2 hours at 390 
mA in 2× TBE buffer. The membrane was UV-crosslinked 
with 100 mJ of energy and prehybridized in 10 ml of Rapid 
Hyb buffer (Amersham) containing salmon sperm DNA (50 
μg/ml) at 42 °C. For radiolabeling of the complementary 
DNA probe 50 pmol of oligonucleotide, U7DTex23 (5′-32P-
GTTAGTGTAAATGAACTTC-3′) or endogenous U2snRNA 
(5′-32P-CTGATAAGAACAGATAC-3′), was end-labeled using 
γ-32P-ATP (Amersham, 6 000 Ci/mmol) and T4 PolyNucle-
otide Kinase (New England BioLabs, Ipswich, MA) for 1 hour 
at 37 °C. The probe was purified from unincorporated label 
using G-25 MicroSpin Columns (Amersham), and heated for 
1 minute at 95 °C before addition to the hybridization solu-
tion and incubation overnight at 42 °C. The following day 3 
successive washes of increasing stringency were realized 
for 15 minutes at 42 °C before placing the blots in a cas-
sette with an autoradiogram. The films were exposed for 
72 hours.
MDX mice injection. Five-month-old mdx mice were anes-
thetized with isoflurane and injected in the tibialis anterior 
with 5 × 109, 2 × 1010, or 1011 viral genome copies of AAV2/8-
U7DTex23 or AAV2/8-MHCK-U7DTex23 (n = 3 for each con-
dition). For each mouse, contra-lateral muscle was injected 
with PBS as a negative control. Mice were sacrificed 4 
weeks after injection and tibialis anterior muscles were iso-
lated and snap frozen in liquid nitrogen-cooled isopentane. 
All animal experiments were carried out in Biomedical Sci-
ence Building, University of Oxford, Oxford, UK and per-
formed according to the guidelines and protocols approved 
by the Home Office.
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Supplementary Material
Figure S1. The MHCK enhancer increases GFP expression 
in myogenic cells.
Figure S2. Dose-dependent accumulation of read through 
U7 RNAs transcripts generated from AAV vector genome 
concatemers.
Figure S3. Northern blot analysis of (a) U7DTex23 and 
(b) U7 transcripts expressed in 293T cells transfected with 
AAV constructs containing either the SmOPT sequence 
(AAUUUUGGAG, Figure 1a), or the native U7 Sm sequence 
(AAUUUGUCUAG). 
Figure S4. The MHCK enhancer loses its tissue specificity 
when coupled with a ubiquitous promoter.
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Supplementary Figure S1. MHCK enhancer increases GFP expression in myogenic cells. 
(a) Western blot to detect GFP expression obtained from protein extracts of C2C12 cells 
transduced with self complementary AAV2/5 vectors expressing the PGK-GFP or the 
MHCK-PGK-GFP cassettes (MOI = 104 vg /cell). The non-transduced cells (NT) and the 
endogenous control β-actin are shown. C2C12 protein extracts were obtained by incubation 
30 minutes at 4°C in lysis buffer (1× complete protease inhibitor cocktail (Roche Diagnostics, 
Basel, Switzerland), 0.5% NP-40, 20 mM Tris pH 7.5, 10% glycerol, 100 mM (NH4)2SO4). 
Equal amounts of protein were separated on a 12% polyacrylamide gel 1 hour at 110 V and 
transferred to a PVDF membrane (Amersham, UK) 90 minutes at 100 V. The membrane 
was blocked with PBS 5% milk 0,1% Tween 20 and probed with rabbit polyclonal anti-GFP 
antibody (sc-8334; Santa Cruz Biotechnology, Santa Cruz, CA - dilution 1:500) and mouse 
anti-actin antibody (A-5441; Sigma - dilution 1:15000). The secondary antibodies goat anti-
mouse and goat anti-rabbit, conjugated with peroxidase (Sigma), were used at a 1:2000 
dilution. Signals were detected with the ECL kit (Amersham). 
(b) Representation of GFP expression levels relative to β-actin in the transduced cells. The 
quantification was performed from the western blot presented in (a). The membrane was 
converted to a numerical picture and band intensities were analysed by densitometry using 
the GeneTools analysis software (Syngene, UK). GFP levels are expressed as a percentage 
compared with β-actin levels. 
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Supplementary Figure S2. Dose-dependent accumulation of readthrough U7 RNAs 
transcripts generated from AAV vector genome concatemers  
Northern blot analysis of U7DTex23 transcripts expressed from C2C12 cells transduced with 
AAV2/5-U7DTex23 (-MHCK) or AAV2/5-MHCK-U7DTex23 (+MHCK) at a MOI of 105 or 106 
viral genome per cell. The non-transduced cells (NT) and the endogenous U2snRNA 
transcripts are shown as controls. The same samples as in Fig. 2b were analysed, using a 
probe complementary to the U7 3' box, that allows detection of unprocessed U7 transcripts. 
A representation of the primary U7 transcript and the position of the probe are shown on top. 
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Supplementary Figure S3. Northern blot analysis of U7DTex23 (a) and U7 (b) transcripts 
expressed in 293T cells transfected with AAV constructs containing either the SmOPT 
sequence (AAUUUUGGAG, Fig 1a), or the native U7 Sm sequence (AAUUUGUCUAG).  
U7 contains the natural antisense sequence against histone H1 pre-mRNA. The non-
transfected samples (NT) are shown as controls. The blots were hybridized with 32P end-
labeled probes recognizing the U2 snRNA and either the U7DTex23 chimera (a) or U7 (5’-
32P-CTAAAAGAGCTGTAACACTT-3’) (b). U2 snRNA shows up as a 187 nt band. Two 
bands of 86nt and approximately 66 nt react with the U7DTex23 probe. Two bands of 62nt 
and approximately 42nt react with the U7WT probe. In both cases, the shorter species are 
detected in presence of the SmOPT sequence only. 
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Supplementary Figure S4. The MHCK enhancer loses its tissue-specificity when coupled 
with a ubiquitous promoter. 
Northern blot analysis of U7DTex23 transcripts expressed in 293T cells transduced with 
AAV2/5-U7DTex23 (MHCK-) or AAV2/5-MHCK-U7DTex23 (MHCK+) at a MOI of 105. The 
non-transduced cells (NT) and the endogenous U2snRNA transcripts are shown as controls. 
The expression of the U7DTex23 increases when driven by the MHCK enhancer in non-
muscular cells, highlighting the absence of tissue-specificity. 
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